promethazine profile

Promethazine is an antihistamine medication used to treat allergies, motion sickness, and nausea and vomiting. It is also used as a sedative. Promethazine is a phenothiazine derivative and is synthesized through a multi-step process involving the reaction of phenothiazine with a substituted alkyl halide. It acts by blocking the action of histamine, a chemical released by the body in response to allergens. Promethazine has a wide range of effects including sedation, antiemetic, anticholinergic, and antihistaminic effects. Its importance lies in its ability to treat various symptoms associated with allergies, motion sickness, and nausea and vomiting. Promethazine is studied to understand its mechanism of action, its efficacy in different conditions, and its potential side effects. It is also investigated for its potential use in other medical conditions, such as pain management.'

1,3-dimethylimidazolium: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1,3-dimethylimidazolium : A 1-alkyl-3-methylimidazolium in which the alkyl substituent at C-1 is methyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	20335
CHEMBL ID	1229272
CHEBI ID	61322
MeSH ID	M0017706
PubMed CID	4927
CHEMBL ID	643
CHEBI ID	8461
SCHEMBL ID	4700
MeSH ID	M0017706

Synonym
1,3-dimethylimidazol-1-ium
1,3-dimethyl-1h-imidazol-3-ium
[dmim]
1,3-dimethylimidazolium
CHEBI:61322 ,
CHEMBL1229272
45470-32-4
DTXSID1048095
AKOS032954361
CS-0184054
Q27131029
AC-15939
AB00053535-12
10h-phenothiazine-10-ethanamine, n,n,.alpha.-trimethyl-
10h-phenothiazine-10-ethanamine,n,.alpha.-trimethyl-
10-(2-(dimethylamino)-2-methylethyl)phenothiazine
diprazine
pyrethia
romergan
fargan
pilpophen
10-[2-(dimethylamino)propyl]phenothiazine
lilly 1516
phenothiazine, 10-(2-dimethylaminopropyl)-
prorex
isophenergan
(2-dimethylamino-2-methyl)ethyl-n-dibenzoparathiazine
proazaimine
n-(2'-dimethylamino-2'-methyl)ethylphenothiazine
promezathine
3389 r.p.
wln: t c666 bn isj b1y1&n1&1
hiberna
avomine
4182 r.p.
thiergan
prometazin
promazinamide
phenothiazine, 10-[2-(dimethylamino)propyl]-
prothazin
nsc-30321
wy 509
protazine
lilly 01516
(dimethylamino-2-propyl-10-phenothiazine hydrochloride
a-91033
promethazin
dimethylamino-isopropyl-phenthiazin
fenazil
histargan
rp 3277
proazamine
valergine
tanidil
diprozin
phargan
lercigan
diphergan
dimapp
phensedyl
promethiazine
iergigan
nsc30321
prometasin
fenetazina
vallergine
provigan
procit
n-dimethylamino-2-methylethyl thiodiphenylamine
skf 1498
phenargan
KBIO1_000005
DIVK1C_000005
NCI60_001878
prothazine
SPECTRUM_000868
SPECTRUM5_000977
CHEBI:8461 ,
n,n,alpha-trimethyl-10h-phenothiazine-10-ethanamine
prometazina
n,n-dimethyl-1-(10h-phenothiazin-10-yl)propan-2-amine
promethazinum
BSPBIO_002777
IDI1_000005
LOPAC0_000899
PRESTWICK2_000888
BSPBIO_000676
BPBIO1_000744
OPREA1_758749
AB00053535
prometh
pipolphene
dimethylamino-isopropyl-phenthiazin [german]
camergan
metaryl
phenoject-50
phenerzine
promethazine [inn:ban]
hsdb 3173
einecs 200-489-2
brn 0088554
pilothia
promesan
pyrethiazine
nsc 30321
10h-phenothiazine-10-ethanamine, n,n,alpha-trimethyl-
fenetazine
ccris 7056
pro-50
promacot
prometazina [inn-spanish]
promergan
promethazinum [inn-latin]
10-(2-(dimethylamino)propyl)phenothiazine
nci-c60673
antiallersin
promethazinehcl
pelpica
3277 rp
10-(2-dimethylaminopropyl)phenothiazine
C07404
60-87-7
promethazine
n,n-dimethyl-1-phenothiazin-10-yl-propan-2-amine
DB01069
promethazine (jan/inn)
D00494
NCGC00089735-03
KBIOGR_001697
KBIO2_003916
KBIO2_001348
KBIOSS_001348
KBIO2_006484
KBIO3_001997
PRESTWICK0_000888
SPECTRUM2_000840
NINDS_000005
SPBIO_002895
SPECTRUM3_001019
SPBIO_000799
PRESTWICK1_000888
SPECTRUM4_001149
PRESTWICK3_000888
NCGC00089735-02
HMS2089E08
NCGC00015817-10
rp-3277
CHEMBL643 ,
L000495
inchi=1/c17h20n2s/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13h,12h2,1-3h3
pwwvaxiegoywee-uhfffaoysa-
n,n-dimethyl-1-phenothiazin-10-ylpropan-2-amine hydrochloride
n,n-dimethyl-1-phenothiazin-10-ylpropan-2-amine
bdbm50017696
NCGC00015817-05
dtxcid803518
tox21_110227
cas-60-87-7
dtxsid7023518 ,
38878-40-9
10h-phenothiazine-10-ethanamine, n,n,alpha-trimethyl-, radical ion(1+)
CCG-109848
sr-01000002993
SR-01000002993-10
AKOS015962127
NCGC00015817-12
NCGC00015817-03
NCGC00015817-06
NCGC00015817-04
NCGC00015817-11
NCGC00015817-09
NCGC00015817-08
prometazine
4-27-00-01253 (beilstein handbook reference)
unii-ff28ejq494
ff28ejq494 ,
gtpl7282
dimethyl[1-(10h-phenothiazin-10-yl)propan-2-yl]amine
n,n,.alpha.-trimethyl-10h-phenothiazine-10-ethanamine
phenothiazine, 10-(2-(dimethylamino)propyl)-
promethazine [vandf]
(+/-)-10-(2-(dimethylamino)propyl)phenothiazine
promethazine [jan]
10-(2-dimethylamino-2-methylethyl)phenothiazine
10h-phenothiazine-10-ethanamine, n,n,.alpha.-trimethyl-, (+/-)-
73745-50-3
promethazine [inn]
promethazine [who-dd]
promethazine [hsdb]
promethazine [mi]
promethazine [mart.]
SCHEMBL4700
NCGC00015817-14
tox21_110227_1
(.+/-.)-promethazine
phenergan base
n,n-dimethyl-1-(10h-phenothiazin-10-yl)-2-propanamine #
pyrethia (salt/mix)
pipolphen (salt/mix)
remsed (salt/mix)
AB00053535_13
(+/-)-promethazine
J-690333
EX-A891
n,n-dimethyl-1-(10h-phenothiazin-10-yl)-2-propanamine
SBI-0050874.P004
FT-0700342
Q422970
60-87-7 (free base)
F17386
SDCCGSBI-0050874.P005
NCGC00015817-24
NCGC00015817-17
()-promethazine
S5196
EN300-708776
d04aa10
n,n,-alpha-trimethyl-10h-phenothiazine-10-ethanamine
camsilate de promathazine
3389 rp
promethazinum (inn-latin)
10h-phenothiazine-10-ethanamine, n,n,alpha-trimethyl-, (+/-)-
prometazina (inn-spanish)
4182 rp
promethazine (mart.)
r06ad02
n-(2'-dimethylamino-2-methyl)ethylphenothiazine

Excerpt	Reference	Relevance
"Promethazine (PMZ) is an effective antihistamine that is used as a nerve tranquilizer to treat mental disorders. "	( A highly selective and sensitive sensor for promethazine based on molecularly imprinted interface coated Au/Sn bimetal nanoclusters functionalized acupuncture needle microelectrode. Fan, K; Fang, L; Li, L; Liu, H; Lü, Z; Ren, C; Wang, C; Yin, ZZ; Zhang, C; Zhang, Y, 2023)	2.61
"Promethazine is an antihistamine agent used commonly for nausea and allergy. "	( Acute onset of orofacial dystonia from promethazine treatment: A case report. Huang, J; Lai, J; Zhang, R, 2019)	2.23
"Promethazine is a medicinal product, available on its own or in combination with other ingredients including dextromethorphan, paracetamol and/or expectorants. "	( Beyond the 'purple drank': Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reports. Chiappini, S; Corkery, JM; Guirguis, A; Schifano, F, 2021)	2.34
"Promethazine is a phenothiazine derivative antihistamine first introduced in the 1940s that is used in multiple medical conditions as a sedative/hypnotic agent. "	( [Promethazine - an old pharmaceutical that has got a renaissance. An avalanche-like increase in the number of overdose cases in Sweden]. Höjer, J; Tellerup, M, 2018)	2.83
"Promethazine hydrochloride is a first-generation H1 receptor antagonist, antihistamine, and antiemetic medication that can also have strong sedative effects. "	( Topical promethazine side effects: our experience and review of the literature. Calvieri, S; Cantisani, C; Faina, V; Grieco, T; Paolino, G; Ricci, S; Silvestri, E, 2013)	2.27
"Promethazine is a phenothiazine derivative with antihistaminic (H(1)), sedative, antiemetic, anticholinergic, and antimotion sickness properties that can induce QT prolongation, which may lead to torsades de pointes. "	( H(1) antihistamine drug promethazine directly blocks hERG K(+) channel. Choe, H; Chong, SH; Hong, HK; Jo, SH; Lee, HS, 2009)	2.1
"Promethazine is a phenothiazine derivative that has been used in children for a number of nonpsychiatric indications."	( Promethazine treatment of steroid-induced psychosis in a child. Hagemann, TM; Ingram, DG, )	2.3
"Promethazine is an antihistamine with sedative properties that has no antiseizure effects and therefore can be administered before ECT to prevent the onset of agitation."	( Promethazine for the treatment of agitation after electroconvulsive therapy: a case series. Amiaz, R; Grunhaus, L; Vishne, T, 2005)	2.49
"Promethazine (PMZ) is an FDA-approved antihistaminergic drug that was identified as a potentially neuroprotective compound in the NINDS screening program. "	( Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Beal, MF; Calingasan, NY; Chen, J; Cleren, C; Lorenzo, BJ; Starkov, AA, 2005)	3.21
"Promethazine was found to be an effective agent for symptom-control of chronic rhinitis in the pre-school child."	( Chronic rhinitis in the pre-school child. Arora, NV; Hyde, JS; Kumar, CM; Moore, BS, 1978)	0.98
"Promethazine is an antihistamine commonly used for sedation in clinical pediatric medicine. "	( Pulmonary and systemic vascular response to promethazine in conscious lambs. Covert, RF; Drummond, WH; Gimotty, PA; Webb, IB, 1988)	1.98

Excerpt	Reference	Relevance
"Promethazine abuse has been reported. "	( Abuse and Intentional Misuse of Promethazine Reported to US Poison Centers: 2002 to 2012. Anderson, BD; Klein-Schwartz, W; Procopio, G; Tsay, ME, )	1.86
"Promethazine has been reported to be misused in conjunction with opioids in several settings. "	( Promethazine misuse among methadone maintenance patients and community-based injection drug users. Cheng, HY; Kral, AH; Lutnick, A; Lynch, KL; Shapiro, BJ; Toochinda, T, )	3.02
"Promethazine has been recognised as an effective antiplasmid agent in cultures containing a single bacterial species such as Escherichia coli, Yersinia enterocolitica, Staphylococcus aureus and Agrobacterium tumefaciens. "	( Antiplasmid effect of promethazine in mixed bacterial cultures. Amaral, L; Molnár, A; Molnár, J, 2003)	2.08
"Promethazine has intermediate activity."	( On the nature of the chemical mediators involved in anaphylactic reactions in mice. HALPERN, BN; NEVEU, T; SPECTOR, S, 1963)	0.96
"Promethazine has been reported to cause significant sedation, agitation, hallucinations, seizures, dystonic reactions, and possibly apparent life-threatening events or sudden infant death syndrome."	( Should promethazine in liquid form be available without prescription? Altemeier, WA; Clayton, EW; Hickson, GB, 1990)	1.46
"Promethazine given i.v. has important cardiovascular effects."	( Pulmonary and systemic vascular response to promethazine in conscious lambs. Covert, RF; Drummond, WH; Gimotty, PA; Webb, IB, 1988)	1.26
"Promethazine has been shown to possess definite immunosuppressive activity in clinical and experimental organ transplantation. "	( Influence of promethazine on immune reactions. I. Characterization of promethazine effects on natural killer cell-mediated cytotoxicity. Rychlik, E; Rychlik, G; Wasik, M, )	1.94

Excerpt	Reference	Relevance
"Promethazine does not inhibit these systems to the same extent as it does the NADPH(2)-ADP-Fe(2+) lipid-peroxidation system."	( The inhibitory effects in vitro of phenothiazines and other drugs on lipid-peroxidation systems in rat liver microsomes, and their relationship to the liver necrosis produced by carbon tetrachloride. Slater, TF, 1968)	0.97

Excerpt	Reference	Relevance
"Promethazine treatment of zymosan-activated macrophages led to a concomitant reduction in both phagocytosis and TxB2 synthesis."	( Effects of thiazinamium chloride, promethazine and chlorpromazine on thromboxane B2 synthesis, phagocytosis and respiratory burst by rat alveolar macrophages. Chang, J; Lewis, AJ; Piperata, S; Skowronek, M, 1983)	1.27
"Promethazine treatment by either route increased mean arterial pressure among surviving dogs throughout the 6-hour experimental period."	( Effects of promethazine on hemorrhagic shock in the dog. Goetsch, DD; Huber, TL; Wilson, RC, 1982)	1.38
"promethazine and 6 of 8 treated with promethazine suppositories after symptom development had immediate (within 1-2 h) symptom relief and required no additional medication."	( Comparison of treatment strategies for Space Motion Sickness. Beck, BG; Davis, JR; Jennings, RT, 1993)	1.01
"Promethazine treatment caused a small but significant HVA rise in the substantia nigra only."	( Comparison of effects of drugs on dopamine metabolism in the substantia nigra and the corpus striatum of rat brain. Korf, J; Westerink, BH, 1976)	0.98
"Promethazine pretreatment is much less expensive than droperidol pretreatment."	( Antiemetic prophylaxis with promethazine or droperidol in paediatric outpatient strabismus surgery. Blanc, VF; Jacob, JL; Milot, J; Ruest, P; Tang, A, 1991)	1.3
"Pretreatment with promethazine significantly decreased mivacurium-induced histamine release in children and provided stable hemodynamics during administration of anesthesia."	( Effects of promethazine or dexamethasone pretreatment on mivacurium-induced histamine release in children. Guang-Jun, H; Guo-Shen, G; Jun, T; Min, C; Ming-Chun, W; Ming-Zhe, Q; Qing-Li, W; Xiang, Z; Xiao-Yang, S; Yan-Hui, Z; Yan-Liang, Q; Zhong-Bing, L, 2014)	1.13
"Pretreatment with promethazine (20 mug/ml) protected 80 percent of P388D(1) macrophages against silica toxicity although lysosomal rupture occurred in 60-70 percent of the cells."	( Dissociation of intracellular lysosomal rupture from the cell death caused by silica. Dobson, ME; Farber, JL; Kane, AB; Knafelc, ME; Raymond, EG; Stanton, RP, 1980)	0.58
"Pretreatment with promethazine and cimetidine, as H1 and H2 histamine receptor antagonists, markedly prevented the development of phase II, namely the rise in cardiac frequency, LVPs, MAP and TPR, but did not significantly modify phase I and III."	( The pattern of cardiovascular alterations induced by infusion of platelet-activating factor in rabbit is modified by pretreatment with H1-H2 receptor antagonists but not by cyclooxygenase inhibition. Alloatti, G; Camussi, G; Emanuelli, G; Mariano, F; Meda, E; Montrucchio, G; Tetta, C, 1987)	0.6
"Pretreatment with promethazine, phenylbutazone, methysergide and indomethacin resulted in a decrease in foot oedema."	( Turpentine-induced acute inflammatory response in Gallus gallus: oedema, vascular permeability and effects of non-steroidal anti-inflammatory drugs. Böhm, GM; Ito, NM, 1986)	0.59

Excerpt	Reference	Relevance
"Mice were given progressively smaller doses of carbon tetrachloride (CCl4) and at intervals later the LD50 of a second dose was determined."	( Reduction of carbon tetrachloride toxicity by prior administration of a single small dose in mice and rats. Lawson, TA; Pound, AW, 1975)	0.25
" In retrograde perfusion under low oxygen supply with Ca2+, CCl4 produced essentially the same toxic manifestations as those observed in the anterograde perfusion."	( Effects of oxygen deficiency and calcium omission on carbon tetrachloride hepatotoxicity in isolated perfused livers from phenobarbital-pretreated rats. Masuda, Y; Nakamura, Y, 1990)	0.28
" The adverse effects of MPC were studied prospectively in 95 patients undergoing various procedures."	( Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients. Clotz, MA; Krogg, EA; Nahata, MC, 1985)	0.56
" Modifying the toxicity with PM, together with a low dose of CCl4, helped to minimize secondary effects of CCl4, to clarify the sequence of toxic events, and to assess the sensitivity of some standard tests of hepatotoxicity."	( Correlations between common tests for assessment of liver damage: indices of the hepatoprotective activity of promethazine in carbon tetrachloride hepatotoxicity. Cheeseman, KH; Reddrop, CJ; Slater, TF, 1983)	0.48
" To conclude, promethazine hydrochloride appears to be a safe alternative to lignocaine hydrochloride for performing surgery under regional anaesthesia."	( Efficacy and safety of promethazine hydrochloride as a local anaesthetic agent for inguinal hernia repair: a pilot study. Chawla, R; Gupta, RL; Kumar, S, )	0.8
"Intranasal midazolam administered using an atomizer is as safe (as assessed by physiologic parameters) and effective (as assessed by behavior ratings) as oral chloral hydrate/promethazine for conscious sedation of pediatric dental patients."	( Comparing the safety, efficacy and recovery of intranasal midazolam vs. oral chloral hydrate and promethazine. Briskie, DM; Dallman, JA; Ignelzi, MA, )	0.54
" Secondary endpoints were mean change in nausea score, need for second dose of study medications, and adverse events (AEs)."	( Intravenous promethazine versus lorazepam for the treatment of peripheral vertigo in the emergency department: A double blind, randomized clinical trial of efficacy and safety. Amini, A; Asadollahi, S; Habibi, T; Heidari, K; Kariman, H; Mansouri, B; Shahrami, A, 2014)	0.78
" Moreover, using C+P did not lead to any serious adverse effects when compared to the treatment group."	( Low dose concomitant treatment with chlorpromazine and promethazine is safe in acute ischemic stroke. Chandra, A; Cheng, Z; Ding, Y; Du, H; Geng, X; Tong, Y; Zhu, H, 2019)	0.76
"While the addition of low dose chlorpromazine and promethazine to standard of care for acute ischemic stroke did not have any significant improvement in functional outcomes, there were no serious adverse effects."	( Low dose concomitant treatment with chlorpromazine and promethazine is safe in acute ischemic stroke. Chandra, A; Cheng, Z; Ding, Y; Du, H; Geng, X; Tong, Y; Zhu, H, 2019)	1.01

Excerpt	Reference	Relevance
"This article reviews clinical pharmacokinetic data on the H1-receptor antagonists, commonly referred to as the antihistamines."	( Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Paton, DM; Webster, DR, )	0.13
" Also, a one-compartment pharmacokinetic open model with two consecutive first-order input steps is proposed."	( Bioequivalence and pharmacokinetic profile of promethazine hydrochloride suppositories in humans. Geary, R; Hecht, G; Robb, CA; Stavchansky, S; Wallace, JE; Wu, P, 1987)	0.53
" Promethazine concentration was determined by high-performance liquid chromatography, and pharmacokinetic values were calculated with noncompartmental methods."	( Pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories and oral syrup to healthy subjects. Cevallos, W; DeCleene, S; Ermer, J; Mayer, PR; Strenkoski-Nix, LC, 2000)	1.54
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."	( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004)	0.32
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" Therefore, an HPLC-ESI-MS method for simultaneous determination of both drugs, and their metabolites was developed for purpose of pharmacokinetic study."	( An HPLC-ESI-MS method for simultaneous determination of fourteen metabolites of promethazine and caffeine and its application to pharmacokinetic study of the combination therapy against motion sickness. Bai, YQ; Gao, JY; Huang, M; Liang, QL; Luo, GA; Wang, YM; Zhai, ZG, 2012)	0.61
"We present a physiologically based pharmacokinetic (PBPK) model simulating systemic drug concentrations following administration to the human rectum."	( A novel physiologically based pharmacokinetic model of rectal absorption, evaluated and verified using clinical data on 10 rectally administered drugs. Dancik, Y; Mittapelly, N; Polak, S; Puttrevu, SK, 2023)	0.91

Excerpt	Reference	Relevance
" A high degree of synergism was observed in vitro when Pz was used in combination with methdilazine and bromodiphenhydramine."	( Drug interaction of promethazine & other non-conventional antimicrobial chemotherapeutic agents. Acharya, DP; Chakrabarty, AN; Dastidar, SG; Neogi, D, 1989)	0.6
"The following double-blind, randomised study dealt with three questions: (1) Is a multidimensional psychometric rating scale suitable for the measurement of mood before anaesthesia? (2) What are the effects of the new benzodiazepine-like drug zolpidem on preoperative mood compared with phenobarbital? (3) Is the combination with Promethazine suggestive? METHODS."	( [Multidimensional psychometric assessment of preoperative mood. Effects of zolpidem compared to phenobarbital combined with promethazine as premedication]. Hüppe, M; Nidermaier, B; Uhlig, T, 1995)	0.67
" The study compared preanesthesiological treatment by zolpidem and phenobarbital in combination with promethazine in a clinical setting."	( Mood effects of zolpidem versus phenobarbital combined with promethazine in an anesthesiological setting. Hüppe, M; Nidermaier, B; Pestel, G; Uhlig, T, 1996)	0.75
" The study shows that a combination with promethazine is recommended, because promethazine has a selective deactivating effect."	( [Optimizing anesthesiologic premedication with reference to biopsychological theories. Exemplified by the effect of dipotassium clorazepate and zolpidem in combination with promethazine]. Schmucker, P; Schön, J; Uhlig, T, 1997)	0.76
" After the onset of ECF clinical signs, the animals in the first two groups were treated with buparvaquone in combination with either dexamethasone (group I) or promethazine (group II), and the third group was treated with buparvaquone alone."	( The effect of dexamethasone and promethazine in combination with buparvaquone in the management of East Coast fever. Boniphace, S; Gwamaka, M; Maselle, RM; Matovelo, JA; Mbassa, GK; Mtambo, MM, 2004)	0.8
" Drug eruption due to a drug combination appears to be very rare."	( Multiple fixed drug eruption due to drug combination. Hara, H; Yokoyama, A, 2005)	0.33

Excerpt	Reference	Relevance
" The relative bioavailability as compared to intramuscular injection seems to be of the order of 10%."	( Variations in the bioavailability of thiazinamium methylsulfate. De Zeeuw, RK; Jonkman, JH; Orie, NG; Van Bork, LE; Wijsbeek, J, 1977)	0.26
" Based on the potency of its pharmacological action, diphenhydramine had a lower bioavailability after oral administration than the other antihistamines."	( Action of stobadine on respiratory and vascular smooth muscle in vivo: evidence for histamine receptor antagonist activity. Babul'ová, A; Bauer, V; Buran, L, )	0.13
" The bioavailability of cefmetazole, determined by area under the blood concentration curve method, increased 20 to 30% by the coadministration of calmodulin inhibitors."	( Effects of phenothiazines and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide on rat colonic absorption of cefmetazole. Furuya, A; Kamada, A; Nishihata, T; Suzuka, T, 1986)	0.27
" From the measured serum levels, estimates of the bioavailability parameters (area under the serum concentration versus time curve, time-to-peak serum concentration, and peak serum concentration) were obtained by least-squares digital computer fitting."	( Bioequivalence and pharmacokinetic profile of promethazine hydrochloride suppositories in humans. Geary, R; Hecht, G; Robb, CA; Stavchansky, S; Wallace, JE; Wu, P, 1987)	0.53
" Diminished systemic bioavailability may result from extensive first-pass hepatic metabolism that occurs after both oral and rectal dosing."	( Comparison of the bioavailability of oral, rectal and intramuscular promethazine. Chung, VS; Dittert, LW; Juhl, RP; Kroboth, FJ; Melethil, SK; Schwinghammer, TL, )	0.37
" As a conclusion, it is suggested that altered sensitivity of brain tissue rather than changes in bioavailability must explain variations in dose-response relationship which are frequently believed to be seen when fentanyl is used in patients with chronic drug administration."	( [Biotransformation of fentanyl. III. Effect of chronic drug exposure on the distribution, metabolism and excretion in the rat]. Brandt, K; Daub, D; Hunger, L; Lehmann, KA, 1983)	0.27
" Our data illustrate the practicability of the method for bioavailability studies after oral or rectal administration of promethazine hydrochloride."	( Determination of promethazine in serum by liquid chromatography. Harris, SC; Shimek, EL; Stavchansky, S; Wallace, JE, 1981)	0.81
"The absolute bioavailability of the three phenothiazine neuroleptics, promazine (Sinophenin, CAS 58-40-2), chlorpromazine (Propaphenin, CAS 50-53-3) and promethazine (Prothazin, CAS 60-87-7) was tested in three single-dose cross-over studies."	( [Absolute bioavailability of chlorpromazine, promazine and promethazine]. Alken, RG; Kirkov, V; Koytchev, R; Kunter, U; Neshev, G; Vagaday, M, 1994)	0.73
"A method of analysis has been developed to quantify promethazine in human serum with a sensitivity that was suitable for bioavailability studies following a 50."	( Rapid, sensitive high-performance liquid chromatographic method for the quantification of promethazine in human serum with electrochemical detection. Fox, AR; McLoughlin, DA, 1993)	0.76
" Bioavailability after an oral dose of PMZ during space flight is thought to be impaired because of gastrointestinal disturbances associated with weightlessness and space motion sickness."	( Bioavailability of intranasal promethazine dosage forms in dogs. Bourne, DW; Geary, RS; Putcha, L; Ramanathan, R, 1998)	0.59
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
" The mean relative bioavailability for the three suppository treatments ranged from 70% to 97%."	( Pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories and oral syrup to healthy subjects. Cevallos, W; DeCleene, S; Ermer, J; Mayer, PR; Strenkoski-Nix, LC, 2000)	0.63
" While studies have revealed the bioavailability of enteric promethazine to be 25%, current dosing references suggest identical dosing regardless of the route of administration."	( No more than necessary: safety and efficacy of low-dose promethazine. Caldwell, JB; Moser, JD; Rhule, FJ, 2006)	0.82
"Sunitinib is an orally bioavailable small molecule that inhibits multiple receptor tyrosine kinases."	( Successful desensitization protocol for hypersensitivity reaction caused by sunitinib in a patient with a gastrointestinal stromal tumor. Atrash, F; Bar-Sela, G; Hadad, S; Haim, N; Kedem, E; Pollack, S; Shahar, E, 2010)	0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" The dose-response curves were shifted to the right in a parallel fashion by promethazine (3 x 10(-6)M)+."	( Cardiac histamine receptors: differences between left and right atria and right ventricle. McNeill, JH; Verma, SC, 1977)	0.49
" Improvement was recorded in a double blind study of 18 patients treated with maximum tolerated dosage (mean 18."	( Tardive dyskinesia treated with pimozide. Calne, DB; Claveria, LE; Haskayne, L; Lodge-Patch, IC; Pallis, CA; Petrie, A; Teychenne, PF, 1975)	0.25
" The dose-response curves were carefully checked in each experiment to confirm that the second protectors did not interfere with the specific coverage provided by the first protector."	( Purification of histamine receptor (VI). An improved double labeling method with "double protection". Uchida, M, 1977)	0.26
" Chloral hydrate in dosages of 25 mg/kg to 100 mg/kg is the most common drug used for sedation; DPT, a combination of parenteral Demerol (meperidine), Phenergan (promethazine), and Thorazine (chlorpromazine), at a maximum dose of 2 mg/1 mg/1 mg/kg is the second; and pentobarbital in a dosage of 5 mg/kg to 7 mg/kg is the third."	( Sedation of children for technical procedures: current standard of practice. Alexander, ME; Bass, JW; Cook, BA; Nomizu, S, 1992)	0.48
"A colorimetric ion-pair complexation method has been developed which provides a simple and rapid way of quantifying Eudragit RS100 and RL100 in pharmaceutical dosage forms."	( A simple and rapid method for the quantification of Eudragit RS100 and RL100 poly(methacrylates) in sustained-release dosage forms. Hansraj, BR; Khan, KA; Melia, CD; Wilding, IR, 1991)	0.28
" Hyposmotic stress during added verapamil dosage (50 mumol/L) also resulted in 23% greater cell swelling compared with control."	( Involvement of cell calcium and transmembrane potential in control of hepatocyte volume. Khalbuss, WE; Wondergem, R, 1991)	0.28
"Rectal thiopental is superior to this drug combination for pediatric sedation because it can be administered painlessly, has a more rapid onset and offset of action, and is of equal safety and efficacy at the dosage studied."	( Rectal thiopental compared with intramuscular meperidine, promethazine, and chlorpromazine for pediatric sedation. Carey, BE; Falk, JL; Malone, LC; O'Brien, JF, 1991)	0.53
" It is concluded that when a healthy child receives a sedative agent for dental treatment, the type of drug and drug dosage depend more on the biases of the individual practitioner, than on the requirements of the patient."	( Report of project USAP: the use of sedative agents in pediatric dentistry. Houpt, M, )	0.13
" Head injuries and a lower mean initial meperidine dosage were more prevalent in patients requiring repeat sedation (P less than ."	( Intramuscular meperidine, promethazine, and chlorpromazine: analysis of use and complications in 487 pediatric emergency department patients. Cantor, RM; Madden, CM; Terndrup, TE, 1989)	0.58
"During a multiple dosing regimen, the area under the promethazine blood concentration-time profile progressively decreased indicating auto-induction of metabolism."	( Changes in the disposition of promethazine during multiple dosing in the rabbit. Houston, JB; Taylor, G, 1985)	0.81
" Fifteen paid healthy male volunteers completed a randomized five-way crossover design which included a 25 mg and 50 mg dose of the innovator dosage form, a 50 mg dose of a generic dosage form, a 50 mg solution dosage form, and a placebo."	( Rotary pursuit, a measure of human performance, and plasma concentrations of promethazine. Brown, WJ; Francisco, GE; Honigberg, IL; Kotzan, JA; Stewart, JT; Zaman, R, )	0.36
" The sigmoid Emax model was fitted to the observed composite effect, and dose-response characteristics for two opposite effects were described."	( Promethazine both facilitates and inhibits nociception in rats: effect of the testing procedure. Paalzow, GH; Paalzow, LK, 1985)	1.71
"1 ml/kg is recommended for cardiac catheterization, but no specific guidelines for dosing or frequency of monitoring have been established for patients undergoing other types of procedures."	( Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients. Clotz, MA; Krogg, EA; Nahata, MC, 1985)	0.56
" The RNA phosphorus redistribution, the decrease in inorganic pyrophosphatase and the increases in neotetrazolium reductase activities were at least partially prevented by a concomitant dosing with promethazine."	( The effects of carbon tetrachloride on rat liver microsomes during the first hour of poisoning in vivo, and the modifying actions of promethazine. Sawyer, BC; Slater, TF, 1969)	0.64
" The ED50s of the effective neuroleptics for this inhibition were similar to those reported for antagonism of amphetamine-induced stereotypic behavior in the rat and the slopes of the dose-response curves were parallel indicating a common site and mechanism of action, presumably blockade of postsynaptic dopaminergic receptors."	( Effect of neuroleptics and tricyclic antidepressants upon d-amphetamine discrimination. Schechter, MD, 1980)	0.26
" Dose-response curves were constructed for the 6 most active compounds and characterized in terms of the IC50, the slope and the maximum response attainable relative to that of histamine."	( Histamine H1-agonist potentiation of adenosine-stimulated cyclic AMP accumulation in slices of guinea-pig cerebral cortex: comparison of response and binding parameters. Daum, PR; Hill, SJ; Young, JM, 1982)	0.26
" Simultaneous application of Hi and 10 micrograms of diphenhydramine, pyrilamine or promethazine, apparently causing no analgesic effect from a single administration, caused a parallel shift of the dose-response curve of Hi to the right."	( Analgesic effect of histamine induced by intracerebral injection into mice. Chung, YH; Kamei, C; Miyake, H; Tasaka, K, 1984)	0.49
" The large increases in plasma activities of GOT, GPT and LDH produced by dosing with CCl4 were partially inhibited by the administration of PM."	( Correlations between common tests for assessment of liver damage: indices of the hepatoprotective activity of promethazine in carbon tetrachloride hepatotoxicity. Cheeseman, KH; Reddrop, CJ; Slater, TF, 1983)	0.48
" Of the remaining 15 patients, six needed a reduction in dosage because of drowsiness: one of these was taking promethazine and five diazepam."	( Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. Geddes, DM; Gross, ER; Woodcock, AA, 1981)	0.71
" As a conclusion, it is suggested that altered sensitivity of brain tissue rather than changes in bioavailability must explain variations in dose-response relationship which are frequently believed to be seen when fentanyl is used in patients with chronic drug administration."	( [Biotransformation of fentanyl. III. Effect of chronic drug exposure on the distribution, metabolism and excretion in the rat]. Brandt, K; Daub, D; Hunger, L; Lehmann, KA, 1983)	0.27
" Intravenous supplementation of the sedation was limited by the protocol to a maximum secobarbital dosage of 2 mg/kg."	( The choice of sedation for computed tomography in children: a prospective evaluation. Ashwal, S; Hasso, AN; Hinshaw, DB; Holden, BS; Schneider, S; Thompson, JR, 1982)	0.26
"Changes in EEG and cEEG were studied in two groups of patients premedicated with promethazine in a dosage of 50 mg iv; study group A consisted of patients whose age ranged from 20-50 years and study group B of patients whose age was above 70 years."	( [Eeg-effects of promethazine. study on 17 patients (author's transl)]. Lips, U; Pichlmayr, I, 1980)	0.83
" Prior promethazine treatment, at dosage regimes that preclude CCl4 induced liver necrosis at 24 hours, did not significantly prevent the CCl4 induced decrease in arachidonic acid content."	( Promethazine administration to rats and CCl4 induced lipid peroxidation of liver microsomal lipids. Castro, JA; de Toranzo, EG; Marzi, A, 1980)	2.16
"Doctors' prescription and dosing behaviour was investigated using data from 9 clinical trials in 550 patients treated with psychotropics."	( Correct titration of non-drugs and some other methodological issues. Beneke, M; Fritze, J; Rasmus, W; Rød, IS, 1994)	0.29
", owing to the higher dosage used in our study (50 mg as against 20 mg)."	( [Oral premedication with clorazepate dipotassium. Comparison with oral premedication with flunitrazepam and intramuscular premedication with promethazine, pethidine and atropine in adults]. Gonzales, I; Kretz, FJ; Peidersky, P, 1993)	0.49
" There is no information on either long term dosing with these drugs or their use in patients with cancer related breathlessness."	( The therapeutics of dyspnoea. Davis, CL, 1994)	0.29
" Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug."	( Two cases of mequitazine-induced photosensitivity reactions. Kang, JS; Kim, TH; Lee, HS; Youn, JI, 1995)	0.29
" In an attempt to find an alternative dosage form for use in space, we evaluated two intranasal (i."	( Bioavailability of intranasal promethazine dosage forms in dogs. Bourne, DW; Geary, RS; Putcha, L; Ramanathan, R, 1998)	0.59
" The system of activities put into practice in the Clinic of Gynaecology includes in the field of pharmacological prophylaxis a systemic and intraperitoneal use of dexamethasone and promethazine before, during and after the operation, in total doses respectively: 250 mg and 300 mg, as well as intraperitoneal dosing of 500 ml of dextran 70, just before closing the peritoneal cavity."	( [The influence of cumulative dexamethasone, promethazine and dextran 70 used as protection against intraperitoneal adhesions on selected parameters of humoral immunity in women operated on for infertility]. Puchalski, A, 1998)	0.75
"The study was designed to investigate the feasibility of developing a transdermal drug dosage form of promethazine hydrochloride (PMH)."	( In vitro release and diffusion studies of promethazine hydrochloride from polymeric dermatological bases using cellulose membrane and hairless mouse skin. Babar, A; Gogineni, P; Patel, NK; Plakogiannis, FM; Ray, SD, 1999)	0.78
" Because there is a lack of chromatographic data available for its determination, the objective of the present investigation was to develop a sensitive and rapid HPLC method for the quantitative estimation of thiazinamium methylsulphate in a pharmaceutical dosage form, applicable to routine analysis."	( A validated HPLC method for the determination of thiazinamium methylsulphate in pharmaceutical preparations. Baeyens, WR; Kiekens, F; Remon, JP; Smet, E; Van der Weken, G; Vervaet, C, 2000)	0.31
"The pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories at three dosage strengths and oral syrup were studied."	( Pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories and oral syrup to healthy subjects. Cevallos, W; DeCleene, S; Ermer, J; Mayer, PR; Strenkoski-Nix, LC, 2000)	0.94
" When the dosage is doubled, no adverse effects are found, but there are no effects different from placebo either."	( Zolpidem and promethazine in pre-anaesthetic medication. A pharmacopsychological approach. Brand, K; Heinze, J; Hüppe, M; Schmucker, P; Uhlig, T, 2000)	0.68
" Only the 25-mg dosage significantly increased motion sickness tolerance when compared with the placebo."	( Promethazine as a motion sickness treatment: impact on human performance and mood states. Cowings, PS; DeRoshia, C; Miller, NE; Toscano, WB, 2000)	1.75
" The specific objectives of research are to identify physiologic, pharmacokinetic, and pharmacodynamic changes in space; to develop simple, reliable, non-invasive, safe and effective acute and sustained-release dosage forms and regimens for pharmacological interventions in space; and to create and maintain a comprehensive space PK-PD and therapeutics database."	( Pharmacotherapeutics in space. Putcha, L, 1999)	0.3
" However, this drug has significant sedative effects with its standard dosage of 25 mg, especially when used in conjunction with narcotic analgesics."	( No more than necessary: safety and efficacy of low-dose promethazine. Caldwell, JB; Moser, JD; Rhule, FJ, 2006)	0.58
" leukocyte infiltration) in the nasal epithelium when dosed at PMZ HCl concentrations greater than the cytotoxic limit."	( Microcapsule-gel formulation of promethazine HCl for controlled nasal delivery: a motion sickness medication. Boland, EJ; Dixon, H; McDonough, JA; Nino, JA; Persyn, JT; Putcha, L; Wang, Z, 2007)	0.62
" Excipients present in either of the dosage forms analyzed did not interfere with the analysis indicating the specificity of the method."	( Development and validation of a HPLC method for the analysis of promethazine hydrochloride in hot-melt extruded dosage forms. Repka, MA; Thumma, S; Zhang, SQ, 2008)	0.58
"Intravenous injection of PHC is a relatively common practice among young injection heroin users in Hanoi, Vietnam who use it on a situational basis to substitute for heroin (when heroin is not available or when heroin is too costly) or to augment the effects of an inadequate heroin dosing (delaying onset of heroin withdraw)."	( Nonmedical use of promethazine hydrochloride among heroin injectors in Vietnam: unrecognized risks and unintended consequences. Clatts, M; Colón-López, V; Giang, le M; Goldsamt, L, 2010)	0.69
" Since transdermal promethazine does not exist world wide, and, since this medicine has significant added values compared to the oral/rectal dosage forms, compounding pharmacists should offer physicians transdermal promethazine as a second-line therapy in nausea and vomiting in pregnancy."	( Nausea and vomiting in pregnancy: a review of the pathology and compounding opportunities. Zur, E, )	0.46
" Patients recorded details of the treated migraine on a diary card and rated pain severity immediately before dosing and 30 minutes, 1 hour, 2 hours, and 4 hours after dosing using a 4-point scale (0 = none to 3 = severe)."	( Promethazine plus sumatriptan in the treatment of migraine: a randomized clinical trial. Amini, A; Asadollahi, S; Forouzanfar, MM; Heidari, K; Shahrami, A; Vafaee, R, 2014)	1.85
"Limited information is available regarding sedation and motor function following repeat dosing of antihistamines."	( Drowsiness and motor responses to consecutive daily doses of promethazine and loratadine. Anoopkumar-Dukie, S; Baumann-Birkbeck, L; Grant, GD; Kavanagh, JJ, 2014)	0.64
" A reduced tremor response was also observed following consecutive daily dosing of promethazine, in contrast to loratadine which caused an increase in tremor amplitude with the consecutive daily dose."	( Drowsiness and motor responses to consecutive daily doses of promethazine and loratadine. Anoopkumar-Dukie, S; Baumann-Birkbeck, L; Grant, GD; Kavanagh, JJ, 2014)	0.87
"Sufferers of allergic rhinitis often require antihistamine dosing regimens that continue over multiple days."	( Drowsiness and motor responses to consecutive daily doses of promethazine and loratadine. Anoopkumar-Dukie, S; Baumann-Birkbeck, L; Grant, GD; Kavanagh, JJ, 2014)	0.64
" Except for benzodiazepines, which were dosed higher in women than men, equal doses of sedation were given to female and male patients."	( Practice patterns of sedation for colonoscopy. Childers, RE; Sonnenberg, A; Williams, JL, 2015)	0.42
" Despite their abilities to avoid swallowing difficulties, frequency of dosing stood as a barrier for these formulations."	( Nano-engineering chitosan particles to sustain the release of promethazine from orodispersables. Al-Kinani, A; Alany, RG; ElShaer, A; Elwerfalli, AM, 2015)	0.66
" Hence, rationalising dosage and diet regimens should be taken into account in clinical application of PMT."	( Studies on the interaction between promethazine and human serum albumin in the presence of flavonoids by spectroscopic and molecular modeling techniques. Gao, YP; He, LL; Liu, B; Liu, XP; Wang, X; Wang, YX; Wang, ZX; Yang, YJ, 2016)	0.71
"Drug combinations are commonly used in pain management, which can produce potent analgesic effects with reduced dosage and adverse effects."	( Flupirtine and antihistamines exert synergistic anti-nociceptive effects in mice. Bao, Y; Chen, Y; Huang, C; Qin, H; Xiao, X; Zhang, G; Zhou, H; Zhu, J; Zhuang, T, 2023)	0.91

Role	Description
H1-receptor antagonist	H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
sedative	A central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
antiemetic	A drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors.
local anaesthetic	Any member of a group of drugs that reversibly inhibit the propagation of signals along nerves. Wide variations in potency, stability, toxicity, water-solubility and duration of action determine the route used for administration, e.g. topical, intravenous, epidural or spinal block.
antipruritic drug	A drug, usually applied topically, that relieves pruritus (itching).
anti-allergic agent	A drug used to treat allergic reactions.
anticoronaviral agent	Any antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
1-alkyl-3-methylimidazolium	An imidazolium ion with an alkyl substituent at the 1-position and a methyl substituent at the 3-position.
phenothiazines
tertiary amine	A compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Promethazine H1-Antihistamine Action	8	7

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
acetylcholinesterase	Homo sapiens (human)	Potency	0.7762	0.0025	41.7960	15,848.9004	AID1347398
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	10.9201	0.1000	20.8793	79.4328	AID488773; AID588453; AID588456
phosphopantetheinyl transferase	Bacillus subtilis	Potency	50.1187	0.1413	37.9142	100.0000	AID1490
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	25.4905	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
GLS protein	Homo sapiens (human)	Potency	17.7828	0.3548	7.9355	39.8107	AID624146
TDP1 protein	Homo sapiens (human)	Potency	25.6651	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	12.3845	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	26.1191	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	39.8107	0.0112	12.4002	100.0000	AID1030
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	29.8493	0.0006	57.9133	22,387.1992	AID1259378
progesterone receptor	Homo sapiens (human)	Potency	2.9849	0.0004	17.9460	75.1148	AID1346795
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	23.7555	0.5318	15.4358	37.6858	AID504845
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	10.9640	0.0123	7.9835	43.2770	AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	26.8325	0.0002	14.3764	60.0339	AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	28.4033	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	33.4915	0.0015	30.6073	15,848.9004	AID1224841; AID1259401
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	27.4681	0.0002	29.3054	16,493.5996	AID743069; AID743075; AID743077; AID743078; AID743079; AID743091
cytochrome P450 2D6	Homo sapiens (human)	Potency	2.4545	0.0010	8.3798	61.1304	AID1645840
glucocerebrosidase	Homo sapiens (human)	Potency	17.7828	0.0126	8.1569	44.6684	AID2101
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	23.3129	0.0355	20.9770	89.1251	AID504332; AID588346
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	15.0890	19.7391	45.9784	64.9432	AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	1.8721	0.0578	21.1097	61.2679	AID1159526; AID1159528
D(1A) dopamine receptor	Homo sapiens (human)	Potency	6.6321	0.0224	5.9449	22.3872	AID488982; AID488983
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	100.0000	0.3548	28.0659	89.1251	AID504847
chromobox protein homolog 1	Homo sapiens (human)	Potency	39.8107	0.0060	26.1688	89.1251	AID488953
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	11.2202	0.0178	9.6374	44.6684	AID588834
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	27.1236	0.0003	23.4451	159.6830	AID743065; AID743067
huntingtin isoform 2	Homo sapiens (human)	Potency	28.1838	0.0006	18.4198	1,122.0200	AID1688
serine/threonine-protein kinase mTOR isoform 1	Homo sapiens (human)	Potency	14.6892	0.0037	8.6189	23.2809	AID2667; AID2668
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	27.3060	0.0006	27.2152	1,122.0200	AID651741
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	16.1366	0.0056	12.3677	36.1254	AID624032
M-phase phosphoprotein 8	Homo sapiens (human)	Potency	26.6795	0.1778	24.7352	79.4328	AID488949
lamin isoform A-delta10	Homo sapiens (human)	Potency	0.0562	0.8913	12.0676	28.1838	AID1487
Cellular tumor antigen p53	Homo sapiens (human)	Potency	33.4915	0.0023	19.5956	74.0614	AID651631
D(1A) dopamine receptor	Sus scrofa (pig)	Potency	14.6892	0.0037	8.1081	23.2809	AID2667
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	35.4813	0.0096	10.5250	35.4813	AID1479145
Inositol monophosphatase 1	Rattus norvegicus (Norway rat)	Potency	1.4125	1.0000	10.4756	28.1838	AID1457
Ataxin-2	Homo sapiens (human)	Potency	17.7828	0.0119	12.2221	68.7989	AID588378
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	33.8078	0.0601	10.7453	37.9330	AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Spike glycoprotein	Betacoronavirus England 1	IC50 (µMol)	13.6450	0.0300	2.7283	9.5100	AID1804127
Replicase polyprotein 1ab	Betacoronavirus England 1	IC50 (µMol)	13.6450	0.0040	3.4388	9.5100	AID1804127
Solute carrier family 22 member 1	Homo sapiens (human)	IC50 (µMol)	35.1000	0.2100	5.5537	10.0000	AID386625
Transmembrane protease serine 2	Homo sapiens (human)	IC50 (µMol)	13.6450	0.0180	2.6198	9.5100	AID1804127
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
5-hydroxytryptamine receptor 4	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	0.0120	0.0001	1.0076	8.7800	AID625218
5-hydroxytryptamine receptor 4	Cavia porcellus (domestic guinea pig)	Ki	0.0065	0.0000	0.8871	10.0000	AID625218
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	134.0000	0.1100	7.1903	10.0000	AID1443980; AID1473738
Procathepsin L	Homo sapiens (human)	IC50 (µMol)	13.6450	0.0002	1.6661	9.5100	AID1804127
Aldo-keto reductase family 1 member B1	Rattus norvegicus (Norway rat)	IC50 (µMol)	4.2380	0.0004	1.8773	10.0000	AID625207
Aldo-keto reductase family 1 member B1	Rattus norvegicus (Norway rat)	Ki	4.2030	0.0032	2.2887	9.3160	AID625207
Muscarinic acetylcholine receptor M2	Homo sapiens (human)	IC50 (µMol)	0.0350	0.0000	1.2326	7.7930	AID625152
Muscarinic acetylcholine receptor M2	Homo sapiens (human)	Ki	0.0120	0.0000	0.6902	10.0000	AID625152
Muscarinic acetylcholine receptor M4	Homo sapiens (human)	IC50 (µMol)	0.0076	0.0000	1.1546	7.5858	AID625154
Muscarinic acetylcholine receptor M4	Homo sapiens (human)	Ki	0.0011	0.0000	0.7951	9.1201	AID625154
Muscarinic acetylcholine receptor M5	Homo sapiens (human)	IC50 (µMol)	0.0046	0.0001	0.9917	8.0000	AID625155
Muscarinic acetylcholine receptor M5	Homo sapiens (human)	Ki	0.0033	0.0000	0.7292	6.9183	AID625155
Alpha-2A adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	0.6810	0.0000	1.4421	7.3470	AID625201
Alpha-2A adrenergic receptor	Homo sapiens (human)	Ki	0.2560	0.0001	0.8074	10.0000	AID625201
Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus	IC50 (µMol)	13.6450	0.0300	2.2971	9.5100	AID1804127
Replicase polyprotein 1ab	Human coronavirus 229E	IC50 (µMol)	13.6450	0.0300	2.1441	9.5100	AID1804127
Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus	IC50 (µMol)	13.6450	0.0040	2.9266	9.9600	AID1804127
Calmodulin-1	Homo sapiens (human)	IC50 (µMol)	60.0000	5.1700	6.8100	8.0000	AID1297610
Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2	IC50 (µMol)	13.6450	0.0002	2.4585	9.9600	AID1804127
Muscarinic acetylcholine receptor M1	Homo sapiens (human)	IC50 (µMol)	0.0140	0.0000	1.4039	10.0000	AID625151
Muscarinic acetylcholine receptor M1	Homo sapiens (human)	Ki	0.0033	0.0000	0.5972	9.1201	AID625151
D(2) dopamine receptor	Homo sapiens (human)	IC50 (µMol)	0.4395	0.0000	0.7472	8.0000	AID1054120; AID625253
D(2) dopamine receptor	Homo sapiens (human)	Ki	0.2600	0.0000	0.6518	10.0000	AID625253
Alpha-2B adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	0.0530	0.0000	1.2380	8.1590	AID625202
Alpha-2B adrenergic receptor	Homo sapiens (human)	Ki	0.0240	0.0002	0.7257	10.0000	AID625202
Alpha-2C adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	2.4310	0.0000	1.4725	7.8980	AID625203
Alpha-2C adrenergic receptor	Homo sapiens (human)	Ki	0.3530	0.0003	0.4834	10.0000	AID625203
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.5960	0.0003	1.3833	8.4000	AID625190
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	Ki	1.4840	0.0001	0.7396	10.0000	AID625190
Muscarinic acetylcholine receptor M3	Homo sapiens (human)	IC50 (µMol)	0.0200	0.0001	1.0104	9.9280	AID625153
Muscarinic acetylcholine receptor M3	Homo sapiens (human)	Ki	0.0041	0.0000	0.5405	7.7600	AID625153
D(1A) dopamine receptor	Homo sapiens (human)	IC50 (µMol)	2.7440	0.0003	1.8473	9.2250	AID625252
D(1A) dopamine receptor	Homo sapiens (human)	Ki	1.3720	0.0001	0.8363	10.0000	AID625252
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	IC50 (µMol)	4.2380	0.0008	1.5416	20.0000	AID625207
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	Ki	4.2030	0.0003	1.4656	10.0000	AID625207
Histamine H2 receptor	Homo sapiens (human)	IC50 (µMol)	1.1650	0.0220	2.2987	10.0000	AID625270
Histamine H2 receptor	Homo sapiens (human)	Ki	1.1460	0.0006	2.1973	10.0000	AID625270
Alpha-1D adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	0.1830	0.0002	0.7568	8.8970	AID625200
Alpha-1D adrenergic receptor	Homo sapiens (human)	Ki	0.0900	0.0000	0.3609	10.0000	AID625200
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	IC50 (µMol)	0.0450	0.0001	0.8801	8.8500	AID1054119; AID625192
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	Ki	0.0190	0.0000	0.3855	10.0000	AID625192
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	IC50 (µMol)	0.0120	0.0001	1.0302	9.0000	AID625218
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	Ki	0.0065	0.0001	0.9549	10.0000	AID625218
5-hydroxytryptamine receptor 1B	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.5960	0.0005	1.4835	7.8000	AID625190
5-hydroxytryptamine receptor 1B	Rattus norvegicus (Norway rat)	Ki	1.4840	0.0003	1.2967	9.2440	AID625190
Trypanothione reductase	Trypanosoma cruzi	IC50 (µMol)	271.0000	5.8000	5.8000	5.8000	AID214488
Trypanothione reductase	Trypanosoma cruzi	Ki	216.0000	0.0760	5.1529	7.6000	AID214654
Sodium-dependent serotonin transporter	Homo sapiens (human)	IC50 (µMol)	5.8000	0.0001	0.8645	8.7096	AID1054118; AID625222
Sodium-dependent serotonin transporter	Homo sapiens (human)	Ki	2.1300	0.0000	0.7048	8.1930	AID625222
Pleiotropic ABC efflux transporter of multiple drugs	Saccharomyces cerevisiae S288C	IC50 (µMol)	17.7000	1.3000	3.3727	9.6000	AID581672
Histamine H1 receptor	Homo sapiens (human)	IC50 (µMol)	0.0041	0.0000	0.4436	5.1768	AID1054121; AID625269
Histamine H1 receptor	Homo sapiens (human)	Ki	0.0003	0.0000	0.5110	10.0000	AID625269
D(3) dopamine receptor	Homo sapiens (human)	IC50 (µMol)	0.5590	0.0001	1.0178	8.7960	AID625254
D(3) dopamine receptor	Homo sapiens (human)	Ki	0.1900	0.0000	0.6020	10.0000	AID625254
5-hydroxytryptamine receptor 2B	Homo sapiens (human)	IC50 (µMol)	0.0680	0.0001	1.1873	8.9125	AID625217
5-hydroxytryptamine receptor 2B	Homo sapiens (human)	Ki	0.0430	0.0003	0.7693	10.0000	AID625217
5-hydroxytryptamine receptor 6	Homo sapiens (human)	IC50 (µMol)	2.4290	0.0017	0.8381	5.4200	AID625221
5-hydroxytryptamine receptor 6	Homo sapiens (human)	Ki	1.1280	0.0002	0.5229	10.0000	AID625221
5-hydroxytryptamine receptor 7	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	35.1000	2.0300	5.5313	9.9000	AID386625
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	IC50 (µMol)	13.6450	0.0300	2.7731	9.5100	AID1804127
Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)	IC50 (µMol)	18.0000	0.0400	4.1137	10.0000	AID1850268
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Sigma non-opioid intracellular receptor 1	Homo sapiens (human)	IC50 (µMol)	0.2870	0.0003	0.7028	5.3660	AID625223
Sigma non-opioid intracellular receptor 1	Homo sapiens (human)	Ki	0.1200	0.0000	0.4901	10.0000	AID625223
Angiotensin-converting enzyme 2	Homo sapiens (human)	IC50 (µMol)	13.6450	0.0004	2.2079	10.0000	AID1804127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Spike glycoprotein	Betacoronavirus England 1	EC50 (µMol)	9.6700	0.0030	4.5755	9.8200	AID1804127
Replicase polyprotein 1ab	Betacoronavirus England 1	EC50 (µMol)	9.6700	0.0030	4.5755	9.8200	AID1804127
Transmembrane protease serine 2	Homo sapiens (human)	EC50 (µMol)	9.6700	0.0030	4.5168	9.8200	AID1804127
Major prion protein	Homo sapiens (human)	EC50 (µMol)	8.0000	0.3000	4.9000	10.0000	AID161627
Procathepsin L	Homo sapiens (human)	EC50 (µMol)	9.6700	0.0030	4.4874	9.8200	AID1804127
Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus	EC50 (µMol)	9.6700	0.0030	4.6136	9.8200	AID1804127
Replicase polyprotein 1ab	Human coronavirus 229E	EC50 (µMol)	9.6700	0.0030	4.6136	9.8200	AID1804127
Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus	EC50 (µMol)	9.6700	0.0030	4.4554	9.8200	AID1804127
Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2	EC50 (µMol)	9.6700	0.0030	4.1105	9.8200	AID1804127
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	EC50 (µMol)	9.6700	0.0030	4.5755	9.8200	AID1804127
Calmodulin	Bos taurus (cattle)	Kd	50.0000	1.8000	2.9333	3.5000	AID1297606
Angiotensin-converting enzyme 2	Homo sapiens (human)	EC50 (µMol)	9.6700	0.0030	4.5755	9.8200	AID1804127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Snq2p	Saccharomyces cerevisiae EC1118	INH	117.0000	3.2000	6.2600	8.8000	AID581808
Pleiotropic ABC efflux transporter of multiple drugs	Saccharomyces cerevisiae S288C	INH	285.0000	4.2000	6.1833	8.3000	AID581806
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 1	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 1	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 1	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
metanephric proximal tubule development	Solute carrier family 22 member 1	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
monoatomic cation transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
acyl carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
viral translation	Transmembrane protease serine 2	Homo sapiens (human)
proteolysis	Transmembrane protease serine 2	Homo sapiens (human)
protein autoprocessing	Transmembrane protease serine 2	Homo sapiens (human)
positive regulation of viral entry into host cell	Transmembrane protease serine 2	Homo sapiens (human)
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cellular response to copper ion	Major prion protein	Homo sapiens (human)
negative regulation of protein phosphorylation	Major prion protein	Homo sapiens (human)
intracellular copper ion homeostasis	Major prion protein	Homo sapiens (human)
response to oxidative stress	Major prion protein	Homo sapiens (human)
learning or memory	Major prion protein	Homo sapiens (human)
long-term memory	Major prion protein	Homo sapiens (human)
negative regulation of protein processing	Major prion protein	Homo sapiens (human)
protein destabilization	Major prion protein	Homo sapiens (human)
negative regulation of type II interferon production	Major prion protein	Homo sapiens (human)
negative regulation of interleukin-17 production	Major prion protein	Homo sapiens (human)
negative regulation of interleukin-2 production	Major prion protein	Homo sapiens (human)
negative regulation of apoptotic process	Major prion protein	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Major prion protein	Homo sapiens (human)
positive regulation of neuron apoptotic process	Major prion protein	Homo sapiens (human)
negative regulation of activated T cell proliferation	Major prion protein	Homo sapiens (human)
response to cadmium ion	Major prion protein	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Major prion protein	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Major prion protein	Homo sapiens (human)
positive regulation of calcium-mediated signaling	Major prion protein	Homo sapiens (human)
negative regulation of T cell receptor signaling pathway	Major prion protein	Homo sapiens (human)
protein homooligomerization	Major prion protein	Homo sapiens (human)
regulation of cell cycle	Major prion protein	Homo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascade	Major prion protein	Homo sapiens (human)
cellular response to xenobiotic stimulus	Major prion protein	Homo sapiens (human)
positive regulation of protein targeting to membrane	Major prion protein	Homo sapiens (human)
dendritic spine maintenance	Major prion protein	Homo sapiens (human)
negative regulation of long-term synaptic potentiation	Major prion protein	Homo sapiens (human)
regulation of glutamate receptor signaling pathway	Major prion protein	Homo sapiens (human)
positive regulation of glutamate receptor signaling pathway	Major prion protein	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Major prion protein	Homo sapiens (human)
negative regulation of amyloid-beta formation	Major prion protein	Homo sapiens (human)
negative regulation of dendritic spine maintenance	Major prion protein	Homo sapiens (human)
negative regulation of amyloid precursor protein catabolic process	Major prion protein	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Major prion protein	Homo sapiens (human)
response to amyloid-beta	Major prion protein	Homo sapiens (human)
cellular response to amyloid-beta	Major prion protein	Homo sapiens (human)
regulation of calcium ion import across plasma membrane	Major prion protein	Homo sapiens (human)
neuron projection maintenance	Major prion protein	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
adaptive immune response	Procathepsin L	Homo sapiens (human)
proteolysis	Procathepsin L	Homo sapiens (human)
protein autoprocessing	Procathepsin L	Homo sapiens (human)
fusion of virus membrane with host plasma membrane	Procathepsin L	Homo sapiens (human)
receptor-mediated endocytosis of virus by host cell	Procathepsin L	Homo sapiens (human)
antigen processing and presentation	Procathepsin L	Homo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class II	Procathepsin L	Homo sapiens (human)
collagen catabolic process	Procathepsin L	Homo sapiens (human)
zymogen activation	Procathepsin L	Homo sapiens (human)
enkephalin processing	Procathepsin L	Homo sapiens (human)
fusion of virus membrane with host endosome membrane	Procathepsin L	Homo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitment	Procathepsin L	Homo sapiens (human)
symbiont entry into host cell	Procathepsin L	Homo sapiens (human)
antigen processing and presentation of peptide antigen	Procathepsin L	Homo sapiens (human)
proteolysis involved in protein catabolic process	Procathepsin L	Homo sapiens (human)
elastin catabolic process	Procathepsin L	Homo sapiens (human)
macrophage apoptotic process	Procathepsin L	Homo sapiens (human)
cellular response to thyroid hormone stimulus	Procathepsin L	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Procathepsin L	Homo sapiens (human)
positive regulation of peptidase activity	Procathepsin L	Homo sapiens (human)
immune response	Procathepsin L	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
regulation of heart contraction	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
response to virus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
cell surface receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
regulation of locomotion	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
gastric acid secretion	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
dopamine transport	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
transmission of nerve impulse	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylation	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
positive regulation of cytokine production	Alpha-2A adrenergic receptor	Homo sapiens (human)
DNA replication	Alpha-2A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
Ras protein signal transduction	Alpha-2A adrenergic receptor	Homo sapiens (human)
Rho protein signal transduction	Alpha-2A adrenergic receptor	Homo sapiens (human)
female pregnancy	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2A adrenergic receptor	Homo sapiens (human)
actin cytoskeleton organization	Alpha-2A adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of cell migration	Alpha-2A adrenergic receptor	Homo sapiens (human)
activation of protein kinase activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
cellular response to hormone stimulus	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2A adrenergic receptor	Homo sapiens (human)
vasodilation	Alpha-2A adrenergic receptor	Homo sapiens (human)
glucose homeostasis	Alpha-2A adrenergic receptor	Homo sapiens (human)
fear response	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of potassium ion transport	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion-dependent exocytosis	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2A adrenergic receptor	Homo sapiens (human)
intestinal absorption	Alpha-2A adrenergic receptor	Homo sapiens (human)
thermoception	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of lipid catabolic process	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of membrane protein ectodomain proteolysis	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion transport	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulus	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of uterine smooth muscle contraction	Alpha-2A adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathway	Alpha-2A adrenergic receptor	Homo sapiens (human)
positive regulation of wound healing	Alpha-2A adrenergic receptor	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Alpha-2A adrenergic receptor	Homo sapiens (human)
negative regulation of calcium ion transmembrane transporter activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modification	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modification	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
G2/M transition of mitotic cell cycle	Calmodulin-1	Homo sapiens (human)
regulation of heart rate	Calmodulin-1	Homo sapiens (human)
detection of calcium ion	Calmodulin-1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Calmodulin-1	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Calmodulin-1	Homo sapiens (human)
negative regulation of peptidyl-threonine phosphorylation	Calmodulin-1	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum	Calmodulin-1	Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion	Calmodulin-1	Homo sapiens (human)
autophagosome membrane docking	Calmodulin-1	Homo sapiens (human)
substantia nigra development	Calmodulin-1	Homo sapiens (human)
positive regulation of protein autophosphorylation	Calmodulin-1	Homo sapiens (human)
regulation of cytokinesis	Calmodulin-1	Homo sapiens (human)
positive regulation of phosphoprotein phosphatase activity	Calmodulin-1	Homo sapiens (human)
positive regulation of protein dephosphorylation	Calmodulin-1	Homo sapiens (human)
cellular response to interferon-beta	Calmodulin-1	Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STAT	Calmodulin-1	Homo sapiens (human)
regulation of calcium-mediated signaling	Calmodulin-1	Homo sapiens (human)
positive regulation of cyclic-nucleotide phosphodiesterase activity	Calmodulin-1	Homo sapiens (human)
response to calcium ion	Calmodulin-1	Homo sapiens (human)
regulation of cardiac muscle contraction	Calmodulin-1	Homo sapiens (human)
regulation of ryanodine-sensitive calcium-release channel activity	Calmodulin-1	Homo sapiens (human)
negative regulation of ryanodine-sensitive calcium-release channel activity	Calmodulin-1	Homo sapiens (human)
positive regulation of ryanodine-sensitive calcium-release channel activity	Calmodulin-1	Homo sapiens (human)
cellular response to type II interferon	Calmodulin-1	Homo sapiens (human)
positive regulation of protein serine/threonine kinase activity	Calmodulin-1	Homo sapiens (human)
regulation of cardiac muscle cell action potential	Calmodulin-1	Homo sapiens (human)
organelle localization by membrane tethering	Calmodulin-1	Homo sapiens (human)
negative regulation of high voltage-gated calcium channel activity	Calmodulin-1	Homo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conduction	Calmodulin-1	Homo sapiens (human)
negative regulation of calcium ion export across plasma membrane	Calmodulin-1	Homo sapiens (human)
mitochondrion-endoplasmic reticulum membrane tethering	Calmodulin-1	Homo sapiens (human)
positive regulation of monoatomic ion transport	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
neuromuscular synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of locomotion	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
saliva secretion	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cognition	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of postsynaptic membrane potential	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of glial cell proliferation	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
positive regulation of intracellular protein transport	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
temperature homeostasis	D(2) dopamine receptor	Homo sapiens (human)
response to hypoxia	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of protein phosphorylation	D(2) dopamine receptor	Homo sapiens (human)
response to amphetamine	D(2) dopamine receptor	Homo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressure	D(2) dopamine receptor	Homo sapiens (human)
regulation of heart rate	D(2) dopamine receptor	Homo sapiens (human)
regulation of sodium ion transport	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor internalization	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of neuroblast proliferation	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of receptor internalization	D(2) dopamine receptor	Homo sapiens (human)
autophagy	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
neuron-neuron synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
neuroblast proliferation	D(2) dopamine receptor	Homo sapiens (human)
axonogenesis	D(2) dopamine receptor	Homo sapiens (human)
synapse assembly	D(2) dopamine receptor	Homo sapiens (human)
sensory perception of smell	D(2) dopamine receptor	Homo sapiens (human)
long-term memory	D(2) dopamine receptor	Homo sapiens (human)
grooming behavior	D(2) dopamine receptor	Homo sapiens (human)
locomotory behavior	D(2) dopamine receptor	Homo sapiens (human)
adult walking behavior	D(2) dopamine receptor	Homo sapiens (human)
protein localization	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cell population proliferation	D(2) dopamine receptor	Homo sapiens (human)
associative learning	D(2) dopamine receptor	Homo sapiens (human)
visual learning	D(2) dopamine receptor	Homo sapiens (human)
response to xenobiotic stimulus	D(2) dopamine receptor	Homo sapiens (human)
response to light stimulus	D(2) dopamine receptor	Homo sapiens (human)
response to toxic substance	D(2) dopamine receptor	Homo sapiens (human)
response to iron ion	D(2) dopamine receptor	Homo sapiens (human)
response to inactivity	D(2) dopamine receptor	Homo sapiens (human)
Wnt signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
striatum development	D(2) dopamine receptor	Homo sapiens (human)
orbitofrontal cortex development	D(2) dopamine receptor	Homo sapiens (human)
cerebral cortex GABAergic interneuron migration	D(2) dopamine receptor	Homo sapiens (human)
adenohypophysis development	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cell migration	D(2) dopamine receptor	Homo sapiens (human)
peristalsis	D(2) dopamine receptor	Homo sapiens (human)
auditory behavior	D(2) dopamine receptor	Homo sapiens (human)
regulation of synaptic transmission, GABAergic	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of cytokinesis	D(2) dopamine receptor	Homo sapiens (human)
circadian regulation of gene expression	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of dopamine secretion	D(2) dopamine receptor	Homo sapiens (human)
response to histamine	D(2) dopamine receptor	Homo sapiens (human)
response to nicotine	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of urine volume	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of renal sodium excretion	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of multicellular organism growth	D(2) dopamine receptor	Homo sapiens (human)
response to cocaine	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleep	D(2) dopamine receptor	Homo sapiens (human)
dopamine metabolic process	D(2) dopamine receptor	Homo sapiens (human)
drinking behavior	D(2) dopamine receptor	Homo sapiens (human)
regulation of potassium ion transport	D(2) dopamine receptor	Homo sapiens (human)
response to morphine	D(2) dopamine receptor	Homo sapiens (human)
pigmentation	D(2) dopamine receptor	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of blood pressure	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of innate immune response	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of insulin secretion	D(2) dopamine receptor	Homo sapiens (human)
acid secretion	D(2) dopamine receptor	Homo sapiens (human)
behavioral response to cocaine	D(2) dopamine receptor	Homo sapiens (human)
behavioral response to ethanol	D(2) dopamine receptor	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	D(2) dopamine receptor	Homo sapiens (human)
response to axon injury	D(2) dopamine receptor	Homo sapiens (human)
branching morphogenesis of a nerve	D(2) dopamine receptor	Homo sapiens (human)
arachidonic acid secretion	D(2) dopamine receptor	Homo sapiens (human)
epithelial cell proliferation	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of epithelial cell proliferation	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of protein secretion	D(2) dopamine receptor	Homo sapiens (human)
release of sequestered calcium ion into cytosol	D(2) dopamine receptor	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
regulation of dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
regulation of synapse structural plasticity	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	D(2) dopamine receptor	Homo sapiens (human)
excitatory postsynaptic potential	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of growth hormone secretion	D(2) dopamine receptor	Homo sapiens (human)
prepulse inhibition	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	D(2) dopamine receptor	Homo sapiens (human)
regulation of locomotion involved in locomotory behavior	D(2) dopamine receptor	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cellular response to hypoxia	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor production	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	D(2) dopamine receptor	Homo sapiens (human)
hyaloid vascular plexus regression	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of neuron migration	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cytosolic calcium ion concentration	D(2) dopamine receptor	Homo sapiens (human)
regulation of dopamine secretion	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of adenylate cyclase activity	D(2) dopamine receptor	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of voltage-gated calcium channel activity	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of MAPK cascade	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
MAPK cascade	Alpha-2B adrenergic receptor	Homo sapiens (human)
angiogenesis	Alpha-2B adrenergic receptor	Homo sapiens (human)
regulation of vascular associated smooth muscle contraction	Alpha-2B adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2B adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2B adrenergic receptor	Homo sapiens (human)
female pregnancy	Alpha-2B adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2B adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2B adrenergic receptor	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
secondary active organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
identical protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
serine-type endopeptidase activity	Transmembrane protease serine 2	Homo sapiens (human)
protein binding	Transmembrane protease serine 2	Homo sapiens (human)
serine-type peptidase activity	Transmembrane protease serine 2	Homo sapiens (human)
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
type 8 metabotropic glutamate receptor binding	Major prion protein	Homo sapiens (human)
amyloid-beta binding	Major prion protein	Homo sapiens (human)
protease binding	Major prion protein	Homo sapiens (human)
copper ion binding	Major prion protein	Homo sapiens (human)
protein binding	Major prion protein	Homo sapiens (human)
lamin binding	Major prion protein	Homo sapiens (human)
glycosaminoglycan binding	Major prion protein	Homo sapiens (human)
microtubule binding	Major prion protein	Homo sapiens (human)
tubulin binding	Major prion protein	Homo sapiens (human)
aspartic-type endopeptidase inhibitor activity	Major prion protein	Homo sapiens (human)
type 5 metabotropic glutamate receptor binding	Major prion protein	Homo sapiens (human)
signaling receptor activity	Major prion protein	Homo sapiens (human)
identical protein binding	Major prion protein	Homo sapiens (human)
ATP-dependent protein binding	Major prion protein	Homo sapiens (human)
transmembrane transporter binding	Major prion protein	Homo sapiens (human)
protein-containing complex binding	Major prion protein	Homo sapiens (human)
protein-folding chaperone binding	Major prion protein	Homo sapiens (human)
molecular adaptor activity	Major prion protein	Homo sapiens (human)
molecular function activator activity	Major prion protein	Homo sapiens (human)
molecular condensate scaffold activity	Major prion protein	Homo sapiens (human)
cupric ion binding	Major prion protein	Homo sapiens (human)
cuprous ion binding	Major prion protein	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
fibronectin binding	Procathepsin L	Homo sapiens (human)
cysteine-type endopeptidase activity	Procathepsin L	Homo sapiens (human)
protein binding	Procathepsin L	Homo sapiens (human)
collagen binding	Procathepsin L	Homo sapiens (human)
cysteine-type peptidase activity	Procathepsin L	Homo sapiens (human)
histone binding	Procathepsin L	Homo sapiens (human)
proteoglycan binding	Procathepsin L	Homo sapiens (human)
serpin family protein binding	Procathepsin L	Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic process	Procathepsin L	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
arrestin family protein binding	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein kinase binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha-1B adrenergic receptor binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
alpha-2C adrenergic receptor binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
thioesterase binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
heterotrimeric G-protein binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
norepinephrine binding	Alpha-2A adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2A adrenergic receptor	Homo sapiens (human)
RNA-dependent RNA polymerase activity	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activity	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activity	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activity	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
calcium ion binding	Calmodulin-1	Homo sapiens (human)
protein binding	Calmodulin-1	Homo sapiens (human)
adenylate cyclase activator activity	Calmodulin-1	Homo sapiens (human)
calcium channel inhibitor activity	Calmodulin-1	Homo sapiens (human)
protein kinase binding	Calmodulin-1	Homo sapiens (human)
titin binding	Calmodulin-1	Homo sapiens (human)
protein serine/threonine kinase activator activity	Calmodulin-1	Homo sapiens (human)
transmembrane transporter binding	Calmodulin-1	Homo sapiens (human)
calcium-dependent protein binding	Calmodulin-1	Homo sapiens (human)
protein phosphatase activator activity	Calmodulin-1	Homo sapiens (human)
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoesters	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
protein guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(2) dopamine receptor	Homo sapiens (human)
G-protein alpha-subunit binding	D(2) dopamine receptor	Homo sapiens (human)
protein binding	D(2) dopamine receptor	Homo sapiens (human)
heterotrimeric G-protein binding	D(2) dopamine receptor	Homo sapiens (human)
dopamine binding	D(2) dopamine receptor	Homo sapiens (human)
ionotropic glutamate receptor binding	D(2) dopamine receptor	Homo sapiens (human)
identical protein binding	D(2) dopamine receptor	Homo sapiens (human)
heterocyclic compound binding	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(2) dopamine receptor	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2B adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2B adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2B adrenergic receptor	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
signaling receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
acetylcholine binding	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gs	D(1A) dopamine receptor	Homo sapiens (human)
G-protein alpha-subunit binding	D(1A) dopamine receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity	D(1A) dopamine receptor	Homo sapiens (human)
protein binding	D(1A) dopamine receptor	Homo sapiens (human)
heterotrimeric G-protein binding	D(1A) dopamine receptor	Homo sapiens (human)
dopamine binding	D(1A) dopamine receptor	Homo sapiens (human)
arrestin family protein binding	D(1A) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(1A) dopamine receptor	Homo sapiens (human)
actin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
protein binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
alpha-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
beta-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
histamine receptor activity	Histamine H2 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H2 receptor	Homo sapiens (human)
neurotransmitter receptor activity	Histamine H2 receptor	Homo sapiens (human)
protein binding	Alpha-1D adrenergic receptor	Homo sapiens (human)
identical protein binding	Alpha-1D adrenergic receptor	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1D adrenergic receptor	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
virus receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein tyrosine kinase activator activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein-containing complex binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
integrin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoatomic cation channel activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin:sodium:chloride symporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
antiporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
syntaxin-1 binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
cocaine binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
identical protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
nitric-oxide synthase binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
actin filament binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
histamine receptor activity	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H1 receptor	Homo sapiens (human)
neurotransmitter receptor activity	Histamine H1 receptor	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(3) dopamine receptor	Homo sapiens (human)
protein binding	D(3) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(3) dopamine receptor	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G-protein alpha-subunit binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
GTPase activator activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
histamine receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 6	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
calcium ion binding	Calmodulin	Bos taurus (cattle)
protein binding	Calmodulin	Bos taurus (cattle)
protein domain specific binding	Calmodulin	Bos taurus (cattle)
amyloid-beta binding	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
calcium ion binding	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
protein binding	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
ATP binding	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
G protein-coupled opioid receptor activity	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
protein binding	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
virus receptor activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
endopeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
carboxypeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
metallocarboxypeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
protein binding	Angiotensin-converting enzyme 2	Homo sapiens (human)
metallopeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
peptidyl-dipeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
zinc ion binding	Angiotensin-converting enzyme 2	Homo sapiens (human)
identical protein binding	Angiotensin-converting enzyme 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
lateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
presynapse	Solute carrier family 22 member 1	Homo sapiens (human)
extracellular region	Transmembrane protease serine 2	Homo sapiens (human)
nucleoplasm	Transmembrane protease serine 2	Homo sapiens (human)
plasma membrane	Transmembrane protease serine 2	Homo sapiens (human)
extracellular exosome	Transmembrane protease serine 2	Homo sapiens (human)
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
dendrite	Major prion protein	Homo sapiens (human)
cytoplasm	Major prion protein	Homo sapiens (human)
endoplasmic reticulum	Major prion protein	Homo sapiens (human)
Golgi apparatus	Major prion protein	Homo sapiens (human)
cytosol	Major prion protein	Homo sapiens (human)
plasma membrane	Major prion protein	Homo sapiens (human)
external side of plasma membrane	Major prion protein	Homo sapiens (human)
cell surface	Major prion protein	Homo sapiens (human)
postsynaptic density	Major prion protein	Homo sapiens (human)
inclusion body	Major prion protein	Homo sapiens (human)
extrinsic component of membrane	Major prion protein	Homo sapiens (human)
nuclear membrane	Major prion protein	Homo sapiens (human)
terminal bouton	Major prion protein	Homo sapiens (human)
intracellular membrane-bounded organelle	Major prion protein	Homo sapiens (human)
membrane raft	Major prion protein	Homo sapiens (human)
extracellular exosome	Major prion protein	Homo sapiens (human)
postsynapse	Major prion protein	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
extracellular region	Procathepsin L	Homo sapiens (human)
extracellular space	Procathepsin L	Homo sapiens (human)
nucleus	Procathepsin L	Homo sapiens (human)
lysosome	Procathepsin L	Homo sapiens (human)
multivesicular body	Procathepsin L	Homo sapiens (human)
Golgi apparatus	Procathepsin L	Homo sapiens (human)
plasma membrane	Procathepsin L	Homo sapiens (human)
apical plasma membrane	Procathepsin L	Homo sapiens (human)
endolysosome lumen	Procathepsin L	Homo sapiens (human)
chromaffin granule	Procathepsin L	Homo sapiens (human)
lysosomal lumen	Procathepsin L	Homo sapiens (human)
intracellular membrane-bounded organelle	Procathepsin L	Homo sapiens (human)
collagen-containing extracellular matrix	Procathepsin L	Homo sapiens (human)
extracellular exosome	Procathepsin L	Homo sapiens (human)
endocytic vesicle lumen	Procathepsin L	Homo sapiens (human)
extracellular space	Procathepsin L	Homo sapiens (human)
lysosome	Procathepsin L	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
asymmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
symmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
neuronal cell body	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M5	Homo sapiens (human)
cytoplasm	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
basolateral plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
neuronal cell body	Alpha-2A adrenergic receptor	Homo sapiens (human)
axon terminus	Alpha-2A adrenergic receptor	Homo sapiens (human)
presynaptic active zone membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
dopaminergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
postsynaptic density membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
glutamatergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
GABA-ergic synapse	Alpha-2A adrenergic receptor	Homo sapiens (human)
receptor complex	Alpha-2A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2A adrenergic receptor	Homo sapiens (human)
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
spindle pole	Calmodulin-1	Homo sapiens (human)
extracellular region	Calmodulin-1	Homo sapiens (human)
nucleus	Calmodulin-1	Homo sapiens (human)
nucleoplasm	Calmodulin-1	Homo sapiens (human)
cytoplasm	Calmodulin-1	Homo sapiens (human)
centrosome	Calmodulin-1	Homo sapiens (human)
cytosol	Calmodulin-1	Homo sapiens (human)
spindle microtubule	Calmodulin-1	Homo sapiens (human)
plasma membrane	Calmodulin-1	Homo sapiens (human)
sarcomere	Calmodulin-1	Homo sapiens (human)
vesicle	Calmodulin-1	Homo sapiens (human)
myelin sheath	Calmodulin-1	Homo sapiens (human)
sperm midpiece	Calmodulin-1	Homo sapiens (human)
voltage-gated potassium channel complex	Calmodulin-1	Homo sapiens (human)
protein-containing complex	Calmodulin-1	Homo sapiens (human)
calcium channel complex	Calmodulin-1	Homo sapiens (human)
catalytic complex	Calmodulin-1	Homo sapiens (human)
cytoplasm	Calmodulin-1	Homo sapiens (human)
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic density membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
Golgi membrane	D(2) dopamine receptor	Homo sapiens (human)
acrosomal vesicle	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
cilium	D(2) dopamine receptor	Homo sapiens (human)
lateral plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
endocytic vesicle	D(2) dopamine receptor	Homo sapiens (human)
axon	D(2) dopamine receptor	Homo sapiens (human)
dendrite	D(2) dopamine receptor	Homo sapiens (human)
synaptic vesicle membrane	D(2) dopamine receptor	Homo sapiens (human)
sperm flagellum	D(2) dopamine receptor	Homo sapiens (human)
dendritic spine	D(2) dopamine receptor	Homo sapiens (human)
perikaryon	D(2) dopamine receptor	Homo sapiens (human)
axon terminus	D(2) dopamine receptor	Homo sapiens (human)
postsynaptic membrane	D(2) dopamine receptor	Homo sapiens (human)
ciliary membrane	D(2) dopamine receptor	Homo sapiens (human)
non-motile cilium	D(2) dopamine receptor	Homo sapiens (human)
dopaminergic synapse	D(2) dopamine receptor	Homo sapiens (human)
GABA-ergic synapse	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor complex	D(2) dopamine receptor	Homo sapiens (human)
glutamatergic synapse	D(2) dopamine receptor	Homo sapiens (human)
presynaptic membrane	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
cytosol	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2B adrenergic receptor	Homo sapiens (human)
cell surface	Alpha-2B adrenergic receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-2B adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2B adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-2C adrenergic receptor	Homo sapiens (human)
endosome	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
basal plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
basolateral plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
nucleus	D(1A) dopamine receptor	Homo sapiens (human)
endoplasmic reticulum membrane	D(1A) dopamine receptor	Homo sapiens (human)
plasma membrane	D(1A) dopamine receptor	Homo sapiens (human)
cilium	D(1A) dopamine receptor	Homo sapiens (human)
presynaptic membrane	D(1A) dopamine receptor	Homo sapiens (human)
dendritic spine	D(1A) dopamine receptor	Homo sapiens (human)
postsynaptic membrane	D(1A) dopamine receptor	Homo sapiens (human)
ciliary membrane	D(1A) dopamine receptor	Homo sapiens (human)
non-motile cilium	D(1A) dopamine receptor	Homo sapiens (human)
glutamatergic synapse	D(1A) dopamine receptor	Homo sapiens (human)
GABA-ergic synapse	D(1A) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor complex	D(1A) dopamine receptor	Homo sapiens (human)
plasma membrane	D(1A) dopamine receptor	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
cell surface	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
axon	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Histamine H2 receptor	Homo sapiens (human)
synapse	Histamine H2 receptor	Homo sapiens (human)
plasma membrane	Histamine H2 receptor	Homo sapiens (human)
dendrite	Histamine H2 receptor	Homo sapiens (human)
plasma membrane	Alpha-1D adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1D adrenergic receptor	Homo sapiens (human)
neurofilament	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
caveola	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
axon	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
cytoplasmic vesicle	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
presynaptic membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
neuronal cell body	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
dendritic shaft	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
cell body fiber	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
glutamatergic synapse	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
focal adhesion	Sodium-dependent serotonin transporter	Homo sapiens (human)
endosome membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
endomembrane system	Sodium-dependent serotonin transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane raft	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonergic synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
neuron projection	Sodium-dependent serotonin transporter	Homo sapiens (human)
cytosol	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H1 receptor	Homo sapiens (human)
synapse	Histamine H1 receptor	Homo sapiens (human)
dendrite	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	D(3) dopamine receptor	Homo sapiens (human)
synapse	D(3) dopamine receptor	Homo sapiens (human)
plasma membrane	D(3) dopamine receptor	Homo sapiens (human)
nucleoplasm	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cytoplasm	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 6	Homo sapiens (human)
cilium	5-hydroxytryptamine receptor 6	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 6	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 6	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 6	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
cytosol	Calmodulin	Bos taurus (cattle)
spindle pole	Calmodulin	Bos taurus (cattle)
cytoplasm	Calmodulin	Bos taurus (cattle)
protein-containing complex	Calmodulin	Bos taurus (cattle)
plasma membrane	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
synapse	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
neuronal cell body	Voltage-dependent N-type calcium channel subunit alpha-1B	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
nuclear envelope	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nuclear inner membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nuclear outer membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
lipid droplet	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cytosol	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
postsynaptic density	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
growth cone	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cytoplasmic vesicle	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
anchoring junction	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
postsynaptic density membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular region	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular space	Angiotensin-converting enzyme 2	Homo sapiens (human)
endoplasmic reticulum lumen	Angiotensin-converting enzyme 2	Homo sapiens (human)
plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
cilium	Angiotensin-converting enzyme 2	Homo sapiens (human)
cell surface	Angiotensin-converting enzyme 2	Homo sapiens (human)
membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
apical plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
endocytic vesicle membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
brush border membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
membrane raft	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular exosome	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular space	Angiotensin-converting enzyme 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID29359	Ionization constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID566889	Antifungal activity against Exophiala spinifera by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID311935	Partition coefficient, log P of the compound	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID214488	Inhibitory activity against recombinant Trypanosoma cruzi (Trypanosoma cruzi) Trypanothione reductase	1998	Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2	Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
AID158040	Concentration required to reduce chloroquine IC50 by 50%	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.
AID467613	Volume of distribution at steady state in human	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID386623	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1053264	Antagonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as inhibition of agonist-induced cAMP accumulation at 100 uM preincubated for 10 mins prior to agonist addition measured after 30 mins by HTRF assay relative t	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID205268	Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM	1985	Journal of medicinal chemistry, Mar, Volume: 28, Issue:3	[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1053266	Agonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as stimulation of cAMP accumulation at 100 uM after 30 mins by HTRF assay relative to SKF81297	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID566878	Antifungal activity against Candida parapsilosis by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1161117	Antimicrobial activity against Mycobacterium tuberculosis H37Ra after 5 days by serial macrobroth dilution method	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Incorporation of triphenylphosphonium functionality improves the inhibitory properties of phenothiazine derivatives in Mycobacterium tuberculosis.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID624608	Specific activity of expressed human recombinant UGT1A4	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26296	Partition coefficient (logD7.4)	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID467612	Fraction unbound in human plasma	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID624612	Specific activity of expressed human recombinant UGT1A9	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID23954	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26311	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID624609	Specific activity of expressed human recombinant UGT1A6	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID23976	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID75299	Inhibitory activity against human erythrocyte glutathione reductase; '*' indicates No inhibition	1998	Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2	Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
AID1297599	Association constant, pKa of the compound	2016	European journal of medicinal chemistry, Jun-30, Volume: 116	The chemosensitizing agent lubeluzole binds calmodulin and inhibits Ca(2+)/calmodulin-dependent kinase II.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID624607	Specific activity of expressed human recombinant UGT1A3	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID214654	Inhibitory activity against recombinant Trypanosoma cruzi (Trypanosoma cruzi) Trypanothione reductase (linear competitive type)	1998	Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2	Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID159177	Percent reversal against Plasmodium falciparum W2 at 1 uM DEEA	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1053262	Agonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin at 100 uM by luminometric analysis relative to quinpirol	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID158683	In vitro inhibitory activity against multidrug-resistant Plasmodium falciparum W2 Indochina	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID467611	Dissociation constant, pKa of the compound	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID186205	Log (1/ED50) was measured as histamine releasing activity in rat mast cells; log(1/ED50*10e-3).	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID29812	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1297610	Binding affinity to CaM (unknown origin) by equilibrium dialysis method	2016	European journal of medicinal chemistry, Jun-30, Volume: 116	The chemosensitizing agent lubeluzole binds calmodulin and inhibits Ca(2+)/calmodulin-dependent kinase II.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1054121	Binding affinity to histamine H1 receptor (unknown origin) by radioligand binding assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Polypharmacology - foe or friend?
AID1245889	Cytotoxicity against human NCI-H1650 cells assessed as growth inhibition after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Reengineered tricyclic anti-cancer agents.
AID23955	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID197541	pKa value was measured by water/octanol using shake-flask method.	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID23957	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID75529	Percentage decrease in bronchodilator activity against serotonin-induced bronchospasm reaction in guinea pig by intraveneous administration at dose 250 ug/kg	1985	Journal of medicinal chemistry, May, Volume: 28, Issue:5	New antihistaminic theophylline or theobromine derivatives.
AID25603	Dissociation constant was reported	1981	Journal of medicinal chemistry, Nov, Volume: 24, Issue:11	Side-chain effects on phenothiazine cation radical reactions.
AID173540	Percentage decrease in antiallergic activity against cutaneous reaction to histamine in rat, by oral administration at a dose of 10 mg/kg	1985	Journal of medicinal chemistry, May, Volume: 28, Issue:5	New antihistaminic theophylline or theobromine derivatives.
AID1155068	Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes plasma membrane assessed as reduction of [3H]-chloroquine transportation after 1 to 2 hrs	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Chlorpheniramine Analogues Reverse Chloroquine Resistance in Plasmodium falciparum by Inhibiting PfCRT.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID51927	Cytotoxicity against Chinese hamster ovary cells	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.
AID7783	Unbound fraction (plasma)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID70546	In vitro hemolytic concentration on uninfected erythrocytes.	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID160026	Accumulation coefficient of chloroquine at 1 uM-10 uM of DEEA against Plasmodium falciparum W2; Range is from 37-42	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.
AID566884	Antifungal activity against Aspergillus flavus by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID311934	Dissociation constant, pKa of the compound	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1891669	Inhibition of quorum sensing system in Chromobacterium violaceum wild type 85 assessed as reduction in pigment production incubated for 24 to 48 hrs	2022	Bioorganic & medicinal chemistry letters, 07-01, Volume: 67	New diarylpentanoids and chalcones as potential antimicrobial adjuvants.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID23970	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1054119	Binding affinity to 5HT2A receptor (unknown origin) by radioligand binding assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Polypharmacology - foe or friend?
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1727546	Inhibition of erastin-induced ferroptosis in human HT-1080 cells assessed as cell viability incubated for 48 hrs by MTT assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Structure-activity relationship studies of phenothiazine derivatives as a new class of ferroptosis inhibitors together with the therapeutic effect in an ischemic stroke model.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID27587	Partition coefficient (logP)	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.
AID23973	Partition coefficient (logD, measured by HPLC, log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID566887	Antifungal activity against Aspergillus terreus by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID29338	Dissociation constant (pKa)	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID173539	Percent decrease in antiallergic activity by antigen/antibody reaction assay in rat by oral administration at a dose of 10 mg/kg	1985	Journal of medicinal chemistry, May, Volume: 28, Issue:5	New antihistaminic theophylline or theobromine derivatives.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID566883	Antifungal activity against Aspergillus fumigates by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID311933	Inhibition of ASM in rat PC12 cells assessed as residual activity at 10 uM	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID75527	Percent decrease in bronchodilator activity against acetylcholine-induced bronchospasm reaction in guinea pig by intraveneous administration at dose 250 ug/kg	1985	Journal of medicinal chemistry, May, Volume: 28, Issue:5	New antihistaminic theophylline or theobromine derivatives.
AID781330	pKa (acid-base dissociation constant) as determined by potentiometric titration	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID581807	Inhibition of Saccharomyces cerevisiae MKCDR1h multidrug transporter Cdr1p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID8002	Observed volume of distribution	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID566881	Antifungal activity against Candida guilliermondii by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID566888	Antifungal activity against Cladophialophora carrionii by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID781326	pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID23956	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID566880	Antifungal activity against Candida krusei by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID566882	Antifungal activity against Cryptococcus neoformans by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1054118	Binding affinity to SERT (unknown origin) by radioligand binding assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Polypharmacology - foe or friend?
AID23968	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID28681	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1891670	Inhibition of quorum sensing system in Serratia marcescens AS-1 assessed as reduction in pigment production incubated for 24 to 48 hrs	2022	Bioorganic & medicinal chemistry letters, 07-01, Volume: 67	New diarylpentanoids and chalcones as potential antimicrobial adjuvants.
AID23958	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID781328	pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1850268	Inhibition of endogenous human CaV2.2 in human SH-SY5Y cells in presence of nifedipine by Calcium 4 dye based calcium influx fluorescence-imaging assay	2022	RSC medicinal chemistry, Feb-23, Volume: 13, Issue:2	Inhibition of N-type calcium ion channels by tricyclic antidepressants - experimental and theoretical justification for their use for neuropathic pain.
AID581808	Inhibition of Saccharomyces cerevisiae MKSNQ2h multidrug transporter Snq2p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.
AID386625	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID161627	Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells	2003	Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17	Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID581672	Inhibition of Pdr5p-mediated rhodamine 6G transport in Saccharomyces cerevisiae MKPDR5h plasma membrane by spectrofluorometric assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.
AID205267	Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex	1985	Journal of medicinal chemistry, Mar, Volume: 28, Issue:3	[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1053260	Antagonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin assessed as inhibition of agonist-induced effect at 50 uM after 15 mins by luminometric analysis relative to haloperidol	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID566877	Antifungal activity against Candida albicans by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID23960	logD (measured by HPLC) (as log k')	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1155066	Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes plasma membrane assessed as reduction of [3H]-chloroquine transportation at 100 uM after 1 to 2 hrs	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Chlorpheniramine Analogues Reverse Chloroquine Resistance in Plasmodium falciparum by Inhibiting PfCRT.
AID566879	Antifungal activity against Candida glabrata by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID680715	TP_TRANSPORTER: increase in Rhodamine 123 intracellular accumulation (R123: 150 uM, Promethazine: 20 ug/mL) in MDR1-expressing NIH3T3 cells	2000	The Journal of pharmacology and experimental therapeutics, Dec, Volume: 295, Issue:3	Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID26310	Partition coefficient (logD7.4)	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1891671	Inhibition of quorum sensing system in Chromobacterium violaceum CV026 assessed as reduction in pigment production co-cultured with Sphingomonas paucimobilis Ezf 10-17 for 24 to 48 hrs	2022	Bioorganic & medicinal chemistry letters, 07-01, Volume: 67	New diarylpentanoids and chalcones as potential antimicrobial adjuvants.
AID146870	The compound was tested for its ability to inhibit Na+/K+ ATPase in rat brain.	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID75528	Percent decrease in bronchodilator activity against histamine-induced bronchospasm reaction in guinea pig by intraveneous administration at dose 250 ug/kg	1985	Journal of medicinal chemistry, May, Volume: 28, Issue:5	New antihistaminic theophylline or theobromine derivatives.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID566885	Antifungal activity against Aspergillus niger by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID566890	Antifungal activity against Exophiala oligosperma by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1891667	Inhibition of biofilm formation in Staphylococcus aureus ATCC 25923 at 100 uM incubated for 48 hrs by crystal violet staining based analysis	2022	Bioorganic & medicinal chemistry letters, 07-01, Volume: 67	New diarylpentanoids and chalcones as potential antimicrobial adjuvants.
AID781329	pKa (acid-base dissociation constant) as determined by other workers	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID581806	Inhibition of Saccharomyces cerevisiae MKPDR5h multidrug transporter Pdr5p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.
AID103232	Anti MDR activity was expressed as MDR ratio or MDR fold reversal in doxorubicin resistant human breast carcinoma tumor cell line MCF-7/DOX	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26362	Ionization constant (pKa)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1148003	Dissociation constant, pKa of the compound by UV-visible spectrophotometer analysis	1977	Journal of medicinal chemistry, Mar, Volume: 20, Issue:3	Quantitative correlations between albumin binding constants and chromatographic Rm values of phenothiazine derivatives.
AID566891	Antifungal activity against Exophiala xenobiotica by microdilution test	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1891668	Inhibition of biofilm formation in Staphylococcus aureus 272123 at 100 uM incubated for 48 hrs by crystal violet staining based analysis	2022	Bioorganic & medicinal chemistry letters, 07-01, Volume: 67	New diarylpentanoids and chalcones as potential antimicrobial adjuvants.
AID27167	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID588208	Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset	2010	Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5	Predicting phospholipidosis using machine learning.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID27572	Partition coefficient (logD7.0)	2002	Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15	Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.
AID1297606	Binding affinity to bovine brain CaM by FTPFACE analysis	2016	European journal of medicinal chemistry, Jun-30, Volume: 116	The chemosensitizing agent lubeluzole binds calmodulin and inhibits Ca(2+)/calmodulin-dependent kinase II.
AID1054120	Binding affinity to dopamine D2 receptor (unknown origin) by radioligand binding assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Polypharmacology - foe or friend?
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508629	Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508628	Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627	Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346037	Human H1 receptor (Histamine receptors)	2006	Bioorganic & medicinal chemistry, Oct-01, Volume: 14, Issue:19	Novel ligands for the human histamine H1 receptor: synthesis, pharmacology, and comparative molecular field analysis studies of 2-dimethylamino-5-(6)-phenyl-1,2,3,4-tetrahydronaphthalenes.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1804127	No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\	2021	Medicinal research reviews, 01, Volume: 41, Issue:1	The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1981 (71.62)	18.7374
1990's	265 (9.58)	18.2507
2000's	241 (8.71)	29.6817
2010's	224 (8.10)	24.3611
2020's	55 (1.99)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Trials	299 (9.61%)	5.53%
Reviews	2 (8.70%)	6.00%
Reviews	72 (2.32%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	199 (6.40%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	1 (0.03%)	0.25%
Other	21 (91.30%)	84.16%
Other	2,539 (81.64%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (203)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Pilot Study of Intensified Lymphodepletion Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Systemic Lupus Erythematosus [NCT00076752]	Phase 2	9 participants (Actual)	Interventional	2004-01-30	Completed
Pharmacological Anxiolysis With Promethazine as an Adjunctive Therapy for Acute Low Back Pain in the Adult Emergency Department [NCT01129934]	Phase 4	200 participants (Anticipated)	Interventional	2010-05-31	Not yet recruiting
A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain, With or Without Aura, and the Prevention of Migraine Associated Nausea and Vomiting. [NCT03877718]	Phase 2	475 participants (Actual)	Interventional	2019-02-01	Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis [NCT00282347]	Phase 3	144 participants (Actual)	Interventional	2006-01-31	Completed
Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19) [NCT04456439]		0 participants	Expanded Access		Available
Efficacy of Sodium Bicarbonate for Treatment of Acute Peripheral Vertigo: A Double-blinded Randomized Control Trial [NCT05676216]		225 participants (Anticipated)	Interventional	2023-01-07	Recruiting
[NCT01159548]		400 participants (Anticipated)	Interventional	2010-07-31	Terminated(stopped due to Population of interest was no longer available)
Droperidol on Prevention of Emesis From Cannabinoid Hyperemesis Syndrome [NCT05244460]	Phase 3	45 participants (Anticipated)	Interventional	2021-12-02	Recruiting
Post Operative Analgesia After Pediatric Hip Surgery - PCA, Epidural or Lumbar Plexus Catheter: A Prospective Randomized Control Trial [NCT03435692]		42 participants (Actual)	Interventional	2011-07-15	Terminated(stopped due to Funding was exhausted prior to enrolling intended number of patients.)
TREC-Lebanon Trial: A Randomised Controlled Trial for Rapid Tranquilisation for Agitated Patients in the Emergency Setting [NCT03639558]	Phase 4	100 participants (Actual)	Interventional	2018-08-28	Completed
Metoclopramide for Post-Traumatic Headache. A Pilot Study [NCT03056352]	Phase 1/Phase 2	21 participants (Actual)	Interventional	2017-03-01	Completed
Reduction of Adverse Events and Re-Presentation to Medical Care After Intravenous Immunoglobulin Treatment in Children With Immune Thrombocytopenia With a Scheduled Post-Infusion Medication Strategy [NCT04741139]	Phase 1	20 participants (Anticipated)	Interventional	2021-09-02	Active, not recruiting
Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease [NCT04224558]	Phase 1/Phase 2	15 participants (Anticipated)	Interventional	2020-12-15	Recruiting
Investigating the Efficacy of Using Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department: A Prospective Randomized Clinical Trial [NCT02972502]	Phase 4	66 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to PI lapsed institutional training)
A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and Either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell Leukemia [NCT03805932]	Phase 1	18 participants (Actual)	Interventional	2019-10-03	Active, not recruiting
Effect of Intradermal Morphine Application on Histaminergic and Non-histaminergic Itch and Related TRPV1 and Antihistamine Treatments (2nd Sub-project) [NCT04700007]		26 participants (Actual)	Interventional	2021-01-18	Completed
Neuronal Correlates of Catecholamine Depletion in Patients With Bulimia Nervosa Off Medication and Healthy Controls [NCT02179814]		60 participants (Anticipated)	Interventional	2012-02-20	Suspended(stopped due to Conduct of the first analyses)
Multicenter Clinical Trial, Phase III, Controlled, Open, Parallel Group, Randomized, Comparing the Fixed Dose Combination of Diphenhydramine + Dropropizine + Pseudoephedrine and the Combined Use of Dropropizine and Fixed Dose Combination of Pseudoephedrin [NCT01177852]	Phase 3	0 participants (Actual)	Interventional	2011-10-31	Withdrawn
Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine [NCT01289938]	Phase 1	49 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to To unsuccessful recruitment of rare UM-genotype. All other planned genotype groups are completed (EM, IM and PM).)
Does Diphenhydramine Alter Thermoregulatory Responses During Exercise? [NCT05586477]	Phase 4	20 participants (Actual)	Interventional	2022-11-21	Completed
Cabazitaxel in Combination With Prednisolone With Primary Prophylaxis With PEG-G-CSF for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer [NCT02441894]	Phase 4	21 participants (Actual)	Interventional	2015-04-30	Completed
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation (Carboplatin and Taxol) as First Line Treatment for Patients With Local Regional Advanced Gastric Cancer [NCT04308837]	Phase 2	29 participants (Anticipated)	Interventional	2018-12-03	Recruiting
The Effects of SlumberCurve™ Following Rotator Cuff Surgery: A Randomized Control Trial [NCT04774965]		50 participants (Anticipated)	Interventional	2024-06-30	Not yet recruiting
Individual Differences After Consumption of Alcohol and Other Common Substances and Long-Term Follow-Up of Social Drinking, Young Adults [NCT00961792]		400 participants (Anticipated)	Interventional	2004-03-31	Recruiting
An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma [NCT01998971]	Phase 1	242 participants (Actual)	Interventional	2014-02-18	Active, not recruiting
Therapeutic Rest to Delay Admission in Early Labor: A Prospective Study on Morphine Sleep [NCT03539562]		82 participants (Actual)	Observational	2017-09-27	Completed
Randomized, Double-Blind, Placebo-Controlled, Crossover, In-home Study to Assess the Efficacy of Diphenhydramine Hydrochloride in Subjects With Occasional Sleeplessness [NCT02578186]	Phase 4	33 participants (Actual)	Interventional	2013-11-30	Completed
Sedative Effects of Oral Midazolam in Comparison Promethazine With Nitrous Oxide/Oxygen on Behavior Management of Uncooperative Children Receiving Dental Treatment [NCT01118884]	Phase 3	20 participants (Anticipated)	Interventional	2009-06-30	Active, not recruiting
The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD) [NCT06070649]	Phase 1	63 participants (Anticipated)	Interventional	2024-01-17	Not yet recruiting
Influence of Losartan and Diphenhydramine on Emotional and Cognitive Functions in Healthy Human Subjects [NCT01321021]		80 participants (Actual)	Interventional	2011-03-31	Completed
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence [NCT02061293]	Phase 2	95 participants (Actual)	Interventional	2014-06-30	Completed
An Open Label Crossover Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fasted Conditions [NCT03396250]	Phase 1	36 participants (Actual)	Interventional	2018-02-12	Completed
Intraoperative Electrical Stimulation of the Acupoint P6 to Prevent Post-Operative Nausea and Vomiting in Women Undergoing Breast Cancer Surgery [NCT02473042]		188 participants (Actual)	Interventional	2016-02-29	Active, not recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY) [NCT04221477]	Phase 3	252 participants (Anticipated)	Interventional	2020-08-10	Active, not recruiting
"Therapeutic Effects of Ibuprofen, Diphenhydramine and Aluminium MgS on Recurrent Aphthous Stomatitis" [NCT01293968]	Phase 2	37 participants (Actual)	Interventional	2010-11-30	Completed
A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Cancer [NCT01017731]	Phase 2	68 participants (Actual)	Interventional	2009-11-30	Completed
A Randomized, Two-Way Crossover Evaluation of the Bioequivalence Between Two Oral Formulations of Diphenhydramine: ULTRATAB Tablet Versus KAPSEALS Capsule [NCT00662337]	Phase 1	36 participants (Actual)	Interventional	2006-10-31	Completed
Lumbar Stenosis Outcomes Research (LUSTOR)- A Randomized, Double-blind, Cross-over Trial of Pregabalin vs. Diphenhydramine in Patients With Lumbar Spinal Stenosis and Neuropathic Low Back Pain [NCT00638443]	Phase 4	29 participants (Actual)	Interventional	2008-03-31	Completed
Probiotics and BeRberine on the Efficacy and Change of Gut MicrObiota in paTients With Newly Diagnosed Type 2 diabEtes（PREMOTE Study） [NCT02861261]	Phase 3	400 participants (Anticipated)	Interventional	2016-08-18	Active, not recruiting
Comparison Between the Treatment of Thiamine and Promethazine for Improving Vomiting and Nausea in Pregnancy [NCT00861523]	Phase 3	50 participants (Actual)	Interventional	2009-02-28	Terminated(stopped due to Difficulties in recruiting patients)
An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid Leukemia [NCT04580121]	Phase 1	59 participants (Actual)	Interventional	2020-11-04	Completed
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 at Varying Infusion Rates in Normal Adult Volunteers [NCT02535416]	Phase 1	40 participants (Actual)	Interventional	2015-09-30	Completed
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia [NCT03913559]	Phase 2	32 participants (Anticipated)	Interventional	2019-05-14	Recruiting
A Single-Dose, Four-Period, Four-Treatment, Four-Way Crossover Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions [NCT02465866]	Phase 1	20 participants (Actual)	Interventional	2014-11-30	Completed
Diphenhydramine 5% Ointment for Pain in Knee Osteoarthritis: a Randomised Double-blind Placebo-controlled Pilot Feasibility Study [NCT05036174]		30 participants (Anticipated)	Interventional	2021-09-30	Not yet recruiting
Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the Emergency Department: A Randomized Controlled Trial [NCT02098499]	Phase 4	68 participants (Actual)	Interventional	2013-06-30	Completed
Treg Adoptive Therapy in Subclinical Inflammation in Kidney Transplantation (CTOT-21) [NCT02711826]	Phase 1/Phase 2	14 participants (Anticipated)	Interventional	2016-09-20	Completed
Randomized Placebo-controlled Crossover Trial of Diphenhydramine for Sleep in Children With Autism [NCT05501678]	Phase 2	26 participants (Anticipated)	Interventional	2023-08-09	Recruiting
A Phase II Study: Paclitaxel and Pelvic Radiation for Stage I-IIIA Papillary Serous Carcinoma of the Endometrium [NCT00515073]	Phase 2	30 participants (Actual)	Interventional	2001-04-30	Completed
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma [NCT06043323]	Phase 2	20 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
An Open-Label, Single-Dose Study Evaluating the Pharmacokinetics of Diphenhydramine in Children and Adolescents [NCT00762749]	Phase 1	36 participants (Actual)	Interventional	2008-09-30	Completed
Metoclopramide and Diphenhydramine (MAD): A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective (MAD Headache Study) [NCT02295280]		70 participants (Actual)	Interventional	2012-01-31	Completed
A Prospective,Open-label, Dose Escalation Phase 1 Study to Investigate the Safety, and Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of a HLX07, in Patients With Advanced Solid Cancers. [NCT02648490]	Phase 1	19 participants (Actual)	Interventional	2016-09-30	Completed
Open Label,Balanced,Randomized,Two-treatment,Two-sequence,Two Period,Single-dose,Crossover Oral Bioequivalence Study of Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets of Dr.Reddy's and Advil®PM of Wyeth in Normal,Healthy,Adult,Human Subjects Und [NCT01053208]	Phase 1	40 participants (Actual)	Interventional	2008-04-30	Completed
Qualification of Single Dose Administration of Analgesic Therapy in the Treatment of Chronic Neuropathic Pain in Patients With Painful Diabetic Neuropathy [NCT00837941]	Phase 2	0 participants (Actual)	Interventional	2009-04-30	Withdrawn
A Phase II Trial of Nivolumab/Nab-paclitaxel/Carboplatin Induction Chemotherapy Followed by Response-stratified Locoregional Therapy for Patients With Locoregionally Advanced HPV-related Oropharyngeal Cancer- the OPTIMA II Trial [NCT03107182]	Phase 2	76 participants (Actual)	Interventional	2017-06-27	Active, not recruiting
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) [NCT04918147]	Phase 2	75 participants (Anticipated)	Interventional	2021-10-13	Recruiting
Efficacy of Nasal Migraine Cocktail Used In Pediatric Emergency Department: A Clinical Trial [NCT06083571]	Phase 2	120 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
A Relative Bioavailability Study of Promethazine HCl 50 mg Tablets Under Fasting Conditions [NCT00947063]	Phase 1	36 participants (Actual)	Interventional	2004-07-31	Completed
A Phase I Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology [NCT03330028]	Phase 1	29 participants (Actual)	Interventional	2017-10-27	Completed
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor [NCT05298683]	Phase 2	108 participants (Anticipated)	Interventional	2022-05-31	Not yet recruiting
A Phase 2 Study in Poor Risk Diffuse Large B-cell Lymphoma of Total Lymphoid Irradiation & Antithymocyte Globulin Followed by Matched Allogeneic Hematopoietic Transplantation as Consolidation to Autologous Hematopoietic Cell Transplantation [NCT00482053]	Phase 2	3 participants (Actual)	Interventional	2006-10-31	Terminated(stopped due to Low accrual)
Evaluation of Nasal Congestion Clinical Efficacy for Diphenhydramine 25 mg and Diphenhydramine 50 mg in Seasonal Allergic Rhinitis: a Randomized, Double-blind, Placebo and Pseudoephedrine Controlled Study [NCT00648973]	Phase 4	1,021 participants (Actual)	Interventional	2006-11-30	Completed
A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis [NCT05232825]	Phase 3	236 participants (Actual)	Interventional	2022-05-03	Active, not recruiting
Feasibility of a Randomized Controlled Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel [NCT04237090]	Phase 3	27 participants (Actual)	Interventional	2020-02-14	Completed
A Randomized, Double-Blinded, Placebo-Controlled Trial of Promethazine and Diphenhydramine as Adjunct Sedatives for Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP) [NCT00937924]		465 participants (Anticipated)	Interventional	2008-02-29	Recruiting
A Randomized, Double-Blind, Active- and Placebo-Controlled, Crossover Study Assessing the Effect of 600 mg Gabapentin Enacarbil on Simulated Driving in Healthy Subjects [NCT01411124]	Phase 1	36 participants (Actual)	Interventional	2011-06-30	Completed
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1) [NCT00866788]	Phase 2	90 participants (Actual)	Interventional	2009-03-31	Completed
A Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) in Multiple Myeloma Patients [NCT00899847]	Phase 2	9 participants (Actual)	Interventional	2009-05-31	Completed
[NCT00590590]	Phase 2	105 participants (Actual)	Interventional	2007-10-31	Completed
Rescue Emetic Therapy for Children Having Elective Therapy [NCT01067677]		0 participants (Actual)	Interventional	2010-02-28	Withdrawn(stopped due to We do not have the funding or resources to complete the study at this time)
Assessing Efficacy of Intramuscular Promethazine for the Treatment of Intrathecal Morphine Induced Pruritus [NCT04805073]	Phase 4	110 participants (Anticipated)	Interventional	2021-08-09	Recruiting
A Randomized, Double-blind, Placebo-controlled, Cross-over, Pilot Study to Investigate the Efficacy of Rest-ZZZ Formula in Healthy Participants With Difficulty Falling Asleep or Staying a Sleep [NCT04093271]	Phase 1	27 participants (Actual)	Interventional	2019-09-24	Completed
An Open-label, Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft Versus Host Disease After TLI/ARG Nonmyeloablative Allogeneic Stem Cell Transplantation [NCT00186628]	Phase 2	36 participants (Actual)	Interventional	2005-06-30	Completed
Open Label,Balanced,Randomized,Two-treatment,Two-sequence,Two Period,Single-dose,Crossover Oral Bioequivalence Study of Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets of Dr.Reddy's and Advil®PM of Wyeth in Normal,Healthy,Adult,Human Subjects Und [NCT01053338]	Phase 1	40 participants (Actual)	Interventional	2008-04-30	Completed
A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgical Resection for Locally-Advanced Rectal Cancer [NCT00226941]	Phase 1/Phase 2	23 participants (Actual)	Interventional	2004-06-30	Terminated(stopped due to The response rate observed in the phase 1 portion of the study did not merit further evaluation in phase 2 portion of the study.)
A Phase 2 Exploratory Study of Intravenous QUZYTTIR™ (Cetirizine Hydrochloride Injection) Versus Intravenous Diphenhydramine in the Prevention of Hypersensitivity Infusion Reactions [NCT04189588]	Phase 2	34 participants (Actual)	Interventional	2020-03-25	Completed
Double-blind, Placebo Controlled, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375 After Single Oral Administrations Ranging From 0.5 mg to 100 mg in Healthy Male Subjects (Part 1) Followed by the Asse [NCT01965301]	Phase 1	48 participants (Actual)	Interventional	2014-10-31	Terminated
A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies [NCT04681105]	Phase 1	13 participants (Actual)	Interventional	2020-11-18	Active, not recruiting
The Effect of Antihistamines on Methacholine Challenge Testing in Asthma Patients [NCT01985789]	Phase 4	12 participants (Actual)	Interventional	2013-11-30	Completed
Evaluation and Treatment of Autonomic Failure. [NCT00223691]	Phase 1	389 participants (Actual)	Interventional	2002-03-31	Completed
[NCT02023164]	Phase 3	36 participants (Actual)	Interventional	2013-07-31	Completed
Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma [NCT04268498]	Phase 2	306 participants (Anticipated)	Interventional	2020-02-11	Recruiting
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies [NCT00923910]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2008-02-22	Completed
Chronic Sleep Deprivation Among the Poor: A Lab-in-the-field Approach [NCT03322358]		452 participants (Actual)	Interventional	2017-10-23	Completed
A Phase II Comparative, Open-Label, Randomized, Multicenter, China-Only Study to Investigate the Pharmacokinetics, Efficacy and Safety of Subcutaneous Rituximab Versus Intravenous Rituximab Both in Combination With CHOP in Previously Untreated Patients Wi [NCT04660799]	Phase 2	50 participants (Actual)	Interventional	2021-02-24	Completed
A Randomized, Double Blind, Active- and Placebo-Controlled, Parallel Group Safety Study Assessing Simulated Driving Performance in XP13512-(GSK1838262) Treated Patients With Restless Legs Syndrome [NCT01332318]	Phase 2	130 participants (Actual)	Interventional	2007-04-30	Completed
Phase I/II Clinical Trial Combining TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer [NCT01455389]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to Trial terminated by sponsor after decision to evaluate combination of quaratusugene ozeplasmid and osimertinib instead of further evaluating quaratusugene ozeplasmid and erlotinib.)
A Study to Investigate Safety and Tolerability of Higher Infusion Rate to shORten the duraTion of FabrazymE Infusion [NCT06019728]	Phase 4	18 participants (Anticipated)	Interventional	2023-11-10	Recruiting
Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial [NCT02867800]	Phase 1	24 participants (Actual)	Interventional	2016-07-31	Active, not recruiting
The Use of Doxepin for Urticaria in the Emergency Department [NCT05115136]	Phase 3	160 participants (Anticipated)	Interventional	2022-05-23	Recruiting
A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg (Hydrocodone 5 mg/Acetaminophen 325 mg/Promethazine 12.5 mg) as a Treatment for Moderate-to-Severe Acute Pain and the Prevention of Opioid [NCT03657810]	Phase 3	349 participants (Actual)	Interventional	2017-08-02	Completed
A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose, Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Pain and Opioid-Induced Nausea and Vomiting (OINV) [NCT02462811]	Phase 3	552 participants (Actual)	Interventional	2014-09-30	Completed
Evaluation of Re-administration of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV9-DES-hGAA) in Patients With Late-Onset Pompe Disease (LOPD) [NCT02240407]	Phase 1	2 participants (Actual)	Interventional	2017-10-17	Completed
A Randomized, Facorial Design Study to Optimize the Dose of Parenteral Metoclopramide [NCT00475306]	Phase 4	289 participants (Actual)	Interventional	2007-05-31	Completed
A Phase 2b, Double-Blind, Three Arm, Randomized, Placebo Controlled Trial With Restricted Response Adaptive Randomization Testing the Efficacy and Safety of High Dose Methylprednisolone or Equine Anti-Thymocyte Globulin as Treatment for Acute Liver Failur [NCT04862221]	Phase 2	163 participants (Anticipated)	Interventional	2022-02-09	Recruiting
Comparison of Intrathecal Levobupivacaine Combined With Sufentanil, Fentanyl, or Placebo for Elective Caesarean Section: A Prospective, Randomized, Double-blind, Controlled Study [NCT01858090]	Phase 3	93 participants (Actual)	Interventional	2009-01-31	Completed
Optimizing the Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance. Motion Sickness Countermeasures Field Test [NCT05852730]	Phase 2	80 participants (Anticipated)	Interventional	2021-08-10	Recruiting
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene [NCT01264939]	Phase 3	336 participants (Actual)	Interventional	2011-02-28	Completed
A Pilot Study of Prolonged, Intermittent Exposure to Alfentanil on Opioid-Induced Hyperalgesia in Healthy Volunteers [NCT00991809]		22 participants (Actual)	Interventional	2009-02-28	Completed
A Phase I, Randomized, Subject- and Investigator-Blind, Placebo-Controlled, 4-Period Cross-Over Study Assessing the Duration of Effect of Lasmiditan on Simulated Driving Performance in Healthy Volunteers [NCT03459612]	Phase 1	68 participants (Actual)	Interventional	2018-03-26	Completed
Safety and Efficacy of Four Intramuscular Interventions for the Management of Acute Psychomotor Agitation [NCT01485692]		120 participants (Actual)	Interventional	2009-02-28	Completed
Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL) [NCT02999633]	Phase 2	14 participants (Actual)	Interventional	2017-03-08	Terminated(stopped due to Due to an unsatisfactory benefit/risk ratio, as specified in & 14.8.1 of the protocol, Sanofi decided to stop enrollment and terminate ACT14596 prematurely)
Rapid Tranquilization of Violent or Agitated People in Psychiatric Emergency Settings- A Pragmatic Randomized Controlled Trial of Intramuscular Olanzepine Vs. Intramuscular Haloperidol + Promethazine. [NCT00455234]	Phase 3	300 participants	Interventional	2005-09-30	Completed
A Double-Blind, Randomized, Placebo-Controlled, Multiple-dose Multi-Center Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain [NCT01780428]	Phase 3	460 participants (Actual)	Interventional	2013-01-31	Completed
A Randomized Trial Comparing Auricular Acupuncture and Intravenous Migraine Medications in the Treatment of Status Migrainosus in the Pediatric Emergency Department [NCT02681211]		80 participants (Anticipated)	Interventional	2016-02-29	Recruiting
Psilocybin-facilitated Treatment for Cocaine Use: A Pilot Study [NCT02037126]	Phase 2	40 participants (Actual)	Interventional	2015-05-31	Active, not recruiting
A Randomized Controlled Trial of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department [NCT00429832]	Phase 4	120 participants	Interventional	2003-10-31	Completed
A Pilot Study to Determine the Pruritic Benefits of Ondansetron Versus Diphenhydramine in Burn Patients Undergoing Wound Healing [NCT00137202]		36 participants (Actual)	Interventional	2005-06-30	Completed
Value of Intravenous Fluids in the Emergent Treatment of Pediatric Migraine [NCT06182098]		134 participants (Anticipated)	Interventional	2023-06-27	Recruiting
Phase 2, Single-Arm Study of Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma [NCT05896228]	Phase 2	30 participants (Anticipated)	Interventional	2024-03-01	Recruiting
A Phase I Randomized, Double-blind, Placebo-controlled, Dose-increasing Single Dose Study Evaluating the Safety, Tolerability，Pharmacokinetics and Pharmacodynamics Analysis of Pegloticase in Subjects With Asymptomatic Hyperuricemia [NCT05302388]	Phase 1	45 participants (Actual)	Interventional	2022-04-11	Completed
An Open-label, Single-arm, Multicenter Phase II/III Extension Study to Evaluate the Safety of Rituximab Re-treatment in Subjects With Moderate to Severe Systemic Lupus Erythematosus Previously Enrolled in Protocol U2971g [NCT00381810]	Phase 3	31 participants (Actual)	Interventional	2006-06-22	Terminated(stopped due to During a safety review of studies U2970g and U2971g, the Data Monitoring Committee recommended that enrollment in this extension trial be terminated.)
Phase II Randomized, Double-Blinded Study of an Antiemetic Pump, Using Benadryl®, Avitan® and Decadron® (BAD), for Children Receiving Moderately or Highly Emetogenic Chemotherapy [NCT00429702]	Phase 2	7 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to Closed due to poor accrual and lack of feasibility to finish study per DSMB)
Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels [NCT02136420]	Phase 4	30 participants (Actual)	Interventional	2014-06-30	Completed
Metoclopramide for Acute Migraine: A Dose Finding Study [NCT00682734]	Phase 3	349 participants (Actual)	Interventional	2008-04-30	Completed
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer [NCT00887640]	Phase 2	11 participants (Actual)	Interventional	2009-07-31	Terminated
A Randomised, Double-Blind, Double-Dummy, Placebo And Active Controlled, 4-Way Crossover Methodology Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers [NCT01119222]	Phase 1	19 participants (Actual)	Interventional	2008-07-31	Completed
A 3-Day Investigator Blinded, Randomized Study Evaluating Aurstat Anti-Itch Hydrogel Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus [NCT01905631]	Phase 2	30 participants (Actual)	Interventional	2013-07-31	Completed
An Open-Label Pilot Study to Evaluate the Effectiveness and Tolerability of a Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis [NCT04846348]	Phase 2	10 participants (Anticipated)	Interventional	2021-07-26	Recruiting
Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis [NCT02625181]		27,034 participants (Actual)	Interventional	2016-07-31	Completed
The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin [NCT01669967]		34 participants (Actual)	Interventional	2011-09-30	Completed
Phase 2 Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma (DLCL) [NCT00490009]	Phase 2	9 participants (Actual)	Interventional	2004-09-30	Completed
Randomized Controlled Trial of Infliximab (Remicade®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19) [NCT02495077]	Phase 2	290 participants (Actual)	Interventional	2015-11-02	Completed
A Randomized Trial to Evaluate Resolution of Symptoms Using Vestibular Rehab Versus Conventional Therapy in Patients Presenting to the Emergency Department (ED) With Diagnosis of Benign Paroxysmal Positional Vertigo (BPPV) [NCT00641797]		26 participants (Actual)	Interventional	2006-11-30	Completed
Use of Diphenhydramine as an Adjunctive Sedative for Colonoscopy in Patients Chronically on Opioids [NCT01967433]	Phase 4	120 participants (Actual)	Interventional	2013-12-31	Completed
Studying the Effectiveness of Triple Therapy With Palonosetron, Dexamethasone and Promethazine for Prevention of Post Operative Nausea and Vomiting in High Risk Patients Undergoing Neurological Surgery and General Anesthesia [NCT02635828]	Phase 4	40 participants (Actual)	Interventional	2009-10-31	Completed
"Randomized Trial of Diphenhydramine Versus Continued Midazolam in Difficult-to-sedate Patients Undergoing Colonoscopy" [NCT01769586]		200 participants (Actual)	Interventional	2013-02-28	Completed
A Two-Part Study Evaluating the Combination of Tazemetostat and CPX-351 (Part 1) and Palbociclib With CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia [NCT05627232]	Phase 1	24 participants (Anticipated)	Interventional	2023-08-28	Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) [NCT01086540]	Phase 2	57 participants (Actual)	Interventional	2011-06-24	Completed
Antitussive Effect of a Naturally Flavored, Multi-Component Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo [NCT02062710]	Phase 4	22 participants (Actual)	Interventional	2014-01-31	Completed
[NCT02655354]		635 participants (Actual)	Interventional	2015-10-31	Completed
Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting [NCT01474915]	Phase 4	122 participants (Actual)	Interventional	2007-06-30	Completed
Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease [NCT02765256]	Phase 2	8 participants (Actual)	Interventional	2016-08-31	Completed
Evaluating the Effectiveness of Topical Morphine Compared With a Routine Mouthwash in Managing Cancer Treatment-induced Mucositis in Patients With Head and Neck Cancer in Isfahan [NCT01837446]	Phase 2/Phase 3	30 participants (Actual)	Interventional	2011-07-31	Completed
Principal Investigator [NCT01644838]	Phase 2/Phase 3	93 participants (Actual)	Interventional	2010-08-31	Completed
Low Dose Adrenaline, Promethazine, & Hydrocortisone (Alone and in Combination) to Prevent Acute Adverse Reactions to Antivenom in People Bitten by Snakes: Randomised, Double Blind, Placebo-Controlled Trial [NCT00270777]	Phase 4	1,000 participants (Anticipated)	Interventional	2005-03-31	Completed
A Phase II Clinical Trial of BMS-247550 (NSC 710428), an Epothilone B Analog, in Renal Cell Carcinoma [NCT00030992]	Phase 2	102 participants (Actual)	Interventional	2002-02-28	Completed
A Phase III, International, Multicenter, Randomised Open Label Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Patients With Childhood Onset Idiopathic Nephrotic Syndrome [NCT05627557]	Phase 3	80 participants (Anticipated)	Interventional	2023-03-29	Recruiting
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure [NCT05285813]	Phase 2	42 participants (Anticipated)	Interventional	2022-05-06	Recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety of Obinutuzumab in Patients With Systemic Lupus Erythematosus [NCT04963296]	Phase 3	300 participants (Anticipated)	Interventional	2021-10-26	Recruiting
A Bioavailability Study of Naproxen Sodium and Diphenhydramine Hydrochloride Under Fasting Conditions and Naproxen Sodium and Diphenhydramine Hydrochloride Combination Under Fasting and Fed Conditions [NCT01666678]	Phase 1	32 participants (Actual)	Interventional	2012-01-31	Completed
Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection [NCT00000875]		16 participants	Interventional		Terminated
A Phase 1, Open-Label, Two-Part, Fixed-Sequence Crossover Study to Evaluate the Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Male Subjects [NCT01712828]	Phase 1	31 participants (Actual)	Interventional	2012-10-01	Completed
Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment: a Randomized, Double Blind Clinical Trial [NCT01814189]	Phase 3	350 participants (Actual)	Interventional	2013-01-31	Completed
Promethazine vs. Lorazepam for Treatment of Vertigo in the Emergency Department: A Randomized Clinical Trial [NCT01827293]	Phase 3	210 participants (Actual)	Interventional	2013-04-30	Completed
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology [NCT05977998]	Phase 2	30 participants (Anticipated)	Interventional	2023-09-08	Recruiting
Comparative Efficacy of Dexamethasone, Doxycycline, Nystatin and Promethazine With Triamcinolone in Orabase as Symptomatic Treatment of Oral Lichen Planus, A Randomized Controlled Trial [NCT03237533]	Early Phase 1	32 participants (Anticipated)	Interventional	2017-06-01	Recruiting
An Exploratory Multicenter, Double-Blind, Diphenhydramine- and Placebo-Controlled Safety, Efficacy and Biomarker Study With JNJ-42847922 in Subjects With Major Depressive Disorder [NCT02476058]	Phase 1	48 participants (Actual)	Interventional	2015-06-11	Completed
A Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 1 Study to Determine the Safety, Tolerability, Pharmacokinetics and Effect of Circulating Alpha-1 Antitrypsin Levels of ARC-AAT in Healthy Volunteer Subjects and in Patients With Alpha-1 Antitryps [NCT02363946]	Phase 1	65 participants (Actual)	Interventional	2015-02-28	Terminated(stopped due to Company decision to terminate the trial)
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, CROSS-OVER, PLACEBO-CONTROLLED, SINGLE DOSE, CLINICAL TRIAL TO ASSESS THE NEXT-DAY RESIDUAL EFFECTS OF GABAPENTIN, DIPHENHYDRAMINE AND TRIAZOLAM ON SIMULATED DRIVING PERFORMANCE IN NORMAL VOLUNTEERS [NCT01888497]	Phase 3	59 participants (Actual)	Interventional	2013-07-29	Completed
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients With Active Class III or IV Lupus Nephritis, Including an Evaluation of Open Label Sa [NCT05039619]	Phase 2	40 participants (Anticipated)	Interventional	2022-05-12	Recruiting
Safely Stopping Pre-Medications in Patients Receiving Paclitaxel: A Randomized Trial [NCT04862585]	Phase 2/Phase 3	100 participants (Anticipated)	Interventional	2021-10-07	Recruiting
KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Anti-PD-(L)1 Therapy [NCT04165096]	Phase 2	135 participants (Anticipated)	Interventional	2020-01-21	Active, not recruiting
Efficacy of Melatonin and Diphenhydramine Versus Placebo in Treatment of Nighttime Pruritus in Atopic Dermatitis [NCT03688464]	Early Phase 1	0 participants (Actual)	Interventional	2018-04-01	Withdrawn(stopped due to Study never started)
Droperidol Versus Metoclopramide + Diphenhydramine for the Treatment of Primary Headaches in the Emergency Department: A Prospective Randomized, Double-blinded Trial. [NCT01406860]		19 participants (Actual)	Interventional	2011-07-31	Terminated(stopped due to lack of enrollment/drug shortages)
A Pilot, Randomized, Double-blind, Placebo-controlled Trial of Promethazine for Treatment of Diabetic Gastroparesis. [NCT02130622]	Phase 2	3 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to Lack of recruitment)
"Absorption of ABH Gel (Ativan®, Lorazepam; Benadryl®, Diphenhydramine; and Haldol®, Haloperidol Gel) From the Skin of Normal Volunteers" [NCT01204255]		11 participants (Actual)	Interventional	2010-11-15	Completed
Comparison of Efficacy of Metoclopramide , Promethazine and Prochloroperazine in the Treatment of Vertigo. [NCT05586763]	Phase 3	90 participants (Anticipated)	Interventional	2022-02-01	Recruiting
Intramuscular Paracervical Injection for Headache in the Emergency Department: A Randomized Controlled Trial [NCT04109885]	Phase 2	108 participants (Anticipated)	Interventional	2020-09-15	Active, not recruiting
The Use of Campath-1H, Tacrolimus, and Sirolimus Followed by Sirolimus Withdrawal in Renal Transplant Patients [NCT00078559]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2003-11-30	Completed
A Dose Ranging Effect of Preoperative Diphenhydramine on Postoperative Quality of Recovery After Ambulatory Surgery [NCT01451762]		90 participants (Actual)	Interventional	2011-09-30	Completed
Intravenous Fluids in Benign Headaches Trail: A Randomized Single Blind Clinical Trial [NCT03185130]	Phase 4	58 participants (Actual)	Interventional	2017-05-16	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, [NCT02452528]	Phase 2	4 participants (Actual)	Interventional	2015-08-31	Terminated(stopped due to Company decision to discontinue trial)
Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With Moderate to Severe Systemic Lupus Erythematosus [NCT00137969]	Phase 2/Phase 3	262 participants (Actual)	Interventional	2005-05-10	Completed
Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers [NCT01846455]	Phase 4	43 participants (Actual)	Interventional	2012-09-30	Completed
Safety of Donor Alloantigen Reactive Tregs to Facilitate Minimization and/or Discontinuation of Immunosuppression in Adult Liver Transplant Recipients (CTOTC-12) [NCT02474199]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2016-06-06	Completed
A Phase I Study to Evaluate Safety and Pharmacokinetics of SAR408701 Administered Intravenously as Monotherapy in Japanese Patients With Advanced Malignant Solid Tumors [NCT03324113]	Phase 1	34 participants (Actual)	Interventional	2017-10-17	Completed
The Magnitude and Duration of the Central Nervous System Effects Following Intravenous Infusion of Diphenhydramine Using Pharmacokinetic and Pharmacodynamic Modeling [NCT05219604]	Phase 4	3 participants (Actual)	Interventional	2022-03-15	Terminated(stopped due to Institution decision)
A Double-Blind, Randomized, Pilot Study Assessing the Analgesic and Hypnotic Effect of Naproxen Sodium and Diphenhydramine Combination in Dental Pain [NCT01118273]	Phase 4	162 participants (Actual)	Interventional	2008-01-31	Completed
Role of Nefopam in Rituximab Transfusion Reaction [NCT05648058]	Phase 3	100 participants (Anticipated)	Interventional	2022-12-20	Not yet recruiting
A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy [NCT04629248]	Phase 3	140 participants (Anticipated)	Interventional	2021-06-25	Recruiting
Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results [NCT00324467]	Phase 2	150 participants (Actual)	Interventional	2006-08-31	Active, not recruiting
Hydromorphone Versus Prochlorperazine + Diphenhydramine for Treatment of Acute Migraine. A Randomized, Emergency Department Based, Comparative Efficacy Study [NCT02389829]	Phase 4	127 participants (Actual)	Interventional	2015-03-31	Completed
A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly With Raxibacumab (GSK3068483) [NCT02339155]	Phase 4	573 participants (Actual)	Interventional	2015-02-24	Completed
Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Liver Transplantation (RTB-002) [NCT02188719]	Phase 1	15 participants (Actual)	Interventional	2014-12-17	Terminated(stopped due to The trial could not be completed within the grant timeline.)
Bone Marrow Transplantation and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance (ITN054ST) [NCT02029638]	Phase 2	4 participants (Actual)	Interventional	2014-01-07	Terminated(stopped due to Slow accrual)
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab (SAR650984) in Patients Awaiting Kidney Transplantation [NCT04294459]	Phase 1/Phase 2	23 participants (Actual)	Interventional	2020-06-18	Terminated(stopped due to Terminated due to non-safety reasons)
A Phase III, Multi-center, Double Blind, Randomized, Active Controlled Clinical Trial to Evaluate the Non-Inferiority Comparing Cetirizine Injection 10 mg to Diphenhydramine Injection, 50 mg, for the Treatment of Acute Urticaria [NCT02935699]	Phase 3	262 participants (Actual)	Interventional	2017-03-01	Completed
A Randomized Placebo Controlled Trial of IV Metoclopramide for Acute Post-traumatic Headache [NCT03220958]	Phase 3	160 participants (Actual)	Interventional	2017-08-01	Completed
Prevention of Narcotic-induced Nausea With Promethazine, a Randomized, Double-blind Placebo-controlled Trial [NCT00541671]		25 participants (Actual)	Interventional	2007-02-28	Terminated(stopped due to Terminated: recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated)
A Double-blind Randomized Controlled Study on Influence of E-aid Cognitive Behavioral Therapy for Insomnia to Reduce Incidence of Depression as Well as Suicidal Ideation in Patients With Insomnia [NCT03309527]		1,000 participants (Anticipated)	Interventional	2017-11-01	Enrolling by invitation
Dyphenhidramine Effect on Prevention of Sevoflurane Induced Post Anesthesia Agitation in Pediatric [NCT02463929]	Phase 4	50 participants (Actual)	Interventional	2014-04-30	Completed
Glutaminergic and Histaminergic Pathway Modulation in Acute Ischemic Stroke as an Effective Neuroprotection Strategy. [NCT02142712]	Phase 2	3 participants (Actual)	Interventional	2014-12-31	Completed
Postoperative Sleep Quality Following Total Joint Arthroplasty: A Prospective, Randomized, Controlled Trial of Diphenhydramine and Melatonin Versus Sleep Skills Training [NCT03968939]	Phase 4	375 participants (Anticipated)	Interventional	2019-10-01	Recruiting
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]	Phase 3	407 participants (Actual)	Interventional	2015-01-31	Terminated
Effects of Intravenous Lidocaine on Endometriosis Pain [NCT01968694]		20 participants (Actual)	Interventional	2010-12-31	Completed
A Randomized, Placebo-Controlled, Double-Blind, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants [NCT03142165]	Phase 1	33 participants (Actual)	Interventional	2017-05-11	Completed
An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Two-way Crossover, Oral Comparative Pharmacokinetic (PK) Study of Ibuprofen and Diphenhydramine Hydrochloride Modified-Release Tablets, 400mg/50mg of Overseas Pharm [NCT05729555]	Phase 1	16 participants (Anticipated)	Interventional	2023-04-03	Not yet recruiting
Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia: A Randomized, Double-blinded, Placebo-controlled Study [NCT00588159]		146 participants (Actual)	Interventional	2007-06-30	Completed
A Randomized, Double Blind, and Placebo-Controlled Trial Comparing Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult Emergency Department. [NCT00655642]		171 participants (Actual)	Interventional	2007-03-31	Terminated(stopped due to Conditional analysis showed observed differences were significantly less than power calculations)
An Open-Label Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject [NCT01737931]	Phase 1	120 participants (Actual)	Interventional	2012-08-31	Completed
Median Nerve Acustimulation Plus Medical Anti-emetic Therapy for Control Post-operative Nausea in Patients Undergoing Foregut Surgery: A Randomized Control Trial [NCT01510379]		100 participants (Actual)	Interventional	2011-08-31	Completed
Effect of Metformin and Probiotics in Reproductive-aged Patients With Polycystic Ovary Syndrome: a Randomized, Parallel Study [NCT03336840]		90 participants (Anticipated)	Interventional	2017-06-01	Recruiting
The Check Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine. A Multi-Center, Randomized Double-Blind, Clinical Control Trial. [NCT02657031]	Phase 4	54 participants (Actual)	Interventional	2016-03-17	Completed
An Open Label Crossover Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions [NCT03424135]	Phase 1	60 participants (Actual)	Interventional	2018-03-02	Completed
A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy [NCT02229539]	Phase 3	275 participants (Actual)	Interventional	2014-11-30	Completed
A Randomized, Double-Blinded Controlled Trial of an N-Methyl D-Aspartate Antagonist as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients [NCT02106325]	Phase 2	21 participants (Actual)	Interventional	2013-12-31	Completed
Diphenhydramine as Adjuvant Therapy for Acute Migraine. A Randomized Trial. [NCT01825941]	Phase 4	208 participants (Actual)	Interventional	2013-04-30	Completed
An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or Are Double Refractory to a [NCT01985126]	Phase 2	124 participants (Actual)	Interventional	2013-09-27	Completed
A Pilot Study to Assess Impact of Low Dose Melphalan on Disease Burden Measured by Next Generation Sequencing Before Autologous Hematopoietic Cell Transplant (AHCT) for Multiple Myeloma Patients [NCT05013437]	Early Phase 1	20 participants (Anticipated)	Interventional	2023-03-31	Recruiting
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI) [NCT02260934]	Phase 2	43 participants (Actual)	Interventional	2015-07-09	Completed
"A Randomized Trial of the Effectiveness of Topical ABH Gel (Ativan®, Lorazepam; Benadryl®, Diphenhydramine; and Haldol®, Haloperidol Gel) Versus Placebo in Patients With Nausea" [NCT01556932]		22 participants (Actual)	Interventional	2012-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00030992 (2) [back to overview]	Response Rate
NCT00030992 (2) [back to overview]	Number of Participants With Adverse Events
NCT00076752 (16) [back to overview]	Number of Participants With Adverse Events
NCT00076752 (16) [back to overview]	Relapse-free Complete Clinical Response
NCT00076752 (16) [back to overview]	Absolute Lymphocyte Count
NCT00076752 (16) [back to overview]	Absolute Neutrophil Count
NCT00076752 (16) [back to overview]	Anti-Double Stranded Deoxyribonucleic Acid (DNA) Antibody
NCT00076752 (16) [back to overview]	Anti-Nuclear Antibody
NCT00076752 (16) [back to overview]	Anti-Smith-Ribonuclear Protein Antibody
NCT00076752 (16) [back to overview]	Cluster of Differentiation 19 (CD19) + Cells
NCT00076752 (16) [back to overview]	Cluster of Differentiation 3 (CD3) + Cells
NCT00076752 (16) [back to overview]	Cluster of Differentiation 4 (CD4) + Cells
NCT00076752 (16) [back to overview]	Cluster of Differentiation 8 (CD8) + Cells
NCT00076752 (16) [back to overview]	Extractable Nuclear Antigen (ENA)
NCT00076752 (16) [back to overview]	Natural Killer Cells
NCT00076752 (16) [back to overview]	Platelet Count
NCT00076752 (16) [back to overview]	Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
NCT00076752 (16) [back to overview]	White Blood Cells
NCT00078559 (14) [back to overview]	Number of Acute Rejections in All Enrolled Participants Following Sirolimus Withdrawal
NCT00078559 (14) [back to overview]	Number of Acute Rejections in All Enrolled Participants
NCT00078559 (14) [back to overview]	Number of Acute Rejections Between Initiation of Sirolimus Withdrawal and End of Study
NCT00078559 (14) [back to overview]	Change in Renal Function as Measured by Serum Creatinine, Stratified by Withdrawal Status
NCT00078559 (14) [back to overview]	Number of Deaths Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]	Number of Alemtuzumab Associated Adverse Events, Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]	Time From Transplantation to Acute Rejection in Participants for Whom Sirolimus Withdrawal Was Not Initiated
NCT00078559 (14) [back to overview]	Time From Transplantation to Acute Rejection in Participants for Whom Acute Rejection Occurred During the 1 Year Post-transplant Period
NCT00078559 (14) [back to overview]	Number of Tacrolimus Associated Adverse Events, Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]	Number of Sirolimus Associated Adverse Events, Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]	Number of Side Effects of Conventional Immunosuppression, Stratified by Withdrawal Status
NCT00078559 (14) [back to overview]	Number of Severe Acute Rejections Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]	Number of Participants Who Experienced Graft Loss Stratified by Sirolimus Withdrawal Status
NCT00078559 (14) [back to overview]	Number of Participants Requiring Anti-lymphocyte Therapy for an Acute Rejection, Stratified by Sirolimus Withdrawal Status
NCT00137969 (8) [back to overview]	Time to First Moderate or Severe Flare
NCT00137969 (8) [back to overview]	Number of Participants Who Achieved a Major Clinical Response (MCR), Partial Clinical Response (PCR), or Nonclinical Response (NCR) Defined by British Isles Lupus Assessment Group (BILAG) Scores Over The 52-week Treatment Period
NCT00137969 (8) [back to overview]	Change in SLE Expanded Health Survey Physical Function Score From Baseline
NCT00137969 (8) [back to overview]	Number of Participants Who Achieved a BILAG C or Better in All Domains
NCT00137969 (8) [back to overview]	Number of Participants Who Achieved a PCR (Including MCR)
NCT00137969 (8) [back to overview]	Time-adjusted Area Under The Curve Minus Baseline (AUCMB) of BILAG Score Over The 52-week Treatment Period
NCT00137969 (8) [back to overview]	Number of Participants Who Achieved an MCR (Excluding PCR)
NCT00137969 (8) [back to overview]	Number of Participants Who Achieved an MCR in The ITT Population
NCT00186628 (4) [back to overview]	Overall Survival
NCT00186628 (4) [back to overview]	Chronic Graft-vs-Host Disease (cGvHD)
NCT00186628 (4) [back to overview]	Incidence of Relapse
NCT00186628 (4) [back to overview]	Mortality
NCT00226941 (7) [back to overview]	Tumor Downstaging at Surgical Resection
NCT00226941 (7) [back to overview]	Time-to-Progression (TTP)
NCT00226941 (7) [back to overview]	Survival at 5 Years
NCT00226941 (7) [back to overview]	Pathologic Response Rate
NCT00226941 (7) [back to overview]	Overall Survival (OS)
NCT00226941 (7) [back to overview]	Dose-limiting Toxicity (DLT) - Number of Participants Affected
NCT00226941 (7) [back to overview]	Dose-limiting Toxicity (DLT) - Number of DLTs by Treatment Group
NCT00282347 (9) [back to overview]	British Isles Lupus Assessment Group (BILAG) Index Score Over 52 Weeks
NCT00282347 (9) [back to overview]	Change From Baseline in Anti-double-stranded DNA at Week 52
NCT00282347 (9) [back to overview]	Change From Baseline in the Systemic Lupus Erythematosus Expanded Health Survey Physical Function Score at Week 52
NCT00282347 (9) [back to overview]	Percentage of Participants Who Achieved a Complete Renal Response at Week 24 and Maintained it to Week 52
NCT00282347 (9) [back to overview]	Percentage of Participants Who Achieved a Complete Renal Response at Week 52
NCT00282347 (9) [back to overview]	Percentage of Participants With a Baseline Urine Protein to Creatinine Ratio of > 3.0 Who Achieved a Urine Protein to Creatinine Ratio of < 1.0 at Week 52
NCT00282347 (9) [back to overview]	Time to Achieve a Complete Renal Response
NCT00282347 (9) [back to overview]	Change From Baseline in C3 and C4 Complement Levels at Week 52
NCT00282347 (9) [back to overview]	Percentage of Participants Who Achieved a Complete Renal Response (CRR), a Partial Renal Response (PRR), or no Renal Response (NRR) at Week 52
NCT00381810 (1) [back to overview]	Percentage of Participants With at Least 1 Serious Adverse Event
NCT00429702 (2) [back to overview]	Proportion of Patients Requiring Rescue Medication for Breakthrough Nausea or Emesis After Completion of the First Course of Emetogenic Chemotherapy
NCT00429702 (2) [back to overview]	Proportion of Patients Requiring Rescue Medication for Breakthrough Nausea or Emesis During Inpatient Chemotherapy
NCT00475306 (2) [back to overview]	Nausea Scale
NCT00475306 (2) [back to overview]	Number of Participants With Akathisia
NCT00482053 (7) [back to overview]	Median Time to Platelet Engraftment After Autologous Transplant
NCT00482053 (7) [back to overview]	Median Time to Platelet Engraftment After Allogeneic Transplant
NCT00482053 (7) [back to overview]	Incidence of Chronic Graft vs Host Disease (GvHD)
NCT00482053 (7) [back to overview]	Median Time to Neutrophil Engraftment After Autologous Transplant
NCT00482053 (7) [back to overview]	Event-free Survival (EFS) Per Protocol
NCT00482053 (7) [back to overview]	Overall Survival (OS)
NCT00482053 (7) [back to overview]	Median Time to Neutrophil Engraftment After Allogeneic Transplant
NCT00490009 (3) [back to overview]	Time to Progression (TTP)
NCT00490009 (3) [back to overview]	Clinical Response Rate
NCT00490009 (3) [back to overview]	Overall Survival (OS) Rate
NCT00515073 (1) [back to overview]	Overall Survival at 2 Years and 5 Years
NCT00541671 (1) [back to overview]	Number of Patients Who Became Nauseated After IV Opiate Administration.
NCT00588159 (6) [back to overview]	Average Pain Score at Rest
NCT00588159 (6) [back to overview]	Opioid Consumption in Second 24 Hour Hour Period (Hours 24-48) Postoperatively
NCT00588159 (6) [back to overview]	Opioid Consumption in First 24 Hours Postoperatively
NCT00588159 (6) [back to overview]	Number of Participants With Pain at Thoracotomy Site 3 Months Postoperatively
NCT00588159 (6) [back to overview]	Average Pain Score With Coughing the First Morning Following Surgery
NCT00588159 (6) [back to overview]	Average Pain Score With Coughing on Second Morning After Surgery
NCT00590590 (6) [back to overview]	Mean Marinoff Dyspareunia Scale Score (MDSS) at End of Treatment (12 Weeks)
NCT00590590 (6) [back to overview]	Change From Baseline in Tenderness (on a 0- to 3-point Scale) on Palpation at End of Treatment (12 Weeks) [Scale Rates the Severity of Pain; 0 =Absent and 3 = Severe]
NCT00590590 (6) [back to overview]	Change From Baseline in Overall Vulvar Vestibulitis Symptoms Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Symptoms and 100 = As Bad as They Can be]
NCT00590590 (6) [back to overview]	Change From Baseline in Overall Intercourse-Related Pain Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Pain and 100 = Most Severe Pain]
NCT00590590 (6) [back to overview]	Change From Baseline in Marinoff Dyspareunia Scale Score at End of Treatment (12 Weeks)
NCT00590590 (6) [back to overview]	Change From Baseline in Overall Vulvar Vestibulitis Syndrome (VVS)-Related Discomfort Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Discomfort and 100 = Most Severe Discomfort]
NCT00638443 (12) [back to overview]	Area Under the Curve
NCT00638443 (12) [back to overview]	Swiss Spinal Stenosis (SSS) Score- Symptom Severity
NCT00638443 (12) [back to overview]	Swiss Spinal Stenosis- Physical Function
NCT00638443 (12) [back to overview]	Time to First Symptoms of Moderate Pain
NCT00638443 (12) [back to overview]	Total Distance
NCT00638443 (12) [back to overview]	Visual Analog Scale (VAS)
NCT00638443 (12) [back to overview]	Patient Global Assessment (PGA)
NCT00638443 (12) [back to overview]	Recovery Time
NCT00638443 (12) [back to overview]	Roland Morris Disability Questionnaire
NCT00638443 (12) [back to overview]	Oswestry Disability Index (ODI) Score
NCT00638443 (12) [back to overview]	Modified Brief Pain Inventory (mBPI)- Interference Score
NCT00638443 (12) [back to overview]	Final Pain as Measured by NRS
NCT00641797 (1) [back to overview]	Likert Scale for Satisfaction
NCT00655642 (1) [back to overview]	Change in Visual Analog Scale (VAS) Score for Nausea. This Was Calculated by Subtracting the Patient's Reported Score on the 30 Minute VAS From the Patient's Reported VAS Score on Their Baseline VAS.
NCT00682734 (1) [back to overview]	Pain Intensity Score
NCT00866788 (11) [back to overview]	Area Under the Concentration-time Curve From Time of Dosing Extrapolated to Infinity (AUC-Inf)
NCT00866788 (11) [back to overview]	Number of Participants With Immunogenicity
NCT00866788 (11) [back to overview]	Change in Urticaria Activity Score 7 (UAS7) From Baseline to Week 4
NCT00866788 (11) [back to overview]	Maximum Observed Concentration (Cmax) of Omalizumab
NCT00866788 (11) [back to overview]	Number of Patients With Adverse Events by Severity
NCT00866788 (11) [back to overview]	Change in the Weekly Score for the Amount of Rescue Medication From Baseline to Week 4
NCT00866788 (11) [back to overview]	Time to Maximum Concentration (Tmax) of Omalizumab
NCT00866788 (11) [back to overview]	Change in the Weekly Score for Number of Hives From Baseline to Week 4
NCT00866788 (11) [back to overview]	Change in the Weekly Pruritus Score From Baseline to Week 4
NCT00866788 (11) [back to overview]	Terminal Half-Life (t1/2) of Omalizumab
NCT00866788 (11) [back to overview]	Change in the Weekly Score for Sleep Interference From Baseline to Week 4
NCT00887640 (5) [back to overview]	Maximum Rate of Change of Prostate-Specific Antigen (PSA).
NCT00887640 (5) [back to overview]	Mean Percent of N-cadherin Expression at Baseline and 8 Weeks of Treatment.
NCT00887640 (5) [back to overview]	Safety and Tolerability of Temsirolimus
NCT00887640 (5) [back to overview]	Median Progression-Free Survival (PFS)
NCT00887640 (5) [back to overview]	Change in Circulating Tumor Cell (CTC) Counts in Men With Metastatic Treatment-refractory Castration-resistant Prostate Cancer.
NCT00899847 (8) [back to overview]	Overall Response Rate (ORR)
NCT00899847 (8) [back to overview]	Median Time to Engraftment After Allo-PBSC Transplant
NCT00899847 (8) [back to overview]	Median Time to Engraftment After Auto-PBSC Transplant
NCT00899847 (8) [back to overview]	Complete Response Rate (CRR)
NCT00899847 (8) [back to overview]	Event-free Survival (EFS)
NCT00899847 (8) [back to overview]	Incidence of Graft Versus Host Disease (GvHD)
NCT00899847 (8) [back to overview]	Overall Survival (OS)
NCT00899847 (8) [back to overview]	Partial Response Rate (PRR)
NCT00923910 (7) [back to overview]	Time to Immune Response
NCT00923910 (7) [back to overview]	Number of Participants With Progressive Disease
NCT00923910 (7) [back to overview]	Number of Participants With Graft Versus Host Disease (GVHD) Greater Than or Equal to Grade 3
NCT00923910 (7) [back to overview]	Wilm's Tumor 1 (WT1) Enzyme-Linked Immunospot (ELISpot)
NCT00923910 (7) [back to overview]	Wilm's Tumor (WT1) Delayed-type Hypersensitivity (DTH)
NCT00923910 (7) [back to overview]	Toxicity
NCT00923910 (7) [back to overview]	Keyhole Limpet Hemocyanin (KLH) Delayed-type Hypersensitivity (DTH)
NCT00991809 (2) [back to overview]	Pain Tolerance
NCT00991809 (2) [back to overview]	Pain Threshold
NCT01017731 (6) [back to overview]	Maximum Concentration (Cmax) During Cycle 3
NCT01017731 (6) [back to overview]	Maximum Concentration (Cmax) During Cycle 1
NCT01017731 (6) [back to overview]	Area Under Concentration (AUC) During Cycle 3
NCT01017731 (6) [back to overview]	Area Under Concentration (AUC) During Cycle 1
NCT01017731 (6) [back to overview]	Change From Baseline to Cycle 3 in QT/Corrected QT (QTc) Interval Prolongation in Participants
NCT01017731 (6) [back to overview]	Number of Participants With Drug-Related Adverse Events (AEs)
NCT01086540 (19) [back to overview]	All-Cause Mortality: From Treatment Initiation to Week 104
NCT01086540 (19) [back to overview]	All-Cause Mortality: From Treatment Initiation to Week 48
NCT01086540 (19) [back to overview]	Change From Baseline in Distance Walked During a Six Minute Walk Test
NCT01086540 (19) [back to overview]	Change in Carbon Monoxide Diffusing Capacity (DLCO)
NCT01086540 (19) [back to overview]	Change in Quality of Life as Measured by the Disability Index of the Scleroderma Health Assessment Questionnaire (HAQ-DI)
NCT01086540 (19) [back to overview]	Change From Baseline in Quality of Life as Measured by the Short Form Health Survey (SF-36): Physical Component Summary Score
NCT01086540 (19) [back to overview]	Change From Baseline in Quality of Life as Measured by the Short Form Health Survey (SF-36): Mental Component Summary Score
NCT01086540 (19) [back to overview]	Change in Severity of Raynaud's Phenomenon
NCT01086540 (19) [back to overview]	Change From Baseline in Distance Walked During a Six Minute Walk Test at Week 24 and Week 48
NCT01086540 (19) [back to overview]	Number of Infusion-Related Toxicities
NCT01086540 (19) [back to overview]	Number of New Digital Ulcers
NCT01086540 (19) [back to overview]	Treatment-Related Mortality: From Treatment Initiation to Week 48
NCT01086540 (19) [back to overview]	Time to the Change or Addition of New Pulmonary Arterial Hypertension (PAH) Therapeutic Medications
NCT01086540 (19) [back to overview]	Number of Infection-Related Adverse Events (AEs) Through Week 48
NCT01086540 (19) [back to overview]	Oxygen Saturation Levels at Week 24 and Week 48
NCT01086540 (19) [back to overview]	Time to Clinical Worsening
NCT01086540 (19) [back to overview]	Percent Change From Baseline in Pulmonary Vascular Resistance Measured by Right Heart Catheterization
NCT01086540 (19) [back to overview]	Change From Baseline in Pulmonary Vascular Resistance Measured by Right Heart Catheterization at Week 24
NCT01086540 (19) [back to overview]	Number of Grade 3 or Higher Adverse Events (AEs) Through Week 48
NCT01118273 (26) [back to overview]	Change From Baseline in Visual Analog Scale (VAS) Score
NCT01118273 (26) [back to overview]	Change From Baseline in Categorical Pain Rating Scale Score
NCT01118273 (26) [back to overview]	Activity Mean Measured by Actigraphy
NCT01118273 (26) [back to overview]	Overall Rating of Severity in Visual Analog Scale (VAS) Score
NCT01118273 (26) [back to overview]	Overall Rating of Severity in Categorical Pain Rating Scale Score
NCT01118273 (26) [back to overview]	Overall Rating of Pain Relief
NCT01118273 (26) [back to overview]	Number of Times Participants Took Rescue Medication
NCT01118273 (26) [back to overview]	Karolinska Sleep Diary - Well Rested
NCT01118273 (26) [back to overview]	Karolinska Sleep Diary - Sufficient Sleep
NCT01118273 (26) [back to overview]	Karolinska Sleep Diary - Sleep Quality
NCT01118273 (26) [back to overview]	Karolinska Sleep Diary - Premature Awakening
NCT01118273 (26) [back to overview]	Karolinska Sleep Diary - Easiness to Fall Asleep
NCT01118273 (26) [back to overview]	Karolinska Sleep Diary - Ease of Awakening
NCT01118273 (26) [back to overview]	Karolinska Sleep Diary - Calmness of Sleep
NCT01118273 (26) [back to overview]	Global Assessment of Study Medication as a Sleep-aid
NCT01118273 (26) [back to overview]	Global Assessment of Study Medication as a Pain Reliever
NCT01118273 (26) [back to overview]	Cumulative Proportion of Participants Taking Rescue Medication by Hour
NCT01118273 (26) [back to overview]	Wake Episode Measured by Actigraphy
NCT01118273 (26) [back to overview]	Wake After Sleep Onset (WASO) Measured by Actigraphy
NCT01118273 (26) [back to overview]	Total Wake Time Measured by Actigraphy
NCT01118273 (26) [back to overview]	Total Sleep Time Measured by Actigraphy
NCT01118273 (26) [back to overview]	Total Sleep Time by Subject Assessment
NCT01118273 (26) [back to overview]	Time to Rescue Medication
NCT01118273 (26) [back to overview]	Sleep Quality Index
NCT01118273 (26) [back to overview]	Sleep Latency Measured by Actigraphy
NCT01118273 (26) [back to overview]	Sleep Efficiency Measured by Actigraphy
NCT01119222 (2) [back to overview]	Average Pain (0-120 Seconds): Cold Pain Test Visual Analog Scale (VAS)
NCT01119222 (2) [back to overview]	Interpolated Average Pain (0-8 Hours)
NCT01204255 (2) [back to overview]	Side Effects
NCT01204255 (2) [back to overview]	Lorazepam, Diphenyhydramine, Haloperidol Absorption
NCT01264939 (11) [back to overview]	Percentage of Angioedema-free Days From Week 4 to Week 12
NCT01264939 (11) [back to overview]	Time to Minimally Important Difference (MID) Response in the Weekly Itch Severity Score by Week 12
NCT01264939 (11) [back to overview]	Percentage of Weekly Itch Severity Score MID Responders at Week 12
NCT01264939 (11) [back to overview]	Percentage of Participants With Adverse Events
NCT01264939 (11) [back to overview]	Percentage of Participants With a UAS7 Score ≤ 6 at Week 12
NCT01264939 (11) [back to overview]	Percentage of Complete Responders (UAS7 = 0) at Week 12
NCT01264939 (11) [back to overview]	Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) Score at Week 12
NCT01264939 (11) [back to overview]	Change From Baseline to Week 12 in the Urticaria Activity Score Over 7 Days (UAS7)
NCT01264939 (11) [back to overview]	Change From Baseline to Week 12 in the Weekly Itch Severity Score
NCT01264939 (11) [back to overview]	Change From Baseline to Week 12 in the Weekly Number of Hives Score
NCT01264939 (11) [back to overview]	Change From Baseline to Week 12 in the Weekly Size of the Largest Hive Score
NCT01293968 (1) [back to overview]	Effect of Ibuprofen, Diphenhydramine and Aluminium MgS Measured on Decrease in Pain Level and Burning Sensation
NCT01332318 (28) [back to overview]	Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Average Speed
NCT01332318 (28) [back to overview]	Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Speed Variability
NCT01332318 (28) [back to overview]	Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in the Alertness Visual Analog Scale (VAS) Score
NCT01332318 (28) [back to overview]	Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in the Pittsburgh Sleep Diary (PghSD) Total Sleep Time Item
NCT01332318 (28) [back to overview]	Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) on the Brief Assessment of Cognition (BAC) Composite Score
NCT01332318 (28) [back to overview]	Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) on the Brief Assessment of Cognition (BAC) Scaled Verbal Fluency Test Score
NCT01332318 (28) [back to overview]	Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) on the Brief Assessment of Cognition (BAC) Scaled Verbal Memory Test Score
NCT01332318 (28) [back to overview]	Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) on the Brief Assessment of Cognition (BAC) Scaled Symbol Coding Test Score
NCT01332318 (28) [back to overview]	Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) on the Brief Assessment of Cognition (BAC) Scaled Tower of London (TOL) Score
NCT01332318 (28) [back to overview]	Mean Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in the Pittsburgh Sleep Diary (PghSD) Sleep Quality
NCT01332318 (28) [back to overview]	Mean Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) on the Pittsburgh Sleep Diary (PghSD) Sleep Onset Items
NCT01332318 (28) [back to overview]	Number of Participants in Each Category of the Investigator-Rated Clinician Global Impression of Improvement (CGI-I) Scale at Day 14
NCT01332318 (28) [back to overview]	Number of Participants in Each Category of the Participant-Rated Clinician Global Impression of Improvement (CGI-I) Scale at Day 14
NCT01332318 (28) [back to overview]	Number of Participants With no Reported RLS Symptoms During Each of the 4-hour Periods From the 24-hour RLS Record at Day 14
NCT01332318 (28) [back to overview]	Number of Participants With the Indicated Number of Simulated Crashes on Days 14 (Evening), 15 (Morning After Dose), and 16 (Tmax)
NCT01332318 (28) [back to overview]	Number of Participants With the Indicated Post Sleep Questionnaire (PSQ) Responses at Day 14
NCT01332318 (28) [back to overview]	Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) on the Brief Assessment of Cognition (BAC) Scaled Token Motor Task Test Score
NCT01332318 (28) [back to overview]	Mean Change From Baseline (Day -1) at Day 14 in the International Restless Legs Syndrome (IRLS) Rating Scale Total Score
NCT01332318 (28) [back to overview]	Change From Baseline (Day -1) in Overall Lane Position Variability (LPV) on Day 16 (Tmax)
NCT01332318 (28) [back to overview]	Change From Baseline (Day -1) to Day 14 (Evening) in the Epworth Sleepiness Scale (ESS) Total Score
NCT01332318 (28) [back to overview]	Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Brake Reaction Time
NCT01332318 (28) [back to overview]	Median Time to Onset of a Participant's First RLS Symptoms Using the 24-hour RLS Symptom Record at Day 14
NCT01332318 (28) [back to overview]	Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) on the Brief Assessment of Cognition (BAC) Scaled Digit Sequencing Score (DSS)
NCT01332318 (28) [back to overview]	Number of Participants Who Responded to Treatment Based on Scores on the Investigator-Rated CGI-I at Day 14
NCT01332318 (28) [back to overview]	Number of Participants Who Responded to Treatment Based on Scores on the Participant-Rated CGI-I at Day 14
NCT01332318 (28) [back to overview]	Percentage of Participants With no Reported RLS Symptoms During the 24-hour RLS Record at Day 14
NCT01332318 (28) [back to overview]	Change From Baseline (Day -1) to Day 14 (Evening) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Lane Position Variability (LPV)
NCT01332318 (28) [back to overview]	Change From Baseline (Day -1) to Day 14 (Evening) and Day 16 (at Tmax) and Change From Baseline (Day 1) to Day 15 (Morning After Dose) in Overall Average Lane Position
NCT01451762 (1) [back to overview]	Quality of Recovery 40 at 24 Hours
NCT01474915 (2) [back to overview]	Post Operative Nausea and Vomiting (PONV) Scores on a Verbal Response Scale
NCT01474915 (2) [back to overview]	Proportion of Patients With a Complete Response/Complete Control During the First 24 Hours After Neurological Surgery Under General Anesthesia
NCT01510379 (2) [back to overview]	Quantify the Amounts of Phenergan Used Between the Two Groups.
NCT01510379 (2) [back to overview]	Comparison of Postoperative Nausea and Vomiting Scores Between Groups Treated With a ReletexTM Device and Those Without the Device.
NCT01556932 (1) [back to overview]	The Change in Numeric Rating Scale in Self-reported Nausea From Baseline Minus 60 Minutes of Treatment.
NCT01737931 (4) [back to overview]	Skin Irritation Score of the Application Site
NCT01737931 (4) [back to overview]	Skin Irritation Score After Patch Removal
NCT01737931 (4) [back to overview]	Itching of Application Site Evaluated by VAS After Patch Removal
NCT01737931 (4) [back to overview]	Itching of Application Site Evaluated by the Visual Analogue Scale (VAS)
NCT01769586 (1) [back to overview]	Number of Patients Who Achieve Adequate Sedation to Allow Colonoscopy (Defined as MOAA/S ≤3)
NCT01825941 (1) [back to overview]	Number of Participants With Sustained Headache Relief Assessed by Self-evaluation
NCT01846455 (10) [back to overview]	Time to Reach the Maximum Plasma Concentration (Tmax) of Buprenorphine, Norbuprenorphine, Naloxone and Naloxone-3-β-D-Glucuronide
NCT01846455 (10) [back to overview]	Apparent Volume of Distribution During Terminal Phase (Vz/F) of Buprenorphine and Naloxone
NCT01846455 (10) [back to overview]	Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Buprenorphine, Norbuprenorphine, Naloxone and Naloxone-3-β-D-Glucuronide
NCT01846455 (10) [back to overview]	Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUC0-last) of Buprenorphine, Norbuprenorphine, Naloxone and Naloxone-3-β-D-Glucuronide
NCT01846455 (10) [back to overview]	Percentage of Area Under the Concentration-time Curve From Time Zero to Infinity Due to Extrapolation (%AUCextrap) of Buprenorphine, Norbuprenorphine, Naloxone and Naloxone-3-β-D-Glucuronide
NCT01846455 (10) [back to overview]	Terminal Elimination Half-life (t1/2) of Buprenorphine, Norbuprenorphine, Naloxone and Naloxone-3-β-D-Glucuronide
NCT01846455 (10) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Buprenorphine, Norbuprenorphine, Naloxone and Naloxone-3-β-D-Glucuronide
NCT01846455 (10) [back to overview]	Apparent Body Clearance (CL/F) of Buprenorphine and Naloxone
NCT01846455 (10) [back to overview]	Terminal Phase Elimination Rate-Constant (λz) of Buprenorphine, Norbuprenorphine, Naloxone and Naloxone-3-β-D-Glucuronide
NCT01846455 (10) [back to overview]	Time of the Last Measureable Plasma Concentration (Tlast) of Buprenorphine, Norbuprenorphine, Naloxone and Naloxone-3-β-D-Glucuronide
NCT01888497 (3) [back to overview]	Lane Exceedance
NCT01888497 (3) [back to overview]	Speed Deviation
NCT01888497 (3) [back to overview]	Standard Deviation of Lateral Position (SDLP)
NCT01905631 (1) [back to overview]	Reduction of Itching in AD
NCT01967433 (7) [back to overview]	Dosage of Midazolam
NCT01967433 (7) [back to overview]	Dosage of Fentanyl
NCT01967433 (7) [back to overview]	24 Hour Follow up Pain Score
NCT01967433 (7) [back to overview]	24 Hour Follow up Amnesia Score
NCT01967433 (7) [back to overview]	Number of Participants With Adverse Events
NCT01967433 (7) [back to overview]	Quality of Sedation
NCT01967433 (7) [back to overview]	Duration of Procedure
NCT01968694 (4) [back to overview]	Change in Brief Pain Inventory (BPI): Pain on Average
NCT01968694 (4) [back to overview]	Change in Visual Analogue Scale (VAS)
NCT01968694 (4) [back to overview]	Change in Short Form McGill Pain Questionnaire 2
NCT01968694 (4) [back to overview]	Change in Hospital Anxiety and Depression Scale (HADS)
NCT01985126 (7) [back to overview]	Duration of Response
NCT01985126 (7) [back to overview]	Time to Disease Progression
NCT01985126 (7) [back to overview]	Overall Survival
NCT01985126 (7) [back to overview]	Percentage of Participants With Clinical Benefit
NCT01985126 (7) [back to overview]	Percentage of Participants With Overall Response
NCT01985126 (7) [back to overview]	Progression Free Survival
NCT01985126 (7) [back to overview]	Time to Response
NCT02029638 (18) [back to overview]	Number of Transplanted Participants Who Remained Off Immunosuppression for at Least 52 Weeks, Including Those in Whom the 52 Week Biopsy Was Not Performed
NCT02029638 (18) [back to overview]	Number of Transplanted Participants Who Died
NCT02029638 (18) [back to overview]	Percent of Participants Who Achieved Operational Tolerance
NCT02029638 (18) [back to overview]	Number of Transplanted Participants Who Developed Donor-Specific Antibody During Study Participation
NCT02029638 (18) [back to overview]	Number of Transplanted Participants Who Developed Donor- Specific Antibody After Initiation of Immunosuppression Withdrawal
NCT02029638 (18) [back to overview]	Number of Participants Free From Return to Immunosuppression for the Duration of the Study
NCT02029638 (18) [back to overview]	Number of Participants Experiencing an Incidence of Graft-versus-Host Disease Post-Transplant
NCT02029638 (18) [back to overview]	Number of Days Post-Transplant to the First Episode of Acute Rejection Requiring Treatment
NCT02029638 (18) [back to overview]	Number of Days From Transplant to Platelet Count Recovery
NCT02029638 (18) [back to overview]	Number of Days From Neutrophil Nadir to Absolute Neutrophil Recovery
NCT02029638 (18) [back to overview]	Histological Severity of Biopsies Demonstrating Acute Rejection as Defined by Banff 2007 Classification Renal Allograft Pathology
NCT02029638 (18) [back to overview]	Number of Adverse Events (AEs) by Severity- Including Infection, Wound Complications, Post-Transplant Diabetes, Hemorrhagic Cystitis and Malignancy
NCT02029638 (18) [back to overview]	Number of Adverse Events (AEs)- Including Infection, Wound Complications, Post-transplant Diabetes, Hemorrhagic Cystitis and Malignancy
NCT02029638 (18) [back to overview]	Duration in Days of Adverse Events (AEs)- Including Infection, Wound Complications, Post-transplant Diabetes, Hemorrhagic Cystitis and Malignancy
NCT02029638 (18) [back to overview]	Number of Transplanted Participants With Engraftment Syndrome
NCT02029638 (18) [back to overview]	Number of Transplanted Participants With Chronic T Cell-Mediated or Antibody-Mediated Rejection
NCT02029638 (18) [back to overview]	Number of Transplanted Participants With Acute Renal Allograft Rejection
NCT02029638 (18) [back to overview]	Duration in Days of Graft-versus-Host Disease in Transplanted Participants
NCT02061293 (21) [back to overview]	Percentage of Participants Achieving Abstinence From Drinking
NCT02061293 (21) [back to overview]	Percentage of Participants Achieving Abstinence From Drinking
NCT02061293 (21) [back to overview]	Short Inventory of Problems (SIP-2R) Score
NCT02061293 (21) [back to overview]	Short Inventory of Problems (SIP-2R) Score
NCT02061293 (21) [back to overview]	Percent of Participants Achieving WHO Risk Drinking Level Decrease of at Least 1 Level
NCT02061293 (21) [back to overview]	Drinks Per Day
NCT02061293 (21) [back to overview]	Drinks Per Day
NCT02061293 (21) [back to overview]	Drinks Per Day
NCT02061293 (21) [back to overview]	Percent of Drinking Days
NCT02061293 (21) [back to overview]	Percent of Drinking Days
NCT02061293 (21) [back to overview]	Percent of Drinking Days
NCT02061293 (21) [back to overview]	Percent of Heavy Drinking Days
NCT02061293 (21) [back to overview]	Percent of Heavy Drinking Days
NCT02061293 (21) [back to overview]	Percent of Heavy Drinking Days
NCT02061293 (21) [back to overview]	Percent of Participants Achieving No Heavy Drinking Days
NCT02061293 (21) [back to overview]	Percent of Participants Achieving No Heavy Drinking Days
NCT02061293 (21) [back to overview]	Percent of Participants Achieving WHO Risk Drinking Level Decrease of at Least 1 Level
NCT02061293 (21) [back to overview]	Percent of Participants Achieving WHO Risk Drinking Level Decrease of at Least 2 Levels
NCT02061293 (21) [back to overview]	Percent of Participants Achieving WHO Risk Drinking Level Decrease of at Least 2 Levels
NCT02061293 (21) [back to overview]	Percent of Participants Achieving WHO Risk Drinking Level Decrease of at Least 3 Levels
NCT02061293 (21) [back to overview]	Percent of Participants Achieving WHO Risk Drinking Level Decrease of at Least 3 Levels
NCT02062710 (1) [back to overview]	Change in Cough Reflex Sensitivity to Capsaicin
NCT02106325 (9) [back to overview]	Beck Depression Inventory-II (BDI-II)
NCT02106325 (9) [back to overview]	Length of Inpatient Stay
NCT02106325 (9) [back to overview]	Montgomery-Åsberg Depression Rating Scale Suicide Ideation Item (MADRS-SI)
NCT02106325 (9) [back to overview]	Outpatient Follow-up Compliance
NCT02106325 (9) [back to overview]	Beck Scale for Suicidal Ideation (BSSI)
NCT02106325 (9) [back to overview]	Change in Treatment Alliance Score
NCT02106325 (9) [back to overview]	Evaluate the Effects of Ketamine on Depressive Symptomatology by Measuring Change in Score on the Montgomery-Asberg Depressive Rating Scale
NCT02106325 (9) [back to overview]	Hamilton Depression Scale (Ham-D)
NCT02106325 (9) [back to overview]	Inpatient Treatment Alliance Scale (ITAS)
NCT02136420 (5) [back to overview]	Percent Change in Roll Tilt Perception After Exposure to Hypogravity
NCT02136420 (5) [back to overview]	Yaw Perceptual Motion Threshold
NCT02136420 (5) [back to overview]	Percent Change in Manual Control Performance After Exposure to Hypogravity
NCT02136420 (5) [back to overview]	Roll Perceptual Motion Threshold
NCT02136420 (5) [back to overview]	Interaural Perceptual Motion Threshold
NCT02142712 (2) [back to overview]	Glasgow Coma Scale (GCS)
NCT02142712 (2) [back to overview]	National Institutes of Health Stroke Severity (NIHSS) Scale
NCT02188719 (5) [back to overview]	Percent of Participants With Grade 2 or Higher Hematologic Adverse Events (AEs) of Anemia, Neutropenia, and/or Thrombocytopenia
NCT02188719 (5) [back to overview]	Percent of Participants With Biopsy-Proven Acute and/or Chronic Rejection
NCT02188719 (5) [back to overview]	Percent of Participants With Grade 3 or Higher Wound Complication(s) Adverse Event(s)
NCT02188719 (5) [back to overview]	Percent of Participants With Adverse Events (AEs) Attributable to the Donor Alloantigen Reactive Tregs (darTregs) Infusion
NCT02188719 (5) [back to overview]	Percent of Participants With Grade 3 or Higher Infectious Adverse Event(s)
NCT02229539 (1) [back to overview]	Mean Area Under the Curve (AUC) of Total Pain Reduction
NCT02260934 (15) [back to overview]	Count of Participants: Frequency of Non-renal Flares by Week 48
NCT02260934 (15) [back to overview]	Count of Participants: Frequency of Non-renal Flares by Week 24
NCT02260934 (15) [back to overview]	Frequency of Specific Adverse Events of Interest By Event by Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With a Sustained Complete Response
NCT02260934 (15) [back to overview]	Percentage of Participants With Grade 4 Hypogammaglobulinemia by Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants Hypocomplementemic for Complement Component C3 at Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants Hypocomplementemic for Complement Component C4 at Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With Treatment Failure by Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With a Complete Response at Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With an Negative Anti-dsDNA Result at Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With an Overall Response at Week 24, Week 48, and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With At Least One Grade 3 or Higher Infectious Adverse Event By Week 24, Week 48 and Week 96
NCT02260934 (15) [back to overview]	Percentage of Participants With B Cell Reconstitution at Week 24, Week 48 and Week 96
NCT02260934 (15) [back to overview]	Count of Participants: Frequency of Non-renal Flares by Week 96
NCT02260934 (15) [back to overview]	Frequency of Specific Adverse Events of Interest By Participant, By Week 96
NCT02295280 (1) [back to overview]	Number of Participants With Adequate Relief of Headache as a Measure of Efficacy
NCT02339155 (11) [back to overview]	Percentage of Participants Who Seroconvert, at Weeks 4, 8, and 26 (Days 29, 57 and 183) After the First AVA Dose, Between the AVA Alone and the AVA With Raxibacumab Treatment Groups
NCT02339155 (11) [back to overview]	Number of Participants With Urinalysis Parameters
NCT02339155 (11) [back to overview]	Number of Participants With Hematology Parameters Outside Normal Range
NCT02339155 (11) [back to overview]	Number of Participants With Clinical Chemistry Parameters Outside Normal Range
NCT02339155 (11) [back to overview]	Ratio of GMC of Anti-PA Ab at Weeks 8 and 26 (Days 57 and 183) After the First AVA Dose, Between the AVA Alone and AVA With Raxibacumab Treatment Groups
NCT02339155 (11) [back to overview]	Ratio of Geometric Mean Concentrations (GMC) of Anti-protective Antigen (PA) Antibody (Ab) at 4 Weeks (Day 29) After the First AVA Dose (Prior to the Third AVA Dose), Between the AVA Alone and the AVA With Raxibacumab Treatment Groups
NCT02339155 (11) [back to overview]	Change From Baseline in Heart Rate at Indicated Time Points
NCT02339155 (11) [back to overview]	Change From Baseline in Respiratory Rate at Indicated Time Points
NCT02339155 (11) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Indicated Time Points
NCT02339155 (11) [back to overview]	Change From Baseline in Temperature at Indicated Time Points
NCT02339155 (11) [back to overview]	Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (AE)
NCT02363946 (15) [back to overview]	Number of Participants With a Return From Nadir AAT Blood Levels to Above Normal or Within 15% of Baseline in > 100 Days
NCT02363946 (15) [back to overview]	Maximum Percentage Reduction in Mean AAT (Nadir of Mean AAT)
NCT02363946 (15) [back to overview]	Mean Percentage Change in Circulating Blood Levels of Complement Factors 2 Hours Post-Dose
NCT02363946 (15) [back to overview]	Percentage Reduction From Baseline of AAT Up to Day 29
NCT02363946 (15) [back to overview]	Pharmacokinetics of ARC-AAT: Area Under the Plasma Concentration Versus Time Curve From From Zero to Infinity (AUCinf) for the Analytes AD00370 and ARC-MLP (Part A)
NCT02363946 (15) [back to overview]	Pharmacokinetics of ARC-AAT: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time 24 Hours (AUC0-24) for the Analytes AD00370 and ARC-MLP (Part A)
NCT02363946 (15) [back to overview]	Pharmacokinetics of ARC-AAT: Half-Life (t1/2) for the Analytes AD00370 and ARC-MLP (Part A)
NCT02363946 (15) [back to overview]	Pharmacokinetics of ARC-AAT: Maximum Observed Plasma Concentration (Cmax) for the Analytes AD00370 and ARC-Melittin-Like Peptide (MLP; Part A)
NCT02363946 (15) [back to overview]	Pharmacokinetics of ARC-AAT: Terminal Elimination Rate Constant Obtained From the Slope of the Line (Kel) for the Analytes AD00370 and ARC-MLP (Part A)
NCT02363946 (15) [back to overview]	Pharmacokinetics of ARC-AAT: Time to Maximum Observed Concentration (Tmax) for the Analytes AD00370 and ARC-MLP (Part A)
NCT02363946 (15) [back to overview]	Number of Participants With Clinically Significant Treatment-Emergent Abnormalities in Vital Signs, Electrocardiograms (ECGs), Pulmonary Function, Physical Findings, and Other Observations
NCT02363946 (15) [back to overview]	Number of Participants With Clinically Significant Treatment-Emergent Abnormalities in Laboratory Values
NCT02363946 (15) [back to overview]	Number of Participants With AAT Reduction > 30% From Baseline (First Occurrence)
NCT02363946 (15) [back to overview]	Mean Percentage Change in Circulating Blood Levels of Cytokines 2 Hours Post-Dose
NCT02363946 (15) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Discontinuations Due to TEAEs
NCT02389829 (4) [back to overview]	Number of Participants With Sustained Headache Relief Assessed by Self-evaluation
NCT02389829 (4) [back to overview]	Number of Participants Who Achieved Short Term Headache Relief, Assessed by Telphone Questionnaire
NCT02389829 (4) [back to overview]	Number of Participants Who Achieved Short Term Headache Freedom; Assessed by Telephone Questionnaire
NCT02389829 (4) [back to overview]	Number of Participants Needing Rescue Medication as Assessed by Questionnaire
NCT02452528 (1) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to Adverse Events (AEs)
NCT02465866 (16) [back to overview]	Observed Elimination Rate Constant (λz)
NCT02465866 (16) [back to overview]	Observed Terminal Elimination Half-life (T1/2)
NCT02465866 (16) [back to overview]	Percentage of AUCinf [AUCExtrap (%)] Based on Extrapolation
NCT02465866 (16) [back to overview]	Maximum Drug Concentration (Cmax) in Plasma Determined Directly From Individual Concentration-time Data
NCT02465866 (16) [back to overview]	Last Quantifiable Drug Concentration (Clast) Determined Directly From Individual Concentration-time Data
NCT02465866 (16) [back to overview]	Area Under the Concentration-time (AUCinf) Curve From Time-zero Extrapolated to Infinity
NCT02465866 (16) [back to overview]	Time of the Last Quantifiable Concentration (Tlast)
NCT02465866 (16) [back to overview]	Area Under the Plasma Concentration-time (AUClast) Curve From Time-zero to the Time of the Last Quantifiable Concentration
NCT02465866 (16) [back to overview]	Area Under the Plasma Concentration-time Curve (AUC0-0.25) for Hydrocodone and Promethazine
NCT02465866 (16) [back to overview]	AUC0-0.50 for Hydrocodone and Promethazine
NCT02465866 (16) [back to overview]	AUC0-0.75 for Hydrocodone and Promethazine
NCT02465866 (16) [back to overview]	AUC0-1.0 for Hydrocodone and Promethazine
NCT02465866 (16) [back to overview]	AUC0-1.5 for Hydrocodone and Promethazine
NCT02465866 (16) [back to overview]	AUC0-2.0 for Hydrocodone and Promethazine
NCT02465866 (16) [back to overview]	AUC0-4.0 for Hydrocodone and Promethazine
NCT02465866 (16) [back to overview]	Time to Reach Maximum Concentration (Tmax)
NCT02474199 (8) [back to overview]	Count of Participants by Severity of Biopsy Proven Acute Rejection and/or Chronic Rejection
NCT02474199 (8) [back to overview]	Number of Participants Achieving Efficacy Status Post Receipt of a Single Intravenous (IV) Dose of Donor Alloantigen Reactive Regulatory T Cells (darTregs)
NCT02474199 (8) [back to overview]	Proportion of Liver Transplant Recipients Who Are Able to Reduce Calcineurin Inhibitor Dosing by 75 Percent and Discontinue a Second Immunosuppression Drug (if Applicable) With Stable Liver Function Tests (LFTs) for ≥ 12 Weeks
NCT02474199 (8) [back to overview]	Number of Participants With Study Defined Grade 3 or Higher Infections
NCT02474199 (8) [back to overview]	Number of Participants With Any Malignancy
NCT02474199 (8) [back to overview]	Number of Participants Who Experienced Grade 3 or Higher Adverse Events (AEs) Deemed Attributable to darTreg Infusion
NCT02474199 (8) [back to overview]	Number of Participants Who Experience at Least One Episode of Biopsy Proven Acute Rejection, Clinical Acute Rejection, or Chronic Rejection
NCT02474199 (8) [back to overview]	Number of Liver Transplant Recipients Who Experience the Composite Outcome
NCT02495077 (44) [back to overview]	Duration of Delayed Graft Function (DGF), Defined as Time From Transplantation to the Last Required Dialysis Treatment.
NCT02495077 (44) [back to overview]	eGFR Values as Measured by CKD-EPI
NCT02495077 (44) [back to overview]	eGFR Values as Measured by MDRD
NCT02495077 (44) [back to overview]	Change in eGFR Between 6 Months and 24 Months as Measured by MDRD
NCT02495077 (44) [back to overview]	Change in eGFR Between Post-transplant Nadir and 24 Months as Measured by CKD-EPI
NCT02495077 (44) [back to overview]	Number of Dialysis Sessions.
NCT02495077 (44) [back to overview]	eGFR Values as Measured by CKD-EPI
NCT02495077 (44) [back to overview]	Change From Baseline (Immediately After Surgery) in Serum Creatinine.
NCT02495077 (44) [back to overview]	The Percent of Participants With a Serum Creatinine of More Than 3 mg/dL.
NCT02495077 (44) [back to overview]	The Percent of Participants Whose Day 5 Serum CRR Was Less Than 70%.
NCT02495077 (44) [back to overview]	The Percent of Participants Whose Day 2 Serum CRR Was Less Than 30%.
NCT02495077 (44) [back to overview]	The Percent of Participants Who Need Dialysis After Week 1.
NCT02495077 (44) [back to overview]	The Difference Between the Mean eGFR (Modified MDRD) in the Experimental vs. Control Groups.
NCT02495077 (44) [back to overview]	Percent of Participants With Primary Non-Function (PNF), Defined as Dialysis-dependency for More Than 3 Months.
NCT02495077 (44) [back to overview]	Percent of Participants With Only Graft Failure.
NCT02495077 (44) [back to overview]	Percent of Participants With Mycobacterial or Fungal Infections
NCT02495077 (44) [back to overview]	Percent of Participants With Malignancy.
NCT02495077 (44) [back to overview]	Percent of Participants With Locally Treated Rejection, Defined as Treatment Administered for Rejection Based on Clinical Signs or Biopsy Findings.
NCT02495077 (44) [back to overview]	Percent of Participants With Locally Treated Rejection, Defined as Treatment Administered for Rejection Based on Clinical Signs or Biopsy Findings.
NCT02495077 (44) [back to overview]	Percent of Participants With Impaired Wound Healing Manifested by Wound Dehiscence, Wound Infection, or Hernia at the Site of the Transplant Incision
NCT02495077 (44) [back to overview]	Percent of Participants With Death or Graft Failure.
NCT02495077 (44) [back to overview]	Percent of Participants With de Novo DSA.
NCT02495077 (44) [back to overview]	Percent of Participants With CMV Viremia That Require a Change in Immunosuppression or Anti-viral Treatment as Per Standard of Care at the Site
NCT02495077 (44) [back to overview]	Percent of Participants With BK Viremia That Require a Change in Immunosuppression or Anti-viral Treatment as Per Standard of Care at the Site.
NCT02495077 (44) [back to overview]	Percent of Participants With Biopsy Proven Acute Cellular Rejection (BPAR).
NCT02495077 (44) [back to overview]	Percent of Participants With Biopsy Proven Acute Cellular Rejection (BPAR) or Borderline Rejection.
NCT02495077 (44) [back to overview]	Percent of Participants With Biopsy Proven Acute Cellular Rejection (BPAR) or Borderline Rejection
NCT02495077 (44) [back to overview]	Percent of Participants With Biopsy Proven Acute Cellular Rejection (BPAR)
NCT02495077 (44) [back to overview]	Percent of Participants With Biopsy Proven Acute Antibody Mediated Rejection AMR or Suspicious for AMR.
NCT02495077 (44) [back to overview]	Percent of Participants With Biopsy Proven Acute Antibody Mediated Rejection AMR or Suspicious for AMR
NCT02495077 (44) [back to overview]	Percent of Participants With Biopsy Proven Acute Antibody Mediated Rejection (AMR).
NCT02495077 (44) [back to overview]	Percent of Participants That Required at Least One Dialysis Treatment.
NCT02495077 (44) [back to overview]	Change in eGFR Between Post-transplant Nadir and 24 Months as Measured by MDRD
NCT02495077 (44) [back to overview]	eGFR Values as Measured by MDRD
NCT02495077 (44) [back to overview]	Creatinine Reduction Ratio (CRR), Defined as the First Creatinine on Day 2 Divided by he First Creatinine After Surgery
NCT02495077 (44) [back to overview]	Creatinine Reduction Ratio (CRR), Defined as the First Creatinine on Day 5 Divided by the First Creatinine After Surgery.
NCT02495077 (44) [back to overview]	Days From Transplantation Until Event (ACR, AMR, or Hospitalization for Infection and/or Malignancy)
NCT02495077 (44) [back to overview]	Percent of Participants With Biopsy Proven Acute Antibody Mediated Rejection (AMR)
NCT02495077 (44) [back to overview]	Percent of Participants With BANFF Chronicity Scores > or Equal 2 on the 24 Month Biopsy.
NCT02495077 (44) [back to overview]	Percent of Participants With Any Infection Requiring Hospitalization or Resulting in Death.
NCT02495077 (44) [back to overview]	Change in eGFR Between 3 Months and 24 Months as Measured by MDRD
NCT02495077 (44) [back to overview]	BANFF Grades of First AMR.
NCT02495077 (44) [back to overview]	Change in eGFR Between 3 Months and 24 Months as Measured by CKD-EPI
NCT02495077 (44) [back to overview]	Change in eGFR Between 6 Months and 24 Months as Measured by CKD-EPI
NCT02535416 (9) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT02535416 (9) [back to overview]	Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Zero Extrapolated to Infinity (AUCinf) of the Analytes of ARC-520
NCT02535416 (9) [back to overview]	Pharmacokinetics: Apparent Volume of Distribution (V) of the Analytes of ARC-520
NCT02535416 (9) [back to overview]	Pharmacokinetics: Terminal Elimination Rate Constant (Lambda z) of the Analytes of ARC-520
NCT02535416 (9) [back to overview]	Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24) of the Analytes of ARC-520
NCT02535416 (9) [back to overview]	Pharmacokinetics: Maximum Plasma Concentration (Cmax) of the Analytes of ARC-520
NCT02535416 (9) [back to overview]	Pharmacokinetics: Half-Life (t1/2) of the Analytes of ARC-520
NCT02535416 (9) [back to overview]	Pharmacokinetics: Clearance (CL) of the Analytes of ARC-520
NCT02535416 (9) [back to overview]	Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Plasma Concentration (AUClast) of the Analytes of ARC-520
NCT02578186 (1) [back to overview]	Mean Latency to Persistent Sleep
NCT02625181 (4) [back to overview]	Adherence to PONV Guidelines
NCT02625181 (4) [back to overview]	PONV Incidence: Number of Participants With Postoperative Nausea and Vomiting
NCT02625181 (4) [back to overview]	The Number of Prophylactic Interventions for PONV
NCT02625181 (4) [back to overview]	Time to Discharge From the Postanesthesia Care Unit (PACU)
NCT02635828 (2) [back to overview]	PONV Incidence
NCT02635828 (2) [back to overview]	Incidence of Subjects Significant QTc Changes in the EKG
NCT02655354 (13) [back to overview]	SF-36 Quality of Life
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Opioid Use
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Marijuana Use
NCT02655354 (13) [back to overview]	Cognitive Impairment Scale
NCT02655354 (13) [back to overview]	Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Brief Pain Inventory
NCT02655354 (13) [back to overview]	TSOS Patient Satisfaction: Mental Health Care
NCT02655354 (13) [back to overview]	TSOS Patient Satisfaction: Overall Health Care
NCT02655354 (13) [back to overview]	Number of Participants With Suicidal Ideation
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Stimulant Use
NCT02655354 (13) [back to overview]	Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury
NCT02657031 (5) [back to overview]	Anxiety
NCT02657031 (5) [back to overview]	Headache Following Intervention
NCT02657031 (5) [back to overview]	The Number of Participants Experiencing Vomiting
NCT02657031 (5) [back to overview]	The Number of Patients Experiencing Restlessness
NCT02657031 (5) [back to overview]	Nausea
NCT02765256 (4) [back to overview]	Change in Disease Activity by Fecal Calprotectin (FCP)
NCT02765256 (4) [back to overview]	Change in Disease Activity by Harvey Bradshaw Index
NCT02765256 (4) [back to overview]	Safety and Tolerability of the Treatment Regimen Based on Medication Side Effects and/or Adverse Events (AEs).
NCT02765256 (4) [back to overview]	The Change in High-sensitivity C-reactive Protein (hsCRP)
NCT02935699 (4) [back to overview]	Time to Discharge
NCT02935699 (4) [back to overview]	Number of Patients Who Needed to Return to Treatment Center
NCT02935699 (4) [back to overview]	Change of Patient Rated Pruritus Score
NCT02935699 (4) [back to overview]	Patient Sedation Scores
NCT02972502 (1) [back to overview]	Change in Pain Score According to the Numeric Pain Intensity Scale
NCT02999633 (1) [back to overview]	Percentage of Participants With Objective Response
NCT03056352 (3) [back to overview]	Post Concussion Symptoms Assessed by Post-concussive Symptom Scale
NCT03056352 (3) [back to overview]	Number of Participants With Sustained Headache Relief
NCT03056352 (3) [back to overview]	Number of Participants Satisfied With Medication; Assessed by Self-evaluation
NCT03220958 (3) [back to overview]	Sustained Headache Relief
NCT03220958 (3) [back to overview]	Headache Days
NCT03220958 (3) [back to overview]	0-10 Pain Scale on Which 0 = no Pain and 10= the Worst Pain Imaginable
NCT03322358 (12) [back to overview]	Self-reported Pain
NCT03322358 (12) [back to overview]	Physical Fitness
NCT03322358 (12) [back to overview]	Number of Days of Illness in Past Week
NCT03322358 (12) [back to overview]	Memory
NCT03322358 (12) [back to overview]	Happiness
NCT03322358 (12) [back to overview]	Depression
NCT03322358 (12) [back to overview]	Blood Pressure
NCT03322358 (12) [back to overview]	Attention
NCT03322358 (12) [back to overview]	Activities of Daily Living
NCT03322358 (12) [back to overview]	Inhibitory Control
NCT03322358 (12) [back to overview]	Subjective Well-being
NCT03322358 (12) [back to overview]	Sleep Per 24 Hours
NCT03435692 (6) [back to overview]	Muscle Spasm
NCT03435692 (6) [back to overview]	Hospital Length of Stay
NCT03435692 (6) [back to overview]	Total Perioperative Morphine Equivalents
NCT03435692 (6) [back to overview]	Nausea
NCT03435692 (6) [back to overview]	Itching
NCT03435692 (6) [back to overview]	Maximum Pain Score
NCT03459612 (14) [back to overview]	Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan
NCT03459612 (14) [back to overview]	Total Number of Collisions
NCT03459612 (14) [back to overview]	Total Number of Collisions
NCT03459612 (14) [back to overview]	Simulated Driving Performance in Healthy Participants as Measured by Standard Deviation of Lateral Position (SDLP) Using the Cognitive Research Corporation Driving Simulator-MiniSim (CRCDS-MiniSim)
NCT03459612 (14) [back to overview]	Number of Correct Responses in Driving Performance Using CogScreen Symbol Digit Coding (SDC) Test
NCT03459612 (14) [back to overview]	Simulated Driving Performance in Healthy Participants as Measured by Standard Deviation of Lateral Position (SDLP) Using the Cognitive Research Corporation Driving Simulator-MiniSim (CRCDS-MiniSim)
NCT03459612 (14) [back to overview]	PK: Area Under the Concentration Versus Time Curve (AUC) of Lasmiditan to the Last Timepoint (0-tlast)
NCT03459612 (14) [back to overview]	Karolinska Sleepiness Scale (KSS) Score
NCT03459612 (14) [back to overview]	Number of Correct Responses in Driving Performance Using CogScreen Symbol Digit Coding (SDC) Test
NCT03459612 (14) [back to overview]	Number of Correct Responses in Driving Performance Using CogScreen Symbol Digit Coding (SDC) Test
NCT03459612 (14) [back to overview]	Karolinska Sleepiness Scale (KSS) Score
NCT03459612 (14) [back to overview]	Karolinska Sleepiness Scale (KSS) Score
NCT03459612 (14) [back to overview]	Total Number of Collisions
NCT03459612 (14) [back to overview]	Simulated Driving Performance in Healthy Participants as Measured by Standard Deviation of Lateral Position (SDLP) Using the Cognitive Research Corporation Driving Simulator-MiniSim (CRCDS-MiniSim)
NCT03639558 (4) [back to overview]	Time Patient Was Placed in Straitjacket/Restraint Post Intervention Treatment
NCT03639558 (4) [back to overview]	Number of Participants According to the Time Taken for Aggressive Behaviour to Change to Calm and Tranquil
NCT03639558 (4) [back to overview]	Time Noted Where Important Adverse Effects Occurred Post Intervention
NCT03639558 (4) [back to overview]	Time Taken for Patient to Fall Asleep Post Intervention
NCT03657810 (9) [back to overview]	Percentage of Participants With OINV Over 48 Hours
NCT03657810 (9) [back to overview]	Percentage of Patients With Complete Absence of OINV (no Nausea, no Vomiting, and no Use of Anti-emetic Medication) Over 48 Hours
NCT03657810 (9) [back to overview]	Percentage of Patients With Any Post-discharge Nausea and Vomiting (PDNV)
NCT03657810 (9) [back to overview]	Percentage of Patients With Any Vomiting Over 48 Hours
NCT03657810 (9) [back to overview]	Number of Doses of Study Medication Taken Over Days 3to7
NCT03657810 (9) [back to overview]	Percentage of Patients With Any Nausea or Vomiting Over 48 Hours
NCT03657810 (9) [back to overview]	The Sum of Pain Intensity Differences (on PI-NRS) Over 48 Hours (SPID48)
NCT03657810 (9) [back to overview]	Percentage of Patients With Any Nausea Over 48 Hours
NCT03657810 (9) [back to overview]	Number of Doses of Study Medication Taken Per Day Over Days 3to7
NCT03805932 (6) [back to overview]	Number of Participants Who Are Minimal Residual Disease (MRD)-Free
NCT03805932 (6) [back to overview]	Number of Participants Whose Cancer Shrinks or Disappears After Treatment
NCT03805932 (6) [back to overview]	Recommended Safe Dose of Moxetumomab Pasudotox-tdfk
NCT03805932 (6) [back to overview]	Number of Participants With a Dose-limiting Toxicity (DLT)
NCT03805932 (6) [back to overview]	Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
NCT03805932 (6) [back to overview]	Recommended Safe Dose of Rituximab/Ruxience
NCT04189588 (3) [back to overview]	Number of Hypersensitivity Reactions to Treatment With an Anti-CD20 Antibody or Paclitaxel
NCT04189588 (3) [back to overview]	Patient Sedation Scores at 1 Hour and 2 Hours Post-injection of Antihistamine (IV Cetirizine HCl or IV Diphenhydramine) and at Discharge.
NCT04189588 (3) [back to overview]	"Time From Injection to Readiness for Discharge"
NCT04294459 (23) [back to overview]	Time to First Transplant Offer
NCT04294459 (23) [back to overview]	Number of Participants With Abnormal Electrolytes Parameters
NCT04294459 (23) [back to overview]	Number of Participants With Abnormal Metabolism Parameters
NCT04294459 (23) [back to overview]	Number of Participants With Anti-drug Antibodies (ADA) Against Isatuximab
NCT04294459 (23) [back to overview]	Number of Participants With Anti-Human Leukocyte Antigen (HLA)-Antibody Reduction
NCT04294459 (23) [back to overview]	Number of Participants With Liver Function Abnormalities
NCT04294459 (23) [back to overview]	Number of Participants With Renal Function Abnormalities
NCT04294459 (23) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)
NCT04294459 (23) [back to overview]	Number of Participants With Hematological Abnormalities
NCT04294459 (23) [back to overview]	Duration for Achieving Target cPRA
NCT04294459 (23) [back to overview]	PK Parameters: Time of Clast (Tlast) After First Infusion of Isatuximab
NCT04294459 (23) [back to overview]	PK Parameters: Time Taken to Reach Cmax (Tmax) After the First Infusion of Isatuximab
NCT04294459 (23) [back to overview]	PK Parameters: Trough Plasma Concentrations (Ctrough) of Isatuximab
NCT04294459 (23) [back to overview]	Duration of Response (DOR)
NCT04294459 (23) [back to overview]	Time to Transplant
NCT04294459 (23) [back to overview]	Number of Kidney Transplant Offers
NCT04294459 (23) [back to overview]	Number of Participants Achieving Target cPRA
NCT04294459 (23) [back to overview]	Number of Participants With Graft Survival at 6 Months Post-Transplant
NCT04294459 (23) [back to overview]	Percentage of Participants With Response
NCT04294459 (23) [back to overview]	Pharmacokinetics (PK) Parameters: Concentration Observed at the End of First Intravenous Infusion (Ceoi) of Isatuximab
NCT04294459 (23) [back to overview]	PK Parameters: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours Over the Dosing Interval (AUC0-168 Hours) After First Infusion of Isatuximab
NCT04294459 (23) [back to overview]	PK Parameters: Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab
NCT04294459 (23) [back to overview]	PK Parameters: Maximum Concentration Observed (Cmax) After the First Infusion of Isatuximab
NCT04660799 (14) [back to overview]	Subcutaneous Serum Rituximab Trough Concentration (Ctrough SC) and Intravenous Serum Rituximab Trough Concentration (Ctrough IV)
NCT04660799 (14) [back to overview]	Observed SC and IV Rituximab Area Under the Curve (AUCsc and AUCiv)
NCT04660799 (14) [back to overview]	Number of Participants With Rituximab Administration-related Reactions (ARRs)
NCT04660799 (14) [back to overview]	CRR, as Determined by the Investigator Using Lugano Response Criteria for Malignant Lymphoma
NCT04660799 (14) [back to overview]	Complete Response Rate (CRR) as Determined by the Independent Review Committee (IRC) Using Lugano Response Criteria (LRC) for Malignant Lymphoma
NCT04660799 (14) [back to overview]	CRR, as Determined by IRC Using International Working Group (IWG) Response Criteria for Non-Hodgkin's Lymphoma (NHL) 1999 Guidelines
NCT04660799 (14) [back to overview]	Time to Cmax (Tmax) of Rituximab
NCT04660799 (14) [back to overview]	Objective Response Rate (ORR), Complete Response (CR) or Partial Response (PR), as Determined by Investigator and IRC Using Lugano Response Criteria (LRC) for Malignant Lymphoma
NCT04660799 (14) [back to overview]	Trough Serum Concentration (Ctrough) of Rituximab
NCT04660799 (14) [back to overview]	Number of Participants Positive for Anti-rHuPH20 Antibodies
NCT04660799 (14) [back to overview]	Number of Participants Positive for Anti-drug Antibodies (ADAs) to Rituximab
NCT04660799 (14) [back to overview]	Maximum Observed Serum Concentration (Cmax) of Rituximab
NCT04660799 (14) [back to overview]	Area Under the Curve (AUC) of Rituximab
NCT04660799 (14) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Response Rate

Response rate is the percentage of participants with a response assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions, Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions,progressive disease (PD) is at least a 20% increase in the sum of the LD of target lesions or the appearance of one or more new lesions, stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. (NCT00030992)
Timeframe: 6 weeks

Intervention	Percentage of participants (Number)
	Complete response	Partial Response	Progressive disease	Stable disease
BMS-247550	1	9.4	12.6	76.8

Intervention	K/uL (Mean)
	Day -7	Day 0	1 month	3 months	6 months	1 year	18 months	2 years	3 years
Autologous HSCT in SLE	0.54	0.0065	0.42	0.53	0.82	1.75	1.8	1.8	1.75

Intervention	mg/dL (Mean)
Alemtuzumab (Withdrawn From Sirolimus)	-4.2
Alemtuzumab (Not Withdrawn From Sirolimus)	-5.4

Intervention	days (Median)
Rituximab 1000 mg + Prednisone	112.0
Placebo + Prednisone	126.0

Intervention	Participants (Number)
	MCR (excluding PCR)	PCR	Nonclinical Response (NCR)
Placebo + Prednisone	14	11	63
Rituximab 1000 mg + Prednisone	21	29	119

Intervention	Percentage of participants by disease (Number)
Prophylactic Rituximab (CLL Patients)	73
Prophylactic Rituximab (MCL Patients)	69

Intervention	Participants (Number)
	Mortality within 100 days, all causes	Nonrelapse mortality within 1 year	Relapse + mortality within 1 year
Prophylactic Rituximab	0	1	2

Intervention	Participants (Count of Participants)
Group 1 - Cetuximab + Capecitabine-800 + XRT + Oxaliplatin-100	4
Group 2 - Cetuximab + Capecitabine-700 + XRT + Oxaliplatin-85	5
Group A - Cetuximab + Capecitabine-800 + XRT	3
Group B - Cetuximab + Capecitabine-1000 + XRT	5

Intervention	months (Mean)
Group 1 - Cetuximab + Capecitabine-800 + XRT + Oxaliplatin-100	59.7
Group 2 - Cetuximab + Capecitabine-700 + XRT + Oxaliplatin-85	57.0
Group A - Cetuximab + Capecitabine-800 + XRT	54.4
Group B - Cetuximab + Capecitabine-1000 + XRT	53.7

Intervention	participants (Number)
Benadryl® Ativan® Decadron® (BAD) Pump	3
Control Arm Saline	4

Intervention	units on a scale (Median)
Metoclopramide 20mg+Diphenhydramine	0
Metoclopramide 20+Placebo	0
Metoclopramide 10 + Placebo	0
Metoclopramide 10+Diphenhydramine	0

Intervention	participants (Number)
	Clinical Response	Complete Response (CR)	Functional CR	PR	SD	PD
Bexxar	2	0	1	1	6	1

Intervention	scores on a scale (Mean)
Lidocaine/Diphenhydramine (Combination)	1.8
Lidocaine	1.8
Placebo	1.7

Intervention	Score (Mean)
Lidocaine/Diphenhydramine (Combination)	-3.0
Lidocaine	-1.7
Placebo	-2.4

Intervention	Score (Mean)
Lidocaine/Diphenhydramine (Combination)	-10.4
Lidocaine	-5.3
Placebo	-16.3

Intervention	Score (Mean)
Lidocaine/Diphenhydramine (Combination)	-10.3
Lidocaine	-19.6
Placebo	-19.3

Intervention	Score (Mean)
Lidocaine/Diphenhydramine (Combination)	-0.6
Lidocaine	-0.4
Placebo	-0.7

Intervention	Score (Mean)
Lidocaine/Diphenhydramine (Combination)	-9.9
Lidocaine	-3.8
Placebo	-14.6

Intervention	millimeter (Median)
Ondansetron	-22.0
Metoclopramide	-30.0
Promethazine	-29.0
Placebo	-16.0

Intervention	scores on a scale (Mean)
Metoclopramide 10 mg Intravenous	4.7
Metoclopramide 20 mg	4.9
Metoclopramide 40 mg	5.3

Intervention	µg*day/mL (Mean)
Omalizumab 75 mg	317
Omalizumab 300 mg	1260
Omalizumab 600 mg	2800

promethazine

Description

Cross-References

Synonyms (227)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (7)

Drug Classes (3)

Pathways (1)

Protein Targets (87)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (581)

Molecular Functions (174)

Ceullar Components (121)

Bioassays (212)

Research

Studies (2,766)

Market Indicators

Research Demand Index: 118.18

Study Types

Clinical Trials (203)

Trial Overview

Trial Outcomes

Response Rate

Number of Participants With Adverse Events

Number of Participants With Adverse Events

Relapse-free Complete Clinical Response

Absolute Lymphocyte Count

Absolute Neutrophil Count

Anti-Double Stranded Deoxyribonucleic Acid (DNA) Antibody

Anti-Nuclear Antibody

Anti-Smith-Ribonuclear Protein Antibody

Cluster of Differentiation 19 (CD19) + Cells

Cluster of Differentiation 3 (CD3) + Cells

Cluster of Differentiation 4 (CD4) + Cells

Cluster of Differentiation 8 (CD8) + Cells

Extractable Nuclear Antigen (ENA)

Natural Killer Cells

Platelet Count

Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)

White Blood Cells

Number of Acute Rejections in All Enrolled Participants Following Sirolimus Withdrawal

Number of Acute Rejections in All Enrolled Participants

Number of Acute Rejections Between Initiation of Sirolimus Withdrawal and End of Study

Change in Renal Function as Measured by Serum Creatinine, Stratified by Withdrawal Status

Number of Deaths Stratified by Sirolimus Withdrawal Status

Number of Alemtuzumab Associated Adverse Events, Stratified by Sirolimus Withdrawal Status

Time From Transplantation to Acute Rejection in Participants for Whom Sirolimus Withdrawal Was Not Initiated

Time From Transplantation to Acute Rejection in Participants for Whom Acute Rejection Occurred During the 1 Year Post-transplant Period

Number of Tacrolimus Associated Adverse Events, Stratified by Sirolimus Withdrawal Status

Number of Sirolimus Associated Adverse Events, Stratified by Sirolimus Withdrawal Status

Number of Side Effects of Conventional Immunosuppression, Stratified by Withdrawal Status

Number of Severe Acute Rejections Stratified by Sirolimus Withdrawal Status

Number of Participants Who Experienced Graft Loss Stratified by Sirolimus Withdrawal Status

Number of Participants Requiring Anti-lymphocyte Therapy for an Acute Rejection, Stratified by Sirolimus Withdrawal Status

Time to First Moderate or Severe Flare

Number of Participants Who Achieved a Major Clinical Response (MCR), Partial Clinical Response (PCR), or Nonclinical Response (NCR) Defined by British Isles Lupus Assessment Group (BILAG) Scores Over The 52-week Treatment Period

Change in SLE Expanded Health Survey Physical Function Score From Baseline

Number of Participants Who Achieved a BILAG C or Better in All Domains

Number of Participants Who Achieved a PCR (Including MCR)

Time-adjusted Area Under The Curve Minus Baseline (AUCMB) of BILAG Score Over The 52-week Treatment Period

Number of Participants Who Achieved an MCR (Excluding PCR)

Number of Participants Who Achieved an MCR in The ITT Population

Overall Survival

Chronic Graft-vs-Host Disease (cGvHD)

Incidence of Relapse

Mortality

Tumor Downstaging at Surgical Resection

Time-to-Progression (TTP)

Intervention	scores on a scale (Mean)
Placebo	-6.91
Omalizumab 75 mg	-9.79
Omalizumab 300 mg	-19.93
Omalizumab 600 mg	-14.56

Intervention	micrograms per milliliter (µg/mL) (Mean)
Omalizumab 75 mg	11.4
Omalizumab 300 mg	33.1
Omalizumab 600 mg	67

Intervention	participants (Number)
	4 Weeks - Any Adverse Event (n=21,23,25,21)	4 Weeks - Mild (n=21,23,25,21)	4 Weeks - Moderate (n=21,23,25,21)	4 Weeks - Severe (n=21,23,25,21)	Follow-up period-Any adverse event (n=20,18,23,20)	Follow-up period-Mild (n=20,18,23,20)	Follow-up period-Moderate (n=20,18,23,20)	Follow-up period-Severe (n=20,18,23,20)
Omalizumab 300 mg	12	6	5	1	12	4	6	2
Omalizumab 600 mg	10	7	2	1	5	3	1	1
Omalizumab 75 mg	8	4	3	1	9	5	2	2
Placebo	10	8	2	0	7	4	2	1

Intervention	Pills (Mean)
Placebo	-1.38
Omalizumab 75 mg	-1.74
Omalizumab 300 mg	-2.64
Omalizumab 600 mg	-1.69

Intervention	days (Mean)
Omalizumab 75 mg	7.37
Omalizumab 300 mg	8.01
Omalizumab 600 mg	6.24

Intervention	scores on a scale (Mean)
Placebo	-3.46
Omalizumab 75 mg	-5.28
Omalizumab 300 mg	-10.71
Omalizumab 600 mg	-8.10

Intervention	scores on a scale (Mean)
Placebo	-3.45
Omalizumab 75 mg	-4.50
Omalizumab 300 mg	-9.22
Omalizumab 600 mg	-6.46

Intervention	days (Mean)
Omalizumab 75 mg	18.2
Omalizumab 300 mg	17.1
Omalizumab 600 mg	22.5

Intervention	scores on a scale (Mean)
Placebo	-3.23
Omalizumab 75 mg	-3.90
Omalizumab 300 mg	-5.81
Omalizumab 600 mg	-6.85

Intervention	Percent expression (Median)
	Expression at baseline	Expression at 8 weeks
Temsirolimus 25 mg	91	92